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Complete knowledge of a patient’s medications, including over-the-counter and 
alternative medicines, is essential to the healthcare professional in providing quality care.  
In addition to the multiple steps from prescribing, dispensing to administering of a drug 
medication, there are several factors that increase an individual’s risk for an adverse 
event and approaches to reduce medication errors.  The movement of healthcare systems 
to an electronic medical record provides the potential of building a better health care 
system.  This retrospective study compares five sources of medication, medical record 
chart, specialist, electronic medical record, pharmacy, insurance provider and patient, to 
determine what is the most accurate source of documentation, and what factors leading to 
better knowledge and documentation of all of a patient’s medications.  This study also 
identifies additional risk factors, specifically drug affordability and the influence it has on 
a patient’s behavior, and discusses some considerations for reducing medication errors.  
The prevention and reduction of adverse events is of public health significance as there is 
both a health and financial cost to treating these adverse events. 
Edmund M. Ricci, PhD, MLitt 
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1.0  INTRODUCTION 
When the Institute of Medicine (IOM) (IOM 1999) reported in 1999 that medical errors kill 
between 44,000 and 98,000 people in US hospitals per year, there was widespread concern and 
panic about patient-safety amongst healthcare professionals and the public. Even by utilizing the 
lower estimate of 44,000 deaths annually, deaths due to medical errors would rank as the eighth 
leading cause of death making it more prevalent than motor vehicle accidents (43,458) and breast 
cancer (42,297).  Associated with medical errors is a monetary cost.  The total annual cost of 
preventable adverse events (i.e. medical errors resulting in injury) is estimated between $17 and 
$29 billion annually.  Over one half of these costs are due to direct health care costs, such as 
longer stay or treatment.  While there has been conflicting opinions on whether these numbers in 
the IOM Report were exaggerated (McDonald, Weiner et al. 2000) or underestimated (Leape 
2000), the report highlighted to the public and government the issue of medical errors on patient 
safety.   
 
What are some of the underlying causes of medical errors?  The National Ambulatory Care 
Service paints the picture of a growing reality, namely an aging population, multiple coexisting 
conditions (co-morbidity), increase in medicine therapy, and an increasing electronic medical 
record environment.  In a national probability sample of non-federal office-based physicians in 
the United States, the National Ambulatory Medical Care Survey (Cherry, 2007) reported an 
2 
estimated 963.6 million patient visits to physicians offices in 2005, which is an overall rate of 
331.0 visits per 100 persons.  In one-quarter of these office visits, electronic medical records 
(EMR) were used by physicians, and in 83.9% of the office visits, the claims were submitted 
electronically.  There also has been a shift in the age of patients seen as the baby boomer 
generation ages.  In 1995, the majority of the visits were by patients 25-44 years of age, while in 
2005, the majority of visits were by 45-64 years of age.  At least one chronic condition was 
reported in 52.7% of the patients with hypertension being the most prevalent (22.8%), followed 
by arthritis (14.3%), hyperlipidemia (13.5%), and diabetes (9.8%).  Medication therapy 
accounted for 679.2 million (70.5%) of all office visits.  In 2005, there were about 2.0 million 
drugs prescribed, in an overall rate of 210.7 drugs per 100 visits.   The Kaiser Family Foundation 
reported for 2007, the sale of 3,457,595,838 prescription drugs in the United States totaling 
$202,249,087,162.  The retail prescriptions filled by mail order totaled $53.11 billion or 20.5% 
of total prescriptions filled in 2007 (Kaiser Family Foundation 2008).  This is close to a 100 fold 
higher than what was reported by the NDC Health (1991-1998) (NDC Health. 1991-1998), 
which estimated $2.9 billion retail US prescriptions filled in 2000 which was up 62% from a 
decade earlier.   
 
This increasing aging population with multiple illnesses (co-morbidity) requiring many 
medications (poly-pharmacy) increases the risk for medication errors.  Kaufman et al. (2000) 
(Kaufman, Kelly et al. 2002) found that most of elderly patients (over 65 years) in an ambulatory 
population study took at least one prescription or nonprescription drug or a vitamin, mineral or 
herbal supplement weekly.  Women’s rates are higher with 94% who take at least one 
medication; 57% take five or more, and 12% take ten or more.  In comparison, 91% of men use 
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at least one medication, 44% take five or greater, and 12% take ten or greater. Taking several 
medications with different regimens can be confusing, the elderly often have trouble 
understanding instructions (Patel, 2002), and even visiting nurses to the elderly find it difficult to 
reconcile multiple and conflicting medication orders (Strouse 2003).  Complicating the situation 
further are patients buying prescription drugs on the internet (Anonymous. 2003), taking sample 
medications that may not be recorded in their chart (Hubbard, 2003) (Strouse,. 2003) (Ashley, 
Kirk et al, 2002) and sharing of prescription medication (Daniel, Honein, et al. 2003).  It has also 
been well known that there are several patients who are prescribed medications but never get 
them filled, discontinue or alter the prescribed medication regimen, take sample medications, or 
over the counter or herbal medicines without their physician’s knowledge.   
 
A physician’s knowledge of which, how and when medications are taken are essential to the 
management of a patient’s care.  The recurring theme throughout the IOM report is that the 
majority of medical errors are due to basic flaws in the way health systems are organized and not 
solely on individual behavior.  It is estimated that the combination of system flaws and human 
factors leading to adverse drug reactions are estimated to injure or kill more than 770,000 people 
in hospitals annually (Lesar, Lomaestro et al. 1997) which has been seen in multiple populations.   
 
In looking at documented sentinel events submitted to the Joint Commission on 
Accreditation of Healthcare Organization (JCAHO), ‘system flaws’ have included drugs on a 
patient care unit that are toxic until diluted, illegible writing leading to misinterpretation of 
orders in medication records, and coordinating care amongst multiple physicians who may or 
may not have complete information on a patient.  Recent approaches to lowering medical errors 
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have included introducing hospital processes and procedures to reduce human errors, volunteer 
error reporting, to computer-based systems of prescribing, transcribing and dispensing.  In 2003, 
the JCAHO issued “National Patient Safety Goals”.  Five of the six goals relate to medications:  
improve the accuracy of patient identification (requires two independent identifiers); improve the 
effectiveness of communication among caregivers (‘read back’ all verbal and telephone orders 
and use standardized abbreviations); improve the safety of using high-alert medications (remove 
concentrated electrolytes from patient care areas); improve the safety of infusion pumps (free-
flow protection); and improve the effectiveness of clinical alarm systems  (JCAHO 2003).  The 
federal government is encouraging the implementation of systems such as the electronic medical 
record, to strengthen the process of detecting and preventing medication errors, especially 
adverse drug reactions (ADRs). 
 
The idea behind this study originated through a series of observations from being part of a 
care team in an ophthalmology clinic looking at how the medication history is gathered and 
shared with the internal and wider health care team of the patients (i.e. the primary care 
physician, family members, etc.).  There is a growing awareness of how alternative medications 
can interfere or enhance a prescription medication, and a movement of health care organizations 
towards an electronic medical record system with anticipation of creating a safer, health care 
system.  The last compelling thought was in discussion with a colleague.  The hallmark of 
treating patients is that physicians trust that patients get the prescriptions filled and take the 
medications accordingly.  The question of the role of insurance companies came into place.  
Information goes into insurance companies about what has been filled with little to no feedback 
to the prescribing physicians.  While it does not guarantee that the patient has taken the 
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Figure 1:  Medication Prescription Process 
medication, the resultant question became how does one create a safer, health care system? What 
types of information is helpful, timely and should be considered as part of the EMR system or 
any other system.  To answer this question, one first needs to answer what is the best source of a 
patient’s medication history. 
1.1 PROBLEM STATEMENT 
A large part of medication errors are due to the plethora and complexity of medications 
available, the multiple steps involved in prescribing a medication and the number of people 
involved.  In the most simplistic case as illustrated in figure 1, after the physician determines the 
problem, prescribes the appropriate medication including dosage, the patient gets the prescription 
filled, the pharmacist transcribes and dispenses the medication, and the patient takes the 
medication as prescribed whether administered / assisted by a healthcare provider, family 
member / friend, or self.   
 
 
 
 
 
 
Physician determines diagnosis 
and prescribes medication 
Patient has prescription filled 
Pharmacist has the correct 
medication and dose 
Patient takes medication as 
prescribed 
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Within and between each of these steps are many opportunities for potential errors such as 
ordering (wrong dose, wrong choice of drug), transcribing (wrong frequency of drug 
administration, medication not transcribed, unclear handwriting, similar drug names being 
confused), dispensing (wrong drug, wrong dose, drug not available for dispensing), or 
administering (wrong dose of drug, over or under taking a medication, instructions on how to 
take the medicine unclear or not followed by patient), monitoring (not noting the effects of a 
given medication or allergies) and use (over or under taking of a medication).  
 
The United States Pharmacopoeia (USP) (2002) reports that omission errors, incorrect doses, 
and administration of the wrong drug products had remained the same top three causes of 
medication errors in 1999 and 2000 as reported by health systems.  Three percent of errors either 
harmed or killed patients. In direct observation of paper-based prescribing in medical/surgical 
ICU in a tertiary care medical center there were 185 incidents over 16.5 days.  After removing 
the non-preventable and non-clinically significant observations, 110 of the remaining 132 (83%) 
led to potential ADR of which 22 (17%) led to actual, preventable ADR.  Thus there was one 
error for every five doses of medication administered.  All of the actual, preventable ADR 
occurred in the prescribing (77%) and administration (23%) stages.  Errors included omission 
(23%), wrong dose (20%), wrong drug (16%), wrong administration technique (15%) and drug-
drug interaction (10%).  (Koop, Erstad et al. 2006).  Other system errors were identified in a 
2005 National Survey of the Work and Health of Nurses in Canada.  A multivariate association 
was positively associated with working overtime, role overload, perceived staffing or resource 
inadequacy, low co-worker support, and low job security (Wilkins and Shields 2008). 
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In ten-year period looking at the types of ADRs among children in a retrospective chart 
review in a community-based, tertiary care, children’s teaching hospital, Le et al. (Le, Nguyen et 
al. 2006) reported 1087 ADRs.  The severity of most ADRs were low (rash, flushing, puruitus 
were the top three observations) occurring 89% predominantly in the general pediatric unit and 
NICU.  The higher levels of severity (requiring treatment and in two cases resulted in death) 
occurred in 11% of reported cases that led to hospitalization or occurred during surgery and were 
noted among certain classes of drugs (anticonvulsants and anti-neoplastic agents).  In the 
voluntary reporting system, pharmacists reported the most ADRs (89%), followed by nurses 
(10%) and then physicians (<1%).  Of the 93% of ADRs documented, only 29% were noted in 
the patient’s medical chart, 13% included follow-up education for the individuals involved, and 
10% were updated in the allergy profile of the hospital computer system. (Le, Nguyen et al. 
2006).  In another study, a multidisciplinary panel of geriatric health care professionals aimed to 
reach consensus on a list of clinically important drug-disease interactions in older adults and to 
determine the prevalence of these interactions.  Of the 28 individual drug-disease interactions 
involving 14 diseases or conditions, 2.5 (15.3%) of the 1340 veterans in the sample had > 1 
drug-disease interaction.  The two most common drug-disease interactions were use of first-
generation calcium channel blockers in patients with congestive heart failure and use of aspirin 
in patients with peptic ulcer disease (both, 3.7%) (Lindblad, Hanlon et al. 2006).   
 
The JCAHO now requires accurate and complete medication reconciliation for all patients 
admitted to the hospital (JCAHO 2006).  Specifically hospitals are expected to obtain a list of 
home medications from patients and compare it to their list of medications.  Ideally, this should 
be compiled on admission or within the first 24 hours of admission.  What has become 
challenging is the growing interest in complementary and alternative medicines (CAMs). Media 
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hype and disappointment with current conventional medicines, has more patients turning to 
alternative treatments.  As the human body is comprised of several interacting biological 
systems, a medication or CAM benefiting one disease may create potential problems in another 
part of the body.  An example of dual conflicting effects in just the eye is the use of the herb Lily 
of the Valley.  Lily of the Valley is used to treated unspecified conjunctivitis, however, has also 
been associated with disturbance of color perception (Fraunfelder 2004).   
 
In a Canadian sample of 193 older adults with cognitive impairment, 15% used at least one 
herbal remedy and of these, 13.8% used two herbs and 44.8% used three or more herbs (Lee, 
Dergal et al. 2001).  In a survey of herbal supplement use in a sample size of 271 individuals 
older than 50 years, mean use of prescription drugs was 2.26 and 5.91 for herbal and nutritional 
supplements, including 2.66 herbal extracts (Canter and Ernst 2004).  These products were used 
to treat existing health problems (31% of users), prevent a particular disease (27%), promote 
general health (78%) and provide nutrients missing in their diet (52%) (Canter and Ernst 2004).  
Herbal products are also commonly used by patients with certain chronic medical conditions, 
including breast cancer (12%) (Burstein, Gelber et al. 1999), liver disease (21%) (Strader, Bacon 
et al. 2002), human immunodeficiency virus (22%) (Kassler, Blanc et al. 1991), asthma (24%) 
(Blanc, Trupin et al. 2001), and rheumatological disorders (26%) (Rao, Mihaliak et al. 1999).   
 
 
 In a 1990 survey of 1,539 adults, 33.8% of respondents used herbal medicines or 
nutritional supplements.  By 1997, the number had increased to 42.1%, with most people paying 
the cost out-of-pocket (Eisenberg, Kessler et al. 1993; Eisenberg, Davis et al. 1998).  The U.S. 
public spent an estimated $36 billion to $47 billion on alternative therapies in 1997.   Of this 
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amount, between $12 billion and $20 billion was paid out-of-pocket for the services of 
professional alternative health care providers.  These fees represented more than the public paid 
out-of-pocket for all hospitalizations in 1997 and about half of what was paid for all out-of-
pocket physician services.   An estimated $5 billion of out-of-pocket is spent on herbal products 
(NCAM 2007). 
 
Despite the growing interest in herbal medicines, it is estimated that only 23-40% of herb and 
nutritional supplement use by people greater than 65 years of age was known to their doctors 
(Eisenberg, Davis et al. 1998), (Cohen, Ek et al. 2002), (Canter and Ernst 2004).  In a separate 
study, 64% of geriatric patients took CAM, but their use was documented in only 35% of 
medical charts, and 25% of people were taking herbal products with anticoagulant properties at 
the same time as prescribed anticoagulants (Cohen, Ek et al. 2002).  Even if the patients 
informed their providers about their use of complementary and alternative medications, it is not 
clear that the information would be used effectively.  A survey of 165 physicians at the State 
University of New York Health Service Center at Brooklyn found that most physicians lacked 
basic knowledge about CAMs and were reluctant to inquire about their properties (Silverstein 
and Spiegel 2001).   
 
Many physicians do not ask further about CAMs because the mechanism, appropriate dosage 
amount and length of therapy for herbal medicines are unknown.  Prescription drugs and over-
the-counter, nonprescription drugs are monitored by the U.S. Food and Drug Administration 
(FDA) because they are sold for a specific indication and are marketed over state lines.  By 
contrast, herbal medicines and nutritional supplements are not marketed to treat specific diseases, 
are exempt from interstate commerce law, and fall under the purview of the Dietary Supplement 
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and Health Education Act of 1994.  No efficacy or safety has to be proven to sell these agents 
(Fraunfelder 2004).  The National Registry of Drug-Induced Ocular Side Effects lists the impact 
of herbal medicines.  They have received 263 spontaneous reports, in addition to 60 case reports 
from the literature, citing canthaxanthine, chamomile, Datura, Echinacea purpurea, Ginkgo 
biloba, licorice, niacin and vitamin A are all associated with clinically significant ocular side 
effects (Fraunfelder 2004). Thus while the exact mechanism, appropriate dosage amount and 
length of herbal medicines is unknown, herbal medicines do affect the medicine therapies and 
increases a patient’s risk for side effects making it difficult for a physician to determine the 
involvement and significance of CAM. 
 
Checking for medication errors has typically fallen upon various members of the health care 
team most often the physician and nurse.  While not typically considered part of the health care 
team, the role of the pharmacist to determine whether there may be potential adverse drug 
interactions when filling a prescription is becoming an increasing reality.  A pharmacist in a 
behavioral health unit of a community hospital reviewed the patient’s medications within 18 
hours of admission after a technician.  The mean number of medication discrepancies per patient 
was 2.9.  Of these, 48% were related to an omitted or incorrect medication, 31% to an omitted or 
incorrect dose, and 13% to an omitted or incorrect frequency, 8% were miscellaneous (Lizer and 
Brackbill 2007).  However, a pharmacist checking medication discrepancies assumes that the 
patient utilizes the same pharmacist or all of his/her medical information is located in a 
centralized patient-pharmacy database, and the herbal medicines are documented.  This seldom is 
the case.  
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In these various pathways, there are multiple opportunities for medical errors whose affects 
can range from none, allergic reactions to life threatening. As it is a multiple process system, 
reducing medical errors becomes everyone’s responsibility (Peth, 2003).  This study focuses on a 
specific part of the prescription pathway that is the source of medication documentation and 
assumes that the participants were properly diagnosed and treated accordingly with best practice 
medicine.  A physician with inaccurate information can have serious impact on the treatment of a 
patient, it may make the difference between prescribing a new medication, discontinuing or 
renewing a prior medication leading to a healthier or more sick patient.  The physician must 
weigh the patient’s health with the risks and benefits of the prescription.  Thus when inaccurate 
or incomplete information is available, there is a potential risk for declining health status or 
adverse drug events, which is any injury resulting from a medical intervention related to a drug, 
usually undesirable.  The adverse event can range from a rash, reduced effectiveness of a drug, to 
death. 
1.2 PURPOSE OF THE STUDY 
In light of the movement towards more technological aided systems such as the electronic 
medical record and the computer physician order entry (CPOE), there are two main objectives to 
this study that focuses specifically on medication documentation.  The first is a comparative 
analysis looking at the sources of medication documentation.  The specific aims of the study are:   
 
1. Determine whether medication documentation in a (a) chart; (b) computerized physician 
order entry system (CPOE – i.e. EasyScript) in an electronic medical record; (c) 
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pharmacy record; (d) insurance companies; (e) specialist and (f) as reported by the patient 
are comprehensive (i.e. does their medication list includes medications prescribed by all 
healthcare providers).  Comparison of all the sources will allow for some analysis of both 
human and system errors, as well as outline paths of communication of information. 
2. Determine the extent of awareness by the various physicians on which and on how 
medications are taken by a patient (medication discrepancy).  This includes determining 
the extent to which medications are prescribed but not filled, administered differently 
than is prescribed, not taken on a consistent basis, taken in a self-medicated manner 
outside of the prescribed route or is self-medicating. 
3. Determine the potential impact of errors on disease management of a patient and clinical 
alerts (includes drug-drug interactions, drug allergies, dosage checks, duplicate 
therapies). 
 
The second objective given the findings in the first objective is to identify the potential 
feasibility of establishing a collaboration of shared information between the academic medical 
institution utilizing a CPOE system, health plan and pharmacy to help improve patient care and 
thereby reduce medication errors.  The benefits to the physician are readily obvious in providing 
better care by knowing what the individual is taking, and both the physician and pharmacy are 
then able to check for drug-drug- or drug-homeopathic interactions.  Incorporating the use of 
insurance or health plan data, which contains all of the reimbursed medical interactions on a 
patient is extremely helpful to physicians, but as well serves to encourage and be able to market 
to individuals to stay within the medical, pharmacy system as they are able provide 
comprehensive care.  Reducing potential adverse drug events helps all of the individuals 
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involved including avoidable sick time to the patient, physician time and medical expenses to the 
healthcare provider.  This is the first study that looks at comparing so many different sources of 
medication with the hopes of shedding some light on what factors should be considered in order 
to provide healthcare providers and patients with the most accurate, up-to-date and readily 
accessible information. 
1.3 DEFINITION OF TERMS 
Medication or medicine has a variety of definitions but generally is referred to as a drug or 
remedy.   
 
Polypharmacy is the use of multiple medications and / or the administration of more 
medications than are clinical indicated, representing unnecessary drug use (Hajjar, Cafiero et al. 
2007).  Although, there is not a specific number, it commonly refers to patients taking four or 
more medications (Milton and Jackson 2007). 
 
Herbal medicines are plants or plant extract for medicinal purposes.  Herbs are generally 
defined as any form of a plant or plant product, including leaves, stems, flowers, roots and seeds.  
As they are a food source and herbal medicines are not regulated by the federal government like 
prescription medicine.  Sometimes the scope of herbal medicine extends to include fungi and bee 
products, as well minerals, shells and certain animal parts. 
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Conventional or contemporary medicine is health science, biomedical research, and medical 
technology to diagnose and treat injury and disease typically through medication, surgery, or 
some other form of therapy.  Conventional medicine is practiced by holders of M.D. (medical 
doctor) or D.O. (doctor of osteopathy) degrees and by their allied health professionals, such as 
physical therapists, psychologists, and registered nurses.  (NCAM 2007) 
 
Alternative medicine encompasses any healing practice that does not fall within the realm of 
conventional / contemporary medicine (i.e. is used in place of conventional medicine).  
Examples of alternative medicine include naturopathy, chiropractic, herbology, traditional 
Chinese medicine, Ayuveda, meditation, yoga, biofeedback, hypnosis, homeopathy, acupuncture 
and diet-based therapies. 
 
Complementary medicine refers to use of alternative medicines together with conventional / 
contemporary medicine techniques.  An example of complementary therapy is using a special 
diet to treat cancer instead of undergoing surgery, radiation or chemotherapy that has been 
recommended by a conventional doctor.  This is often under the term of complementary and 
alternative medicine (CAM) (NCAM 2007). 
 
Medical Chart is the confidential document that contains detailed and comprehensive 
information on the individual patient and their care experience. 
 
Co-morbidity has been defined as (1) the concurrent presence of two or more chronic diseases 
or conditions; (2) (in people with disabilities) other medical conditions unrelated to the primary 
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disabling condition; and (3) the co-existence of other conditions with a defined index condition 
(Siebens 2007). 
 
Electronic Health Record (EHR) is an individual patient’s medical record in digital format.  
EHR coordinate the storage and retrieval of individual records.  EHRs are usually accessed over 
a network, and may be made up of electronic medical records from multiple locations or sources.   
 
Electronic Medical Record (EMR) is a patient’s localized medical record in digital format.  In 
health informatics, an EMR is considered by some to be one type of electronic health record, but 
in general usage of the terms EHR and EMR are used synonymously. 
 
Computerized Physician Order Entry (CPOE) is the process of electronic entry of physicians’ 
instructions for the treatment of patients under his or her care.  These orders are communicated 
over a computer network to the medical staff (nurses, therapists or other physicians) or to the 
departments (pharmacy, laboratory or radiology) responsible for fulfilling the order (Farlex 
2008). 
 
Medication reconciliation is the process of comparing a patient's medication orders to all of the 
medications that the patient has been taking (JCAHO 2006). 
 
Medication errors are defined as any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the health care 
professional, patient, or consumer. Such events may be related to professional practice, health 
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care products, procedures, and systems, including prescribing; order communication; product 
labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; 
education; monitoring; and use (NCC-MERP 2008). 
 
Adverse event (AE) or drug event (ADE) or reaction (ADR) is any injury resulting from a 
medical intervention related to a drug, usually undesirable. Examples of such injuries include 
heart rhythm disturbances, diarrhea, fever, nausea and vomiting, renal failure, mental confusion, 
rash, low blood pressure, and bleeding (NCC-MERP 2008).  An individual’s response can vary 
from other individuals due to the person’s disease state, age, weight, gender, ethnicity and 
general health.  ADRs can also occur when commencing, decreasing/increasing dosages or 
ending a drug or medication regimen.  ADRs can lead to non-adherence to taking a medication 
when there is a reaction.  When the effect of a drug or medication is severe, the dosage may be 
adjusted or an additional medication may be added.  Potential ADRs are defined as the potential 
to harm a patient (near-misses).  ADRs can be further classified into intercepted (intercepted 
before it reaches a patient) and non-intercepted (reaches the patient but does not cause injury 
because the patients has sufficient physiological reserves). 
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2.0  LITERATURE REVIEW 
There are several factors that can increase a patient’s risk for medical errors.  While each alone is 
a factor, the combination of factors compounds the risk for adverse events and medical errors 
overall.  These risk factors are in addition to the system errors mentioned earlier. 
2.1 RISK FACTORS FOR ADVERSE DRUG REACTIONS 
2.1.1 SIMILAR DRUG NAMES 
Nearly 1,500 commonly used brand and generic drugs have similar names or look alike to other 
drugs that has confused patients.  Together, these drug names contribute to more than 3,170 
confusing drug name pairs (Pharmacopeia).  These look and sound alike drugs are estimated to 
account for 25% of the medication errors that occur every year.  For example, 
 Clonidine (for high blood pressure) and Klonopin (for seizures) 
 Celebrex (a painkiller) and Celexa (an antidepressant) 
 Lamictal (for epilepsy) and Lamisil (an antifungal) 
 Zyprexa (for schizophrenia) and Zyrtec (an antihistamine) 
Many of the mix-ups involve a pharmacist having difficulty reading a physician’s handwriting.  
However, even with computerized prescription systems, errors can occur when a physician could 
18 
incorrectly click on the wrong item.  For example, someone can miss clicking on ‘Actos’ versus 
‘Actonel’.  Alternatively, a pharmacist could end up reaching for the wrong drug which was 
organized alphabetically but in the wrong order. 
 
While the Food & Drug Administration (FDA) rejects about one-third of all proposed new 
drug names each year because they sound or look similar, there are too many drugs on the 
market to track them all.  In a few cases, the mix-ups have been so frequent that the names of 
drugs have changed.  For example after two deaths, the drug Reminyl prescribed for Alzheimer’s 
was confused with the old diabetes drug Amaryl, and is now changed to Razadyne.  Similarly, 
the cholesterol pill Omacor is now named Lovaza after being mixed up with the blood-clotting 
medication Amicar.  The U.S. Pharmacopeia has recently created a USP’s Drug Error Finder 
allowing a user to search more than 1,400 drugs involved in look-alike and/or sound-alike errors.  
They recommend that the indication for use be written beside the name of the medication. 
2.1.2 HEALTH LITERACY 
Health literacy is “the degree to which individuals have the capacity to obtain, process, and 
understand basic health information and services needed to make appropriate health decisions” 
(Ratzan and Parker 2006).  An individual’s health literacy is important because what he/she 
understands helps shape his/her actions.  It can mean the difference of taking a medication or not, 
or unknowingly altering the medication frequency or dose taken. 
 
In a study evaluating knowledge of 172 patients newly prescribed medication after hospital 
discharge, between 4 and 18 days after discharge, patients were contacted via phone and asked 
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about the name, number, dosages, schedule, purpose, and adverse events of the new medication.  
Of the respondents, 86% were aware that they were prescribed a new medication, 64% could 
identify the name, 74% the number of new medications, 56% dosages, 68% schedule, and 64% 
purpose.  Only 11% recalled being told the adverse events, and 22% could name at least 1 
adverse event.  Older patients were found to answer fewer questions correctly (Maniaci, 
Heckman et al. 2008). 
2.1.3 PHARMACOKINETIC AND PHARMACODYNAMIC CHANGES 
The per capita consumption of drugs taken by older people is higher than the rest of the 
population.  For example, in 2005, CAD $24.8 billion was estimated to be spent in Canada on 
drugs of which 44% were prescribed to those aged 65 years and older (2006).  In a study looking 
at the causes of ADRs, beta-blocker, diuretic, angiotensin-converting enzyme inhibitor, aspirin 
and non-steroidal anti-inflammatory drugs accounted for 82% of all ADRs.  These events were 
more common with advanced age of patients, greater number of consultation problems and 
prescribed drug items (Tam, Kwok et al. 2008). 
   
Therefore, in addition to the several types of interactions: drug—drug, drug—disease, drug—
food, drug—alcohol, drug—herbal products, and drug—nutritional status, there are also age-
related changes.  As an individual ages there are changes in pharmacokinetics (what the body 
does to the drug), pharmacodynamics (what the drug does to the body), frailty, inter-individual 
variability (individual genetics, lifelong habits, and environment will result in heterogeneity 
between patients as they age), reduced homoeostatic mechanisms (cellular, organ, and systems 
reserves decrease with age), and psychosocial issues.  These all need to be considered when drug 
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interactions are assessed and contributes to the unpredictability on how an individual will 
respond. 
2.1.4 COGNITIVE IMPAIRMENT OF OLDER POPULATIONS 
Age-related changes in physical functional capacity, sensory acuity, and cognition are prevalent 
in older populations.  It has been found that complexity of medication regimen alone does not 
necessarily lead to difficulties in medication management.  The degree to which older adults 
possess and can apply psychomotor and cognitive abilities to the tasks required to administer 
medications as prescribed or directed also determines their capacity for medication management.  
In a retrospective study of 301 participants that were part of a self-medication program in a 
rehabilitation hospital, they measured the medication complexity index.  The complexity index is 
the number of tablets taken per dose, the number of daily doses of medication taken each day, 
and additional directions that must be followed to manage medication regimens.  As an example, 
one tablet three times a day = 3 versus One tablet three times a day with food is 3 + 3 = 6).  The 
researchers found that the mean probability of making errors increased with Medication regimen 
complexity and MMSE (Mini-Mental State Exam) score.  This was also found to be related to 
their functional ability to cook and MMSE score (Maddigan, Farris et al. 2003). 
2.1.5 PATIENT’S AND CAREGIVER’S KNOWLEDGE 
Successful treatment of patients requires adherence to prescribed medications that have been 
found to be associated with the caregiver’s involvement and patient’s knowledge of drugs and 
drug treatment.  The lack of adherence may lead to therapeutic failure with risks of relapse, 
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progression of disease and prolonged illness and treatment.  Ulfvarson et al. (Ulfvarson, Bardage 
et al. 2006) conducted structured interviews with 200 patients who had been recently treated in a 
medical ward.  The mean age of patients was 79 years.  The number of drugs reported in the 
medical chart ranges from 1 to 17 with the mean of 6.9, the number reported by patients was 7.3.  
When comparing the interview results with the information in the medical charts, 30% of the 
patients showed adherence.  Patients who were non-adherence reported a higher consumption of 
drugs.  There was no association between education level but implicate the quality of 
information influences adherence. 
2.1.6 CO-MORBIDITY 
Co-morbidity is defined as a chronic condition that coexists in an individual with another 
condition that is being described.  For example, the presence of chronic heart failure such as 
arrhythmias in combination with conditions that predicate and contribute to the etiology such as 
hypertension, diabetes mellitus and hyperlipidaemia (Lang and Mancini 2006).  Therefore, 
patients tend to take multiple medications for the various conditions.  It is thus not surprising that 
co-morbidity has been associated with multiple medications and increased ADRs.  It has also 
been associated with physical disability, higher health care use, poorer quality of life, and 
increased mortality (Boyd, Darer et al. 2005). 
2.1.7 POLYPHARMACY 
The use of multiple medications (i.e. polypharmacy) in the elderly population is common, 
comprising 15% of the population.  Twenty-three percent of women and 19% of men older than 
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65 years take at least five prescription drugs.  Fifty-seven percent of women take more than five 
medications including over-the-counter drugs (Kaufman, Kelly et al. 2002).  Polypharmacy can 
occur when multiple medications are being prescribed or when patients remain on the same 
treatment, sometimes unnecessarily. 
 
All medications have the potential for adverse events, therefore, it is not surprising that the 
percentage of ADRs increases with the number of medications.  In looking at emergency 
department visits, out of 205 consecutive visits, there were 226 potential ADRs.  It was found 
that the probability of an ADR increases the risk from 13% for two drugs to 82% for over seven 
drugs.  (Goldberg, Mabee et al. 1996)    In a geriatric nursing home setting, after adjusting for the 
number of days of stay, it was found that for participants taking > 9 different scheduled 
medications was at a 2.33 times higher than controls for experiencing an ADR (Nguyen, Fouts et 
al. 2006).  In reviewing the literature in the countries of the United States, Canada, Australia, and 
Europe, polypharmacy was to be statistically significant predictor of hospitalization, nursing 
home placement, death, hypoglycemia, fractures, impaired mobility, pneumonia, and 
malnutrition. 
 
Haijjer et al. reviewed twenty-one articles on polypharmacy in the elderly, and identified risk 
factors for polypharmacy from nine studies, which can be classified into three groups:  
demographic (increased age, white race and education), health status (poorer health, depression, 
hypertension, anemia, asthma, angina, diverticulosis, osteoarthritis, gout, diabetes mellitus, and 
use of > 9 medications), and access to health care (number of health care visits, supplemental 
insurance, and multiple providers).  They also reported in five studies, the number of 
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medications taken that were suboptimal or unnecessary for patients over 65 years ranging from 
42% to 65%.  These medications were classified into either a medication with no indication, lack 
of effectiveness, or therapeutic duplication (Hajjar, Cafiero et al. 2007).  Similar results were 
found in a study of 128 veterans, 58.6% of patients had > 1 unnecessary prescribed drug of 
which 41.4% was considered inappropriate due to lack of effectiveness.  They identified risk 
factors for this association (P < 0.2) with unnecessary drug use: race (white), income 
(<$30,000/year), number of prescription medications (mean 6.8, SD 2.8) and lack of belief in a 
‘powerful other’ for their health locus of control.  This last factor suggests that those patients 
who are less ‘trusting’ of the health care system are more likely to have unnecessary medication 
use (Rossi, Yong et al. 2007). 
 
Seventy-five percent of elderly leave a doctor’s visit with a new medication (Neary and 
White 2001).  The etiology behind polypharmacy is as complex as the medications and treatment 
regimens.  Ballentine has cited from the patient (hope for benefit, chemophilia, pressure from 
family, multiple chronic medical disorders, media influence, pharmaceutical industry influence), 
healthcare provider (following standards of care, disease parameter goals, research funding, 
perceived therapeutic benefits, pharmaceutical industry influence, cross-titration of lowering one 
drug while increasing another) and pharmaceutical industry (new drugs/improved technology, 
“direct to consumer: advertising”, increased ‘fast line’ new drugs, investigator 
pressure/competition) are some of the multiple reasons contributing to this increase in 
prescribing of medications (Ballentine 2008).  Additionally, as side effects of medications are 
not always immediate, shifting medications can make it difficult to directly pinpoint the cause. 
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However, in some conditions the use of multiple drugs is both beneficial and appropriate.  
For example, diabetes mellitus is often treated with multiple drugs at once.  In tuberculosis, three 
or four drugs are often combined to prevent the emergence of resistant mycobacteria (Aronson 
2006).  It has thus been suggested that the terminology should be rational or obligatory 
polypharmacy to recognize legitimate prescribing versus indiscriminate polypharmacy for 
inappropriate prescribing (Routledge, O'Mahony et al. 2003).  Possibly appropriate causes of 
polypharmacy include:  multiple medical problems; and using further medication to treat ADRs.  
Usually or always inappropriate causes of polypharmacy are: multiple drug prescribers, no 
regular medication review, using further medication to treat ADRs, and prescribing of drugs that 
are not indicated (Milton and Jackson 2007). 
 
Part of the challenge in rational polypharmacy is that it is best guided by validated evidence.  
In accordance with the ethics of clinical research, the participants must be competent to 
participate in a trial, thus subjects tend to be younger and healthier than the general elderly 
population.  In the absence of high-quality evidence to guide prescribing, clinicians are forced to 
extrapolate.  It then becomes a delicate balance between aggressively treating the patient and not 
harming the patient.  As the population ages and concerns for safety increase, reducing 
polypharmacy in the elderly is one of the goals of Healthy People 2010. 
 
To help assess polypharmacy, Bushardt et al. (Bushardt and Jones 2005) have developed nine 
key questions for the clinician to guide and help evaluate polypharmacy: 
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Table 1:  Questions to Assist in Evaluating Polypharmacy 
1. Is each medication necessary? 
2. Is the drug contraindicated in the elderly? 
3. Are there duplicate medications? 
4. Is the patient taking the lowest effective dosage? 
5. Is the medication intended to treat the side effect of another medication? 
6. Can I simplify a drug regimen? 
7. Are there potential drug interactions? 
8. Is the patient adherent? 
9. Is the patient taking an OTC medication, an herbal product, or another person’s medication? 
 
The challenge with these questions is that it takes time to obtain the most accurate 
information, to consider the situation and options, and to follow-up with the patient.  
Additionally, with so many other contributing factors such as pharmacokinetics, adherence, 
reliability of information, etc. that it can be challenging to determine which of the medications, if 
any, could be the source of the adverse event. 
2.1.8 MULTIPLE SOURCES OF PHARMACEUTICALS 
2.1.8.1 Multiple Pharmacy Stores 
Although, mentioned a few times in the literature as a potential risk factor, there is very little 
literature looking at the prevalence or impact of patients utilizing numerous pharmacies to 
concurrently fulfill medications.  Choosing a pharmacy involves many factors:  geographic 
proximity, familiarity, established relationships with the pharmacist/pharmacy, satisfaction with 
service and quality, low waiting times, time efficiency by being able to shop while prescription is 
being filled, lower costs/special deals, the insurance plan is accepted by pharmacy, or based on a 
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recommendation family/friend to name a few.  Whether a patient ends up visiting multiple 
pharmacies by chance or choice, the ability of a pharmacist at one pharmacy to detect an adverse 
event with only a partial medication history increases the risk of an ADR occurring. 
2.1.8.2   Mail-Order Pharmacy 
Mail-order sales have doubled from 1998 to 2001, from $10.4 billion to $20.7 billion, 
representing 12% of U.S. prescription drug sales (Foundation 2002).  This growth is partly 
attributed to drugs that are supplied through distributors at prices are both reduced for the 
customer and the client, such as the employer.  Thus, pharmacy benefit managers of companies 
are encouraging enrollees who take drugs regularly to order their prescriptions by mail. 
 
The U.S. Department of Defense (DoD) converted to a mail order system in the early 1990s.  
Under the co-pay system a 90-day supply for most drugs was $9 for branded products or $3 for 
generics.  The advantages for switching to a mail-order pharmacy include:  (1) savings of 66% in 
filling of 90-day supply versus a 30 day supply in the retail network; (2) the government saves 
on each prescription by using federally-negotiated price discounts with the mail-order pharmacy; 
and (3) convenience of mail order for patients versus traveling to a pharmacy or military base.  In 
1999, sales through the mail order pharmacy order program was $84 million and was expected to 
reach over $1 billion in 2000 and a savings to the DoD of $55 billion (Laurent 2000). 
 
 Ordering medications through the mail breaks the pharmacist-patient relationship as there is 
no longer a face to face interaction.  Additionally, there are fewer insurance companies who 
accept claims through a mail order company causing individuals to pay out-of-pocket.   
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2.1.9 SAMPLE MEDICATIONS 
“Everybody likes something free, and free prescription drug samples are no exception.  Patients 
love to receive them, and doctors feel good about handing them out” (Chimonas and Kassirer 
2009).  Drug samples are prescription medications packaged as one or more dosage units by a 
manufacturer or distributor.  The drug samples are provided by a pharmaceutical company to a 
licensed practitioner free of charge, not to be sold but to promote the eventual sale of the drug.  It 
may be a packet, card, blister pack, bottle, container, or other single package.  Drug samples are 
vital for patients when a pharmacotherapeutic regimen is not well established, are poor, 
uninsured, underinsured, or in need of medications when pharmacies are closed.  Drug samples 
are not to be used for long term or maintenance therapy as this bypasses the pharmacist and the 
typical safety checks. 
 
In a survey of 131 physicians investigating what are their motivators for dispensing sample 
drug medications, physicians were presented with three different scenarios and asked to indicate 
their preferred drug choice, whether they would use a drug sample, and subsequently prescribe 
the sampled medication.  In the first scenario, an insured woman with an uncomplicated lower 
urinary infection, 17% of respondents reported they would dispense a drug sample, of these 
respondents, 95% would dispense a drug sample that differed from their preferred drug choice.  
In the second scenario, 27% of respondents would dispense a drug sample to an uninsured man 
with hypertension, and 91% of these respondents would dispense a drug sample instead of their 
preferred drug choice.  In the third scenario, 82% of respondents reported they would dispense a 
drug sample to an uninsured woman with depression.  Of these respondents, 49% indicated they 
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would dispense a drug different from the preferred drug choice.  In all three scenarios, avoiding 
cost to the patient was the most consistent motivator (Chew, O'Young et al. 2000). 
 
Chimonas and Kassirer (Chimonas and Kassirer 2009) highlighted negative consequences of 
getting something free when it comes to patient-health.  The systems for distributing samples are 
insufficiently controlled, poorly documented, and stored improperly.  The samples also have 
inadequate instructions for use, are poorly labeled or packaged, and aree often expired.  A 
physician giving sample medications directly to the patient by-passes the pharmacist who is 
often involved in identifying potential harmful drug interactions, intercepting inadvertent 
medication errors and providing patient-friendly printout of instructions.  If the distribution of 
drugs is inadequately documented in the patients’ records, these patients would not be informed 
to discontinue the medication in the event of a product recall or emergence of new drug 
complications.  Additionally, sample drugs are usually the newest agents on the market and not 
time-worn or well-tested drugs.  An example is Vioxx which was voluntarily recalled in 2004 by 
Merck & Co., Inc. due to its dangerous and possibly deadly side effects and after the Food and 
Drug Administration issued a public health advisory.  This arthritis drug has been linked to an 
increased risk of heart attacks, strokes, hypertension, and cardiovascular problems.  Physicians 
would be unaware that they needed to follow-up on these patients if it was not documented in the 
patient’s chart. 
 
In looking at who receives the sample medications, in a U.S. nationally represented survey, 
only one-third of all sample recipients were of low income (defined as less than 200% of the 
poverty line).  In contrast, those in the highest income category were most likely to have received 
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the free samples, and those who had continuous health insurance (Cutrona, Woolhandler et al. 
2008).  Many of the samples are appropriated by physicians for personal or family use or end up 
in an ‘unknown destination” (Morelli and Koenignsberg 1992) (Westfall, McCabe et al. 1997).  
In one study, nearly half of the pharmaceutical representatives surveyed reported using samples 
themselves or giving them to their friends and relatives (Tong and Lien 1995).  Additionally, the 
cost of drug samples raises the cost of health care as companies recover marketing costs through 
higher prices and increased sales volume.  The use of samples also promotes the use of 
expensive products as these are the products patients are most likely to receive as samples. 
2.1.10 OVER-THE-COUNTER (OTC) PRODUCTS  
Lam and Bradley looked at the prevalence ofuse and misuse of self-prescribed medications, as 
well as, individuals’s opinions concerning nonprescription medications and dietary supplements 
in assisted living facilities.  Among 29 women and 16 men with a mean (± SD) age of 84.8 ± 6.9 
years and a mean of 9.9 ± 6.4 years of education, 84.4% were using self-prescribed OTC 
medications and dietary supplements at the time of this study. A mean of 3.4 products was used 
per participant. Nutritional supplements were most frequently used (32% of products), followed 
by gastrointestinal products (17%), pain relievers (16.3%), herbals (14.4%), topical products 
(12%), and cold/cough products (8.5%). Potential misuse was identified in 23 (51%) of the 
participants. Problems in the use of products included duplication (70%), potential 
drug/disease/food interactions (20.8%), and other inappropriate use (9.1%). The majority (76%) 
of the participants believed the products were helpful in maintaining health, 56% of them wanted 
more product information, 49% sought product information from family and friends which is 
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more often than their physicians and nurses (40%) or pharmacists (11%) for advice  (Lam and 
Bradley 2006). 
 
 Over-the-counter products can have varying effects on a patient.  The most notable is the use 
of cough and cold medications that contain nasal decongestants, antihistamines, cough 
suppressants, and expectorants commonly used alone or in combination with other medication to 
temporarily relieve symptoms of upper respiratory tract infection in children less than 2 years.  
These coughs and cold medications have been associated with adverse events, including 
overdoses and deaths (CDC 2007). 
2.1.11 HERBAL MEDICINES 
Despite widespread use, the efficacy of many herbal medicines remains unproven or the 
evidence is weak (Ernst 2001).  The decision to use or not use herbal medicine should ideally be 
based on a careful risk/benefit analysis.  Herbal medicines present several types of risk to health, 
including intrinsic toxicity, adulteration with toxic substances, and negative herb-drug or herb-
herb interactions.  Additional specific risks for older people result from reduced clearance risks 
for older people result from reduced clearance rates of pharmacologically active compounds 
(Salmond 2002) and a general increase in susceptibility to toxic effects of drugs (Guyton 1991). 
 
The potential for interactions is augmented because even standardized herbal extracts usually 
contain many rather than a single active ingredient (Guyton 1991) and use of multiple herbal 
medicines at the same time is common.  In a sample size of 804 patients surveyed, 15% used 
herbal medicines.  In 7% of the herb uses (12 cases) there were possible herb-drug reactions that 
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were classified as mild (no significant harm to patients) with the most common among diabetics 
taking nopal (prickly pear cactus) resulting in hypoglycemia (Bush, Rayburn et al. 2007).  Many 
healthcare providers are not aware of CAM use by their patients.  In one study 35% of patients 
discussed their use of CAM with their physicians.  Most patients did not think that it was 
important for their physicians to know about it, and 20% did not think their doctor would 
understand (Eisenberg, Kessler et al. 201).  This is further exacerbated by inadequate 
mechanisms to obtain/report ADRs associated with the use of herbal medicines and herb-drug 
interactions that would enable a physician to properly assess the use of CAMs. 
 
In a survey of 271 individuals aged over 50 years in Britain, a mean of 2.26 prescription 
drugs and 5.91 herbal and nutritional supplements, including 2.66 herbal extracts were reported.  
Of the total number of 1218 herbal and nutritional supplements identified, 32.5% were reported 
to their doctors.  The researchers found neither an obvious trend to either increase or decrease the 
use of herbal and nutritional supplements with age in either gender.  The top seven single herbs 
that are reported used by patients are shown in the table below (Canter and Ernst 2004).  While, 
the possible interactions are listed, it should be noted that the interactions are diverse and 
difficult to define and separate from other symptoms and conditions, i.e. increased effects of 
anticoagulants. 
 
Table 2:  Examples of the Suggested Use and Potential Effects of CAM 
Herb Reported Reasons  for Use 
Adverse Events 
Reported Possible Interactions 
Allium 
salivum 
Heart function; general 
health; treat/prevent URTI; 
lower cholesterol; antiseptic 
/antibacterial; immune 
system; blood pressure; other 
Dilute motion 
Increased effects of anticoagulants, 
antiplatelet drugs; warfarin; reduces blood 
levels of anti-AIDS drug ;  inhibitory 
effect on cytochrome P450 isoenzymes; 
antihypertensive; lipid-lowering drugs 
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Table 2 continued 
Ginkgo 
biloba 
Mental function; circulation; 
general health; peripheral 
vascular disease; tinnitus; 
migraine; other 
Pain behind the 
eyes; bad taste; 
red and swollen 
fingers; 
headache; 
withdrawal 
headache and 
shakes; tingling 
feet; increased 
appetite 
Increased effect of anticoagulants; 
increased risk of seizures with 
antiepileptic drugs and coma with 
trazodone; increased blood pressure with 
thiazide diuretics 
Echinacea Treat/prevent URTI; immune system; other None 
Increased effect of chemotherapy; 
decreased effect of drugs metabolized by 
cytochrome P450 isoenzymes; decreased 
effect of immunosuppressants 
Oenothera 
biennis 
Menopause; hair and skin; 
arthritis; breast pain; general 
health; other 
Blood in urine; 
indigestion 
Interaction with antipsychotics; risk of 
seizure with phenothiazines, other 
antiepileptic drugs and anaesthetics 
Hypericum 
perforatum Depression; anxiety; other 
Increased 
sweating and 
aggravated 
menopausal 
flushes; 
headache; 
nocturnal 
erections and 
facial hair 
growth 
Increased effects of digoxin; MAO 
inhibitors and serotonin uptake inhibitors; 
decreased effect of antiepileptic drugs and 
antidiabetics; increased effect of drugs 
causing photosensitivity; prolonged 
opioid-induced sleeping time; is a hepatic 
enzyme inducer; increases action of P-
glycoprotein, thereby reducing plasma 
levels of drugs metabolized metabolised in 
the liver, including theophylline, 
ciclosporin, phenprocoucmon; warfarin, 
oral contraceptives; delirium with 
Vaeriana officinlis and loperamide 
Ginseng General health; energy; menopause; potency None 
Eleutherococcus senticosus may inhibit 
metabolism of hexobarbital; increase 
execretion of thiamine (vitamin B1); 
riboflavin (vitamin B2) and ascorbic acid 
(vitamin C); interact with cardiac, blood 
pressure medicines, antihyperglycaemics; 
elevate digoxin; increase effects of 
monomycin, kanamycin and insulin, 
Panax ginseng may interact with MAO 
inhibitors, stimulants and phenelzine; 
increase effect of antihyperglycaemics, 
increase INR with warfarin and manic 
symptoms with phenelzine 
Aloe 
barbadensis 
Digestion; general health; 
constipation; arthritis Stomach pains 
Long-term use may potentiate cardiac 
glycosides, corticosteroids or 
antiarrhythmic drugs (loss of potassium); 
reduce intestinal absorption of other drugs; 
increased action of antidiabetics 
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The Dietary Supplement Health and Education Act (DSHEA) of 1994 prohibits the FDA 
from the regulation of dietary supplements as food additives.  Thus without official standards 
governing the production of alternative therapies in the United States, the potency and purity of 
these products produced by different companies are subject to substantial variation (Fraunfelder 
2004).  For example, ginseng (Panax ginseng) was evaluated by the American Botanical Council 
in 2001.  They found that only 52% of products marketed as ginseng actually contained any of 
this botanical (Dharmanada 2002).  Thus the difficulty in determining the extent of interactions 
is exacerbated by the lack of standards in the manufacturing of CAM products being sold 
presenting a risk factor for adverse events.  In an effect to increase public safety, starting 
December, 2007 all adverse event reported to a manufacturer including herbal and nutritional 
products must be reported to the FDA within 15 days, thereby allowing the FDA to look at 
trends. 
2.1.12 HEALTH INFORMATION BY OTHER SOURCES 
Individuals are daily bombarded with messages about how a particular drug/product is beneficial 
to their health.  This is most obviously seen through commercials, magazine advertisements or 
articles, the personal testimonies of friends and family members who can have similar findings 
but do not have the same underlying health status, and the growing access to information through 
the internet whether an advertisement, or an article written by a company or ‘expert’.  The 
amount of information given is often brief and to the point, with the list of risks either quickly 
announced as in a commercial, in small print as in most paper advertisements, or anecdotal as 
from friends and family members.  Regardless, obtaining health information from other sources 
than one’s physician is prevalent. 
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The direct-to-consumer marketing as in the commercials, advertisements and internet can not 
only interfere with the physician-patient relationship but puts the consumer in control of their 
own health.  In a national survey looking at factors influencing consumers’ opinions about the 
utility of direct-to-consumer, the researchers found that consumers of varying demographics 
value the information about both risks and benefits.  Their perception of risk information is more 
important in shaping their opinions than learning about benefits, however, consumers believe 
that the quality of benefit information is better than that of risk information (Deshpande, Menon 
et al. 2004). 
 
In the 2003 Health Information National Trends Survey of 6369 individuals, 63% of the US 
adult population surveyed reported going online for health information.  While 62% of 
respondents expressing a lot of trust in physicians with 49.5% preferred going to the physician 
first for information, 48.6% actually reported going online first (Hesse, Nelson et al. 2005).  The 
ease and availability of information on the internet also presents challenges to consumers with 
them having to sort through the enormous amounts of information, which at times can be 
conflicting.  Therefore, health information over the internet can be considered as a third opinion.  
Searching the internet relies on the consumer’s ability to determine what needs to be searched 
and how.  But even with a good search strategy, the internet can contain inaccurate and 
misleading information.  Molassiotis and Xu searched for information on herbs and cancer over 
the internet.  Forty-three sites were identified by applying the criteria of DISCERN to judge the 
quality of health information.  Most of the sites were rated as low quality on the accuracy of 
information, in revealing the sources of information, in biasness in their presentation of 
information or on the frequency of updates.  It was found that commercial sites had the most 
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inaccurate or misleading information, emphasizing only the positive aspects of the use of herbs, 
with little or no evidence.  Of the 43 sites, 7% of sites discouraged the use of conventional 
medicine.  Additionally most of the websites had a school level of college reading level making 
it difficult for many individuals to understand the information presented (Molassiotis and Xu 
2004). 
 
Information gathered from other sources, whether commercials, advertisements, internet, 
friends or family members requires the individual to process and synthesize the information 
relative to his/her condition.  The ability to do this is related to his/her level of health literacy.  
Can a patient differentiate between ‘good’ and ‘bad’ information, appropriately weigh the risks 
of one medication/CAM with the effects of another medication/CAM?   For example, can an 
individual weigh which ADRs are not clinically significant such as in the combined use of 
angiotensin-converting enzyme inhibitor and a potassium-sparing diuretic.  This combination is 
accepted and used with good results, although, occasionally predisposes a patient to developing 
life-threatening hyperkalemia.  A patient upon reading could discontinue their medication 
without first consulting their physician.  There is undoubtedly a variation in the health literacy of 
individuals, in their understanding of their own condition and the information being 
communicated, whether to discuss this with their physicians, or to try it on their own. 
2.1.13 CHANGING MEDICATION SCHEDULES 
In a case study of 76 year old patient receiving warfarin (coumadin) therapy on an outpatient 
basis due to deep vein thrombosis, the patient’s condition warranted a dosage change.  It was 
changed from 2 MG/day to 4mg of warfarin for 6 days/week and 2mg of warfarin one day/week. 
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The change in dosage was noted in the outpatient EMR chart notes but the initial dosage of 
“WARFARIN (COUMADIN) NA 2MG TAB TAKE AS DIRECTED BY COUMADIN 
CLINIC BY MOUTH EVERY DAY TO PREVENT BLOOD CLOTS” was left unchanged on 
the patient’s medication list. The prior medication was copied and pasted with the instructions 
‘take as directed’.  The change was noted in the EMR chart notes, but left unchanged in the 
patient’s medication list.  Before the exact information was obtained, the patient had three 
hospitalizations.  What is the reason for this discrepancy?  In looking at the patient’s interests of 
costs the physician did a work-around to reduce burden on the patient.  A change in prescription 
would have monetary costs for the patient.  The result is that this leads to confusing information 
and relies upon individuals to remember the correct prescription.  The CPOE is often written 
imprecisely by the anticoagulation clinic to accommodate the frequent dosing changes from 
month to month.  Whenever a dosage is changed it results in a new co-payment.   This work-
around has created a problem of inaccurate information only if the patient knows and can 
verbalize the correct dosing regimen, the clinic note is available and is read, and this ‘work 
around’ is anticipated by all those who use the system (Caudill-Slosberg and Weeks 2005). 
2.1.14 IDENTIFYING AN ADVERSE EVENT 
With the many possible drug interactions – i.e. drug-drug, drug-disease, drug-food, drug-herbal 
and drug- nutritional – combined with management of co-morbidities and polypharmacy, it is 
difficult for anyone to tease out the agent which is causing the adverse event, which may even 
occur several days/weeks after a drug is discontinued.  In the following table Mallet et al. 
(Mallet, Spinewine et al. 2007) has recommended the following questions to help clinicians 
detect drug interactions. 
37 
Table 3:  Questions to Help Assess an Adverse Event 
1. Identification of the nature of the interaction. 
a. Is there a potential interaction between a drug and another drug, disease, food, 
nutrition, or a combination of any of these factors? 
2.    Understanding the mode of action of the interaction. 
a. Can the pharmacokinetic interaction be explained in terms of absorption, 
distribution, metabolism, or elimination of the drug? 
b. Is the interaction pharmacodynamic? 
c. What is the time course of the interaction?  Several factors will affect the time 
course of the interaction, such as the mechanism of the interaction, the 
pharmacokinetics of the object drug, the nature of the interacting drug (inhibitor, 
inductor, substrate), the sequence of prescription, and the baseline concentration 
of the target drug. 
d. Is this interaction well documented in published work, or are there strong 
suspicions (theoretical or clinical) to expect that an adverse drug interaction 
might take place? 
e. Would the potential interaction appear when a drug is added or discontinued? 
3.   Identification of potential or real clinical outcomes for the patient. 
a. What are the short and long-term clinical outcomes for the patient? 
b. Is the patient having new problems (e.g. fallings and gait difficulties, bleeding, 
blood pressure changes, confusion) that can be explained by a drug interaction? 
c. Does the patient have risk factors that might increase the likelihood of an adverse 
outcome (e.g. with regard to comorbidities, other drugs taken, dose and duration 
of treatment, pharmcogenetics)? 
4.   Monitoring and follow-up for potential drug interactions 
a. Is an appropriate monitoring plan in place – e.g. INR, serum drug concentration, 
electrolytes, blood pressure, glucose concentration?  Who is responsible for 
follow-up to promote continuity of care?  Does this plan account for the 
estimated time course of the interaction? 
b. Are caregivers vigilant to monitor for the appearance of new symptoms after any 
changes to drug treatment? 
c. Has the drug interaction been documented in the patient’s medical record? 
 
Many of these questions can be difficult or time consuming to answer.  The mode of action 
of the interaction may require repeat visits through monitoring and additional testing to discern.  
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Thus due to the multiple factors involved, it is very difficult to pin point the exact causation of 
the interaction. Even when the causation is known, there may be limited alternative drugs 
available to treat the condition.  Table 3 looks at the drug interaction, but fails to take into 
account the additional factor of human error or involvement, such as a patient altering or the 
pharmacist dispensing the incorrect dose, both of which may be unknown to the healthcare 
provider without a detailed interview of the patient.  
 
There are numerous possibilities for the root cause of an ADR that makes identifying an 
ADR so difficult and likely underreported.  Several investigators, including researchers at the 
FDA have developed logical evaluation procedures or algorithms to evaluate the probability of 
an ADR.  Algorithms such as the widely accepted Naranjo algorithm all have the aim of helping 
the clinicians investigate whether that particular drug is known to cause such a reaction, rule out 
alternative explanations, and establish a temporal link between the onset of the reaction and drug 
administration (Kelly 2008).  A large part of the challenge is the lack of any mechanism to obtain 
information about the prevalence of an ADR to confirm the observation.  There is not a 
consistent place or requirement to report ADRs for marketed drugs as the question becomes who 
is responsible for verifying these events and the association to a drug?  The other hindrance to 
reporting an ADR is that it takes time to identify and monitor the contributing factors. 
2.2 CAUSE AND EFFECT DIAGRAM 
The Cause and Effect Diagram, also known as the ‘fishbone’ or ‘Ishikawa’ after its creator 
Kaoru Ishikawa, is used to systematically list all of the different causes, potential or real, that 
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result in a single effect or output.  Applying the cause and effect diagram to the prescription 
process, illustrates causes that could be attributed to an adverse event.  This graphical 
representation illustrates the relationship between a given outcome, ADR, and the factors that 
influence the outcome.  It helps to graphically present and identify areas where there may be 
problems.  
 
 
Figure 2:  Cause and Effect Model for Adverse Event 
 
The cause and effect diagram applied to the prescription process revises the medication process 
in Figure 1 by adding in the above risk factors for an ADR.   By diagramming the possible steps 
and causes, one can identify possible root causes and the basic reasons for a specific effect, sort 
out and relate interactions among factors, and analyze existing problems so that corrective action 
can be taken. 
Physician Pharmacist 
Patient 
Adverse Event 
Incorrect 
 
Wrong medication 
 
Incorrect dosage Similar drug 
 
Wrong dosage 
 
Wrong medication filled 
Unclear handwriting 
Patient does not fill 
 
Patient does not take 
medication or as prescribed 
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2.3 APPROACHES TO REDUCING MEDICATION ERRORS 
2.3.1 MEDICATION SHEET / LIST 
The medication list in a patient’s chart quickly conveys all medications the patient is currently 
taking, all past medications and the exact combinations of medications being taken at the time of 
each patient visit.  It commonly lists allergies, medication (brand & generic), dosage (strength 
and frequency) and date reviewed (Rooney 2003).  All if not most of the information is obtained 
by a healthcare professional through the patient/care provider and updated on subsequent visits.  
Herbal medicines (Cockayne, Duguid et al. 2005) and OTC are infrequently gathered and 
documented. 
 
Table 4:  Advantages and Disadvantages to Medication sheet /list 
Advantage Disadvantage 
1. Efficient charting 
2. Safer refills 
3. Communication with other physicians 
4. Facilitates information recall 
5. Documents allergies 
1. Located in only one place 
2. Subject to handwriting errors. 
 
2.3.2  PRE-PRINTED ORDER SHEETS 
Pre-printed order sheets have been introduced to reduce writing and transcription errors.  The 
forms have pre-printed standardized information such as the name of the drug with the remaining 
patient-specific information to be entered in by the healthcare provider.  In a pediatric emergency 
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department out of 2058 visits reviewed, 411 (52.2%) orders were on regular form (blank), and 
376 (47.8%) were given a new form requesting specific fields – date, time, dose, patient weight, 
dose, frequency, route.  The drug errors were noted 68 (16.6%) and 37 (9.8%), respectively.  
Thus the use of a form requesting specific information decreased errors by two-fold. 
2.3.3 MEDICATION RECONCILIATION 
2.3.3.1 Reconciliation by Patients 
Another approach is requesting that the patient keep an updated list.  Varkley et al. (Varkley, 
Cunningham et al. 2007) conducted a study comparing medication histories documented in the 
EMR versus an intervention.  In the intervention, patients were sent a reminder letter to bring 
their medication bottles or an updated list.  The patients were then asked to verify and correct the 
information in the printout from the EMR.  The nurse or pharmacist then updates the EMR list 
and generates a new medication list.  Through this intervention, the researchers observed 
statistical significant showing a 88.9% to 66% reduction in prescription errors.  The majority of 
discrepancies noted were minor. 
2.3.3.2 Reconciliation by a pharmacist 
In a literature review examining (1) studies documenting the interventions made by pharmacists 
and their role in inpatients (2) articles presenting the outcomes of a satellite pharmacy and (3) 
articles examining pharmacist involvement in pediatric outpatient clinics, the researchers 
concluded that the pharmacist review of medication charts is very important in identifying 
medication errors (Sanghera, Chan et al. 2006). 
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In one study, a pharmacist working an emergency department prospectively obtained the 
medical histories from the patients.  There was a noted increased compliance to the hospital’s 
medication reconciliation policy for admitted patients, and the medication histories had fewer 
errors (Hayes, Donovan et al. 2007).  In a separate study, pharmacists also improved the care 
(Kabouli, Hoth et al. 2006) in an emergency department.  The study showed a rate of errors 
16.09 per 100 medication orders with the control group, compared with 5.38 per 100 orders in 
the intervention group (Brown, Barnes et al. 2008).  In a randomized controlled trial, telephone 
counseling and continuous reinforcement by a pharmacist was associated with a 41% reduction 
in the risk of death, and an increase in compliance (Wu, Leung et al. 2006) 
2.3.3.3 Healthcare team 
In a prospective study in an ambulatory internal medicine clinic, the completeness of medication 
documentation in the electronic medical record was analyzed.  The intervention involved 
standardizing the entire visit process from scheduling the appointment to signing of the final 
clinical note by the physician.  Each member of the healthcare checked the accuracy of the 
documented medication list.  Immediately after the intervention, a second data collection was 
done to assess the effectiveness of the intervention.  Completeness of the individual medication 
increased from 9.7% to 70.7% (p<0.001).  However, completeness of the entire medication lists 
only improved from 7.7% to 18.5%.  This was mainly due to the lack of route (85.5%) and 
frequency (22.3%) for individual medications listed.  In addition, documentation of over-the-
counter and ‘as needed’ medication was often incomplete.  The incorrectness in the medication 
list was mainly due to misreporting of medications by patients or failure of clinicians to update 
the medication list when changes were made (Nassaralla, Naessens et al. 2006). 
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In using the exact same intervention separated by one year, clinical pharmacists performed 
drug therapy reviews, educated physicians and patients about drug safety and polypharmacy, and 
determined corrective actions to reduce polypharmacy.  Patients who were prescribed five or 
more different drugs concurrently for long-term use (>199 days) in the six months before the 
search through claims data were considered at a high risk of harm from polypharmacy.  
Pharmacy claims were further evaluated to identify patients with the following combinations:  
two or more narcotics; two or more benzodiazepines; the combination of a nitrate plus sildenafil, 
and in patients with glycoslyated hemoglobin values above 8.5%; or three or more oral 
antidiabetic drugs.  Information on prescription cost/member/month, number of 
prescriptions/member/month, and rates of polypharmacy events/1000 members were measured 
before and after each of the two interventions.  In the first and second interventions, 6693 and 
6039 patients, respectively, were identified.  After the first intervention, the overall rates of 
polypharmacy events decreased from 29.01 to 9.43/1000 patients (67.5% reduction). The number 
of prescriptions/member/month decreased from 4.6 to 2.2 (52.2% reduction), prescription 
cost/member/month decreased from $222 to $113 (49.1% reduction), and overall institutional 
drug cost was reduced by $4.8 million.   Six months after the second intervention, the overall rate 
of polypharmacy events was reduced from 27.99 to 17.07/1000 (39% reduction), the number of 
prescriptions/member/month decreased from 4.5 to 4.0 (11.1% reduction), and prescription 
cost/member/month declined from $264 to $239 (9.5% reduction). Overall institution drug costs 
were reduced by $1.3 million.  Therefore, by providing clinical information and decision support 
there were reductions in both polypharmacy and cost. 
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2.3.4 COMPUTERIZED PHYSICIAN ORDER ENTRY (CPOE) 
CPOE is reported to: decrease delay in order completion; reduce errors related to handwriting or 
transcription; allow order entry at point-of-care or off-site; provide error-checking for duplicate 
or incorrect doses or tests; and simplify inventory and posting of charges (Farlex 2008).  It is also 
reported to saves hundreds of billions of dollars in annual costs, it can offset shortages in nursing 
supply and is strongly advocated by researchers, clinicians, pharmacists, business councils, the 
Institute of Medicine, state legislatures, health care agencies and the lay public.  The use of a 
CPOE implies that medication prescriptions will be written in one location, and all the 
information about the patient’s medicine will be accessible by everyone involved in the patient’s 
healthcare.  
   
Studies have found that CPOE improves time in delivery and accuracy of medications by 
standardized scripting and computer generated prescriptions, thus eliminating confusing written 
physician’s notes (Anonymous. 2003).  Bates et al. (1998) in a controlled trial found that CPOE 
can reduce serious medication orders by 55%.  Evans et al. (1998) found that a clinical decision 
support system can reduce the errors even further. Tierney et al. (1993) in a randomized 
controlled trial, order entry reduced 12.7% in total charges and 0.9 day decrease in length of stay.  
Features of CPOE often include use of a medication list (Payne, Nichol et al. 2002), computer 
alerts notifying when there is a potential drug-drug interaction (Payne, Nichol et al. 2002), 
pharmacy information system (Payne, Nichol et al. 2002), and ability to override the system 
(Carpenter and Gorman 2002).   
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The use of a CPOE in a pediatric clinic reduced the number of non-intercepted serous 
medication errors by 7%.  The researchers also identified several human-machine interface 
problems, particularly surrounding selection and dosing of pediatric mediations (Walsh, 
Landrigan et al. 2008).  Jacobs et al. found similar findings (Jacobs 2007).  In comparing a 
pediatric ward that implemented a CPOE with a ward that did not, there was a 40% decline in 
errors in the ward with the CPOE (Potts, Barr et al. 2004).  There is also a growing pressure to 
use a computer prescription system.  For example in 2008, Massachusetts’ largest health insurer, 
Blue Cross Blue Shield, will require doctors to use computer prescription systems by 2011 if 
they want to qualify for bonus payments.   
 
Table 5:  Advantages and Disadvantages to CPOE System 
Advantages Disadvantages 
1. discrete orders 
2. capability of drug-drug interaction 
3. quality assurance 
4. free of handwriting identification problems 
5. faster to reach the pharmacy 
6. less subject to error associated with similar drug 
names 
7. easily linked to identify the prescribing physician 
8. able to link to ADR reporting systems  
9. available and appropriate for training and education 
10. claimed to generate significant economic savings 
11. with online prompts, CPOE systems can  
a. link to algorithms to emphasize cost-effective 
medications 
1. requires redesigning of 
workflows and analysis of 
information 
2. ongoing training of staff 
3. discrete orders replaced free text 
4. expensive to implement and 
maintain 
a. initial purchase or licensing of 
systems  
b. hardware and other 
infrastructure requirements 
c. the savings are not seen as a line 
item on budgets that can be used 
elsewhere 
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Table 5 continued 
b. reduce underprescribing and overprescribing 
c. reduce incorrect drug choices 
12. increase access to the medical record 
13. efficiency gains – lab, pharmacy 
14. decrease in billing errors and improved cash flow 
15. reduction in costs for paper storage 
16. reduction in prescription drug costs 
17. improved ability to produce patient education 
materials and medication lists 
18. improved ability to access guidelines and standards 
for good prescribing 
19. reduction in ADE 
20. reduction in medical costs associated with ADE 
21. improvements to patient health related QOL 
22. improved ability to conduct research to further 
patient care. 
5. b.   hiring additional staff (eg IT) 
6. cost of implementing systems 
7. integration of systems with 
existing systems 
8. lost productivity while 
becoming familiar with the 
system 
9. upgrade of systems / equipment 
 
  
 
In the National Health Care Survey (NHCS) conducted by the Centers for Disease Control 
(CDC) surveying a variety of health care settings, during 2001-03, electronic medical records 
were used in physician offices (17%), hospital emergency (31%) and outpatient departments 
(29%).  In physician offices, information technology was more frequently used for billing 
patients (73%) than for maintaining medical records electronically (17%) or ordering 
prescriptions electronically (8%).  Additionally, automated drug dispensing systems were 
available in hospital emergency departments (40%) more frequently than in outpatient 
departments (Burt and Hing 2005).  The survey however, did not indicate how many of these 
EMR systems are connected with other offices.  Similarly several years later, in a survey of 
3,350 office-based physician practices nationwide only 12.4% or physicians use comprehensive 
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EMR systems in 2006, which was not significantly up from 9.3% in 2005.  The CDC defined 
comprehensive EMR systems as those with computerized orders for prescriptions and tests and 
has the ability to report test results and clinical notes.  They have found that doctors do not 
always use all EMR features available in their systems.  The CDC found that about 2.3% of 
physicians turn off some available features, which most likely were to result in improved 
management and quality of care.  Of the physician reporting using the full EMR, only 63.7% use 
guideline-base intervention or screening test reminders, 52.9% use CPOE, and 46.5% 
computerized test order entry (Manos 2008).  However, only 30% of hospitals use CPOE 
(Goldrick and ALARIS. 2003) partly due to the expense in setting up a system and the lack of 
interest amongst physicians to use the system. 
 
Despite all of the successes reported by EMRs, 30% of EMR implementation attempts have 
failed over the past few years, due to a variety of reasons (poor project management, technical 
challenges, and a failure to create a compelling business model for the participants (Castro 
2007).  Thus not only is cost a consideration, but also presentation and implementation of the 
EMR are keys to success.  Some of the criticisms against CPOE are that the information can be 
misleading and inaccurate.  Use of an antiquated software and poor system integration whereby 
viewing one patient can be up to 20 screens is a poorly designed system and interface.  One 
study found that 22 potential risks relate more to poor training (Keillor and Morgenstern 2005; 
Levick and Lukens 2005).  To assist in training of the EMR fixed orders facilitated resident 
training but requires less critical thinking (Hegedus 2005).  Many CPOE implementations 
involve agreeing on change on work patterns and thought processes of clinicians, rather than 
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focusing on the organization of work and continually analyzing causes of errors, reassessing and 
refining the system (Bierstock, Kanig et al. 2005). 
 
In a different pediatric clinic, several factors were found to lead to the increased mortality 
rate at Children’s Hospital of Pittsburgh’s Pediatric ICU when a CPOE was introduced.  The 
factors included – prescriber and staff inexperience caused slower entry of orders at first, use 
more staff time, and is slower than person-to-person communication in an emergency situation.  
Physician to nurse communication could worsen if each group works alone at their workstations.  
Additionally, automation creates a false sense of security, a misconception that when technology 
suggests a course of action, errors are avoided (Han, Carcillo et al. 2005).  In other settings, 
shortcut or default selections can override non-standard medication regimens for elderly or 
underweight patients resulting in toxic doses.  Frequent alerts and warnings could interrupt work 
flow, causing these messages to be ignored or overridden.  Additionally, CPOE and automated 
drug dispensing were identified as the cause of error by 84% of over 500 health care facilities 
participating in a surveillance system by the United States Pharmacopoeia (Santell 2004). 
 
In a qualitative and quantitative study of 261 house staff interacting with a CPOE system at a 
tertiary teaching hospital, the researchers found that a widely used CPOE system facilitated 22 
types of medication error risks.  Examples of facilitated medication error risks included CPOE 
displays that prevent a coherent view of the patient’s medications, pharmacy inventory displays 
mistaken for dosage guidelines, antibiotic renewal notices placed on paper charts rather than in 
the CPOE system, separation of functions that facilitate double dosing and incompatible orders, 
and inflexible ordering formats generating wrong orders.  These were classified as: 
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- Information errors: fragmentation and system integration failure 
o Assumed dose information based on pharmacy warehousing and purchasing and not 
clinical guidelines – ie. Guideline is 20-30 mg, but pharmacy stocks 10 mg, so 10 mg is 
displayed. 
o Medication discontinuation failure – ordering new or modifying existing is a separate 
process than discontinuing or cancelling.  Without discontinuing the dose, physicians can 
increase or decrease the amount (i.e. giving a double dose, every 6 hours and every 8 
hours). 
o Procedure-linked medication discontinuation faults – medication linked to procedures or 
tests, if the procedure or test is cancelled, the medication is not. 
o Immediate orders and give-as needed medication discontinuation faults – NOW 
(immediate) and PRN (give as needed) orders may not enter the usual medication 
schedule and are seldom discussed at handoffs. 
o Antibiotic renewal failure. To maximize appropriated antibiotic prescribing, house staff is 
required to obtain approval by infectious disease fellows or pharmacists.  Lack of 
coordination can produce gaps.  Typically before the third day, the house staff request 
continuation or modification and use a sticker on the chart.  However, when house staff 
order medications, they primarily use electronic charts, thus missing the warning stickers.  
It then becomes confusing to discern whether the antibiotic was discontinued or missed. 
o Diluent options are a new CPOE feature on some systems.  House staff is to specify 
diluents, but many house staff were unaware of impermissible combinations.  
Pharmacists catch many of these but it is time-consuming and not ensured. 
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o Allergy information delay.  CPOE provides feedback on drug allergies, after the 
medications are ordered. 
o Conflicting or duplicative mediations – does not display information available on other 
hospital systems 
- Human-machine interface flaws: machine rules that do not correspond to work organization 
or usual behaviors 
o Patient selection – patient’s names do not appear on all screens requiring the user to view 
multiple screens 
o Wrong medication selection – up to 20 screen may be needed to see all of the patient’s 
medications 
o Unclear log on/log off – can result in either unintended patients receiving medication or 
patients not receiving intended medication. 
o Failure to approve medications after surgery – when patients undergo surgery, the CPOE 
cancels their previous medications.  Surgeons must re-enter CPOE or reactivate 
previously ordered medications. 
o Post-surgery ‘suspended’ medications – patients needed to be logged out of post-
anesthesia care before CPOE will process medication orders. 
o Loss of data, time, and focus when CPOE is nonfunctional – periodic maintenance of 
crashes.  The CPOE manager estimated 2 or 3 weekly crashes of at least 15 minutes are 
common. 
o Sending medications to wrong rooms when the computer system has shut down – if the 
computer system is down when the patient is moved, the drug can be sent to the wrong 
room 
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o Late-in-day orders lost for 24 hours – orders requested for 7 am or tomorrow, if an intern 
enters in orders, and it is after midnight, the orders may come in the following day. 
o Process of charting electronically leads to inaccurate and delayed medication 
administration – nurses charting of medications contemporaneously, requires stop 
administering the drug, logging in to the computer, finding patient, individually entering 
medication time.  Up to 60% of nurses report that they do not enter medications in 
contemporaneously. 
The researchers (Koppel, Metlay et al. 2005) thus recommend emphasizing workflow, aggressive 
examination and resolution of technology problems, and diligent investigation of error causes 
that will support resolution. 
 
In a pre- and post-CPOE implementation study, 135 errors prior and 164 post were noted.  
The reported error rate per patient pre-CPOE was 5% and per prescribed dose 0.12%.  For six 
months immediately after CPOE implementation, error rate was 10.75% and 0.25%.  Seventy-
one percent (117/164) of errors were considered CPOE-related.  The majority (79%) did not 
reach the patient, 21% reached the patient with 1 reporting in harm to the patient.  Within the 
medication administration cycle – there were more transcribing errors (not entered by pharmacy, 
wrong dose, wrong medication, wrong patient into the pharmacy system) and fewer dispensing 
and administration errors (unauthorized dose, omissions).  In the prescribing process - 
inappropriate medication, duplicative orders, wrong patient, wrong dose were noted.    Some of 
the contributing causes were – (a) non-compliance to policy and procedure (40%) – e.g. a 
previous order may not have been discontinued when a new dose change was entered, resulting 
in two active orders for the same medication with different dosages. (b) computer entry errors 
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(25%) – wrong patient.  (c) initial load errors (19%) – entered as ‘scheduled’ versus “PRN”.  (d).  
computer design issues (10%) – two printouts for the same medication, thought duplicate but in 
the system stated one for today and one for tomorrow – as the date was not on the printout.  
(Bradley, Steltenkamp et al. 2006) 
 
In a separate study, nurses were asked to highlight concerns with a CPOE.  They noted that 
there is decreased access to nursing narratives - the nursing notes are embedded in huge volumes 
of electronic notes, nursing notes are either shift summaries of templates which are hard to read 
and may have as many of six pages with up to 100% of the fields empty.  Additionally, while 
numerical data is transcribed, written text is often bedside nursing narratives which remain 
handwritten and are not included in the EMR.  In the study, the nursing notes were found to have 
unique information linked to the ADR.  There was also a lack of decision support for medication 
administration (physicians entered 78% of all medication orders directly).  The rest of the 
medications were entered by pharmacists or nurses via verbal or protocol orders.  Drug-drug, 
drug-age, drug-lab alerts were triggered at the time the order was entered.  With multiple 
individuals involved in order entry, the nurses must frequently check the system for new orders 
entered.  The nurses review the orders and sign electronically that they have seen the order.  
However, as there is no decision support offered to nurses at the time of verification nor do they 
have access to the responses of the provider to the alerts given at the time of ordering, they are 
unaware of any drug-drug interaction alerts.  The system incorporated bar-code administration, 
but there were no drug-lab alerts due to lack of an interface.  The system also failed to code 
nursing data that often included bedside notes, decision support regarding questions of dosage, 
indications or expected side effects.  (Weir, Hoffman et al. 2005). 
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Studies on CPOE systems are difficult to replicate and compare due to the various types of 
CPOE systems that are being used.  Several CPOE systems are either bought as a package 
(Beyea, Hicks, et al., 2003) or are developed in house (Peth. 2003) (Schneider, 2002).  
Additionally, it is difficult to compare the local environment in which the CPOE system 
operates.  While many of the studies can be unique to the system and the healthcare environment, 
they outline factors that should be taken into consideration in the development and 
implementation of an EMR system. 
2.3.5 CLINICAL DECISION SUPPORT SYSTEM 
An integrated system includes CPOE, pharmacy and laboratory information systems, and an, 
electronic drug dispensing system.  A clinical decision support system assists healthcare 
professionals by combining a knowledge database with set available data to generate patient-
specific advice.  Through the use of a clinical decision support system most prescribing errors 
decreased in the selected categories studied, drug-allergy detection, excessive dosing, incomplete 
or unclear orders.  Seventy-three administration related errors were intercepted through bar-code 
scanning for every 100,000 doses charted (primarily wrong time, dosing earlier than scheduled).  
(Mahoney, Berard-Collins et al. 2007). 
 
Several CPOE systems use automated drug alerts during order entry to reduce ADRs.  In one 
study, out of 108 alerts, 0.9% were significant crucial alerts and 16% were significant drug 
interaction alerts.  Of the alerts, 61% involved duplication of medication or medication class.  
The rest involved topical medications, inhalers or vaccines.  The healthcare providers classified 1 
out of 9 automated alerts useful.  There was variability in the relevance of alerts, suggesting a 
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smarter system for critical alerts and the option to tailor the alerts to providers (Spina, Glassman 
et al. 2005). 
 
In a retrospective study examining collected medication and laboratory data from a 140-bed 
community hospital over a period of six months, the researchers applied the rules from a 
computerized knowledge base.  The aim was to determine if the resulting alerts might have 
allowed a clinician to prevent or lessen harm related to medication toxicity.  There were 8829 
activations of the rule set, generating a total of 3547 alerts.  In total, 528 were high or critical, 
664 were medium, and 2355 were low priority alerts.  The researchers reviewed 56 charts that 
were of high priority alerts, five were found to be non-preventable and two were preventable.  
Thus, by proportion it is estimated that by applying the rules from a computerized knowledge 
base, one would be able to identify 94 non-preventable and 37 preventable ADEs.  (Seger, Jha et 
al. 2007). 
2.3.6 PERSONAL DIGITAL ASSISTANT 
In contrast to a paper chart system that is moveable anywhere needed, an EMR system requires 
use of a computer linked to a central server.  Thus, a study was conducted to determine whether a 
point-of-care personal digital assistant based patient record and charting system could reduce the 
number of resident progress-note documentation discrepancies in a neonatal intensive care unit.  
There were significantly fewer documentation discrepancies of patient weights in notes written 
by using the PDA system.  There were no significant changes in the number of notes with 
documentation of medications or vascular-lines (Carroll, Tarczy-Hornoch et al. 2004).  This 
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suggests that the portability of a PDA at the point of care, can reduce some of the criticisms 
highlighted with EMRs as noted in the prior section. 
2.3.7 MEDICATION SAFETY VIA THE INTERNET 
In an effort to improve patient-physician communication, adult patients were enrolled into a 
patient internet portal at three primary care offices.  For patients receiving a new prescription or 
a changed prescription, a secure electronic message was sent to patients ten days after their 
appointment.  Patients were asked if they filled the prescription or experienced any medication-
related problems.  Their response was forwarded to their primary care physician.  Out of 1821 
patients, 267 charts were randomly reviewed for three months following the first electronic 
message.  Of the sent messages to patients, 79% were opened and 12% were responded to, of 
which 77% responded within 1 day.  Patients identified problems with filling their prescriptions 
(48%), problems with drug effectiveness (12%), and medication symptoms (10%).  Clinicians 
responded to only 68% of patients’ messages of which 93% were answered within 1 week.  
Clinicians often supplied or requested information (19%), or made multiple recommendations 
(15%).  During this time, patients experienced 21 ADEs of which 17 were reported electronically 
(Weingart, Hamrick et al. 2008), thus this may be an effective method of reporting given the 
information is reviewed and recorded and in a timely manner. 
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Table 6:  Advantages and Disadvantages to Medication Safety via the Internet 
Advantage Disadvantage 
1. Communication tool between the 
physician and the patient 
2. Can help triage questions. 
1. Requires that the patient be somewhat 
knowledgeable in ADRs and their health 
care 
2. Requires that the patient be comfortable 
with email technology. 
 
The above interventions demonstrate a reduction in adverse events and illustrate the 
numerous approaches taken in preventing, identifying and alerting healthcare providers of an 
ADR.  The choice of intervention is highly reliant on the problems, resources, and local 
environment. 
2.4 SOURCES OF MEDICATION DOCUMENTATION 
Medication can be documented in several sources.  The table below shows some of the most 
common sources and where one would expect to find out what medications a patient is taking.  It 
should also be noted that apart from the patient, each source has an element of time.  For 
instance, the source is considered to be accurate when the information is gathered, reviewed and 
updated.  If one of the sources is not updated, than this becomes less accurate and thus reliable 
information.  The check marks represent what information is expected to be located in which 
source. 
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Table 7:  Comparison of documentation sources for expected medication information 
Medication 
Sources of Medication Documentation 
Patient EMR Chart Specialist Pharmacist Insurance Company 
Name √ √ √ √ √ √ 
Dose √ √ √ √ √ √ 
Frequency √ √ √ √ √ √ 
Route √ √ √ √ √ √ 
Cost  √    √ √ 
Sample √ √ √ √   
Over-the-Counter √ √ √ √   
Alternative √ √ √ √   
 
2.4.1 MEDICAL RECORD CHART 
The paper chart is the oldest and most common method of documenting a patient’s history with a 
healthcare provider.  It serves as both the medical and legal record of a patient’s clinical status, 
care, history and healthcare involvement.  The detailed information is intended to provide a 
patient’s clinical condition by detailing diagnoses, treatments, tests, responses to treatment, as 
well as any other factors that may affect the clinical state of a patient.  The advantages and 
disadvantages of the medical record chart are outlined in Table 8. 
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Table 8:  Advantages and Disadvantages of the Medical Record Chart  
Advantages Disadvantages 
1. Easy to use – no specialized training 
needed 
2.   Portable – can be moved anywhere 
3.   Can handle multiple forms of 
communication (i.e. letters, faxes, etc.) 
4.   No technological equipment needed (i.e. 
computers, etc.) 
5.   Require large amounts of storage space 
6.   Requires dedicated staff for continuous 
filing 
7.   Low cost to implement 
1. Handwriting can be illegible 
2. Portable - Easy to misplace 
3. Long-term patients can have multiple  
charts which can be bulking and heavy 
4. Low security / privacy 
5. Chart can only be in one location at a time 
6. If chart is not available for filing, it may not 
contain the most recent information 
7. Sequential information can be difficult to 
synthesize in looking through several pages 
and sections 
 
Although, it is the least secure form, using the patient record does not require specialized 
implementation or equipment other than an office organization system.  One of the biggest 
challenges in keeping the medical chart with current information is having it accessible when 
new information becomes available.  Every time new information becomes available whether 
through a phone call with a patient, lab results, or correspondence from a physician if the chart is 
not present this increases the risk for missed documentation.  Some pieces of information are 
added into the chart at a later time and some never at all.  
 
Jampel et al. (Jampel, Parekh et al. 2005) looked at documentation of glaucoma and 
glaucoma medications by primary care physicians.   Glaucoma medications have potential side 
effects such as low blood pressure, reduced pulse rate, fatigue, and shortness of breath, as well 
as, can interact with other medications including for high blood pressure, colds and breathing 
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difficulties, diabetes, mental depression, mental problems and psychotic disturbances and heart 
rhythm control.  It was found that out of 100 patients, 55% of medical records of the primary 
physicians mentioned eyedrops.  Of the charts, 31% mentioned glaucoma but no eyedrops, 8% 
glaucoma plus eyedrops, 7% mentioned specific eyedrops but no glaucoma and 40% mentioned 
both glaucoma and specific eyedrops. 
2.4.2 ELECTRONIC MEDICAL RECORD 
EMR aims to facilitate communication between the patient-provider in several aspects: 1. 
process of care by mediation discussion, 2. names of medications and list of medications and 3. 
identification of medication themes (dosage information and graphs representing previous and 
current therapies) through the ability to look at the whole prescription profile (Arar, Wen et al. 
2005).   
 
Table 9:  Advantages and Disadvantages of the Electronic Medical Record 
Advantages Disadvantages 
1. Higher level privacy and security 
2. Less amount of space and time required 
for transporting than paper records 
3. Remote access 
4. Structure forms improve readability 
5. improved billing accuracy 
6. reduction in duplication of services 
7. facilitation of clinical trials 
1. difficulty in adding older records to the 
system 
2. synchronization of records utilizing 
different systems 
3. hardware limitations – workstations, 
laptops 
4. cost advantages and disadvantages – cost 
to the organization, benefit to the patient 
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Table 9 continued 
8.   aids in standardization 5. start-up costs and software maintenance 
costs 
6. temporary workers require training 
7. inertia – most organizations resist change 
8. liability barriers – failure or damages 
caused during installation or utilization 
9. ownership of electronic records – who 
responsibility to maintain (company or 
hospital) 
10. un-alterability of records, spurious records 
and digital signatures – simple mistakes 
create spurious documents 
11. customization – cost 
 
Wagner and Hogan measured the accuracy of medication records stored in the electronic 
medical record of an outpatient geriatric center.  The authors analyzed accuracy from the 
perspective of a clinician using the data and the perspective of a computer-based medical 
decision-support system.  During a scheduled office visit, the clinician determined from available 
sources whether the patient, vials, any caregivers, and the medical chart.  In 83% of medication 
records the compound, the dose, and schedule of a current medication were correctly 
represented; 91% represented correctly the compound, and the number of current medications 
were missing per patient was 0.37.  The principal cause of errors was the patient (36.1% of 
errors), who misreported a medication at a previous visit or changed (stopped, started, or dose-
adjusted) a medication between visits.  The second most frequent cause of errors was failure to 
capture changes to mediation made by outside clinicians, accounting for 25.9% of errors.  
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Transcription errors were a relatively uncommon cause (8.2% of errors).  When the accuracy of 
records was analyzed from the perspective of a clinical decision system, 90% were correct for 
compound identity and 1.38 medications were missing or not coded per patient.  The cause of the 
additional errors of omission was a free-text ‘comments’ field.  These are  unreadable by current 
clinical decision support applications, but used by clinicians in 18% of records to record the 
identity of the medication  (Wagner and Hogan 1996). 
2.4.3 PHARMACY 
The pharmacist receives the prescription and dispenses the medication.  Thus, the pharmacist has 
direct information on the name, dose, frequency and route of what was prescribed to the patient.  
They also have information on what, how much, and when a refill was made.  Almost all of the 
pharmacies have a database that contains the specific prescription information filled by the 
patient at that pharmacy.  As the pharmacist is one step removed from the physician who 
prescribes the medication and is able to see the medications that other healthcare providers have 
prescribed, they are often thought to be able to provide the global picture and identify potential 
ADRs.  Many pharmacists are also able to take the time to explain the use and mechanism of a 
drug to a patient.  Being able to thoroughly check ADRs, assumes that a patient sees the same 
pharmacist for all of their medications.  However, several patients for various reasons, e.g. to 
save costs, time, have their prescriptions filled at different pharmacists thus weakening the 
ability of the pharmacist to see the global picture.  Additionally, pharmacists are unaware of 
CAM, OTC, and sample medications that are taken by the patient unless they are told by the 
patient.   
62 
2.4.4 INSURANCE PROVIDER 
The insurance provider is a possible source of medication documentation as regardless of how 
many pharmacies the patient visits, all of the information is forwarded to the insurance provider.  
Thus from a global perspective, the insurance provider can view trends in prescribing, what and 
how often the medication is being filled and can potentially highlight any potential adverse 
events or changes in medications dispensed.  This information collected from the insurance 
provider can also provide indicators of compliance.  For example, how often the prescription is 
filled can help determine the frequency of the medication and whether it is taken.  The 
limitations of the insurance provider as a source of documentation are: OTC and CAM are not 
processed through the insurance company, and many patients in order to save money are 
increasingly paying out of the pocket thus by passing the insurance company.   
2.4.5 PATIENT 
The patient is often thought to be the ultimate source for medication documentation as they are 
the ones who know what, how much and how often a medication is taken, as well as, whether 
there are other medications/CAM being taken.  This assumes that the patient understands and is 
able to recall (whether verbally or written down) the dose, frequency and route, as well as, 
correctly follows the instructions that are provided, e.g. when to take the medication, what foods 
to avoid, what are indications of an ADR, etc.  The patient then becomes an active participant in 
helping the provider understand the most accurate picture including reporting of CAMs, OTCs 
and alterations to drug therapy. 
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2.5 COMPARATIVE SOURCES OF DOCUMENTATION STUDIES 
There is varied literature looking specifically at comparing one source of documentation versus 
another source.  Most of the literature in this area focuses on the implementation of an EMR and 
the benefits, challenges, and effects upon adverse event detection.  The research however, does 
not compare the information against multiple sources.  Thus this study is the first to look at 
multiple sources of documentation for medication accuracy. 
 
Table 10:  Summary of Prior Research on Comparative Medication Documentation 
Review Type Number of cases Results Authors 
Retrospective  90 electronic and 
90 paper chart 
EHR were 40% more complete than 
paper chart; retrieval of information 
was faster by EHR  
Tsai and Bond (Tsai 
and Bond 2008) 
Prospective 500 patients 100% in pharmacy record 
66% in hospital file 
76% structured drug review 
Glintborg et al 
(Glintborg, Poulsen et 
al. 2007) 
 
Prospective 
326 charts 53.7% undocumented prescription 
medication, 51.2% non prescription 
medication or natural products were 
missing in charts. 
Mersfelder and 
Bickel. ((Mersfelder 
and Bickel 2008) 
Prospective 620 patients 41.7% drug discontinuation orders 
and 58.3% changes in drug doses 
were identified by chart review 
versus electronic prescribing 
system.  Changes were most often 
due to ineffective treatment (30.8%) 
and ADRs (21.9%) 
Eguale et al. (Eguale, 
Tamblyn et al. 2008) 
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 Table 10 continued 
Retrospective 84 patients using 
a Patient 
Gateway to 
update 
medications in 
the EMR versus 
79 patient who 
were not 
54% Patient Gateway users were 
slightly reported higher correct than 
non-users (61%).   
Staroselsky et al. 
(Staroselsky, Volk et 
al. 2008) 
Prospective 85 patients 
through phone 
interview 
233 discrepancies between patient 
and EMR.  Most common 
discrepancy medication no longer 
being used by patient (70.4%), 
followed by omission from the 
EMR of a medication being taken 
by a patient (15.5%).  79.8% were 
system errors and 20.2% were 
patient errors.  Most common 
patient-generated omission was 
multivitamin (27.7%), most 
common system omission was an 
expired drug (48.4%). 
Orrico (Orrico 2008) 
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3.0  BACKGROUND OF THE STUDY 
3.1 THE CITY OF PITTSBURGH 
The city of Pittsburgh has a large, diverse population that is comparable to other cities.  
Pittsburgh is the second largest city in the U.S. state of Pennsylvania with a population of 
312,819 at the time of this study. 
3.2 UNIVERSITY HOSPITAL SYSTEM 
The University of Pittsburgh Medical Center Health System (UPMC-HS) is comprised of twenty 
hospitals and a network of satellite clinics and services.  About 4 million people are seen through 
the UPMC-HS every year within the Western Pennsylvania area.  At the time of this study, 
UPMC-HS was in the process of implementing a system-wide CPOE system called PowerOffice 
Chart (PCO), which was custom built for UPMC-HS.  The computer physician order entry 
system part of PCO is called EasyScript.  The advantages of evaluating medication 
documentation in this system is that it allows for comparison of pre- and post- PCO 
implementation by comparing clinics that are currently participating in the system to those who 
are awaiting to ‘go live’.  UPMC-HS has built their own pharmacy database within the system, 
has a pharmacy on the main campus with online ordering and healthcare plan to serve its 
constituents.  With multiple satellite clinics around the city, the patient base reflects the diverse 
66 
population seen in the city.   UPMC offers a health insurance plan and an array of commercial, 
Medicare and Medicaid products. 
3.3 PRIVATE PHYSICIAN PRACTICE 
The practice of Solano and Kokales was chosen as it was one of the first clinics to implement the 
PCO system and use EasyScript.  At the time of this study, only 50% of the physicians were 
actively using the EasyScript system, thus the practice operated in a dual environment of paper 
and electronic medical records.  This was an ideal environment as many of the first challenges in 
dealing with an EMR system were being identified and worked through.   
3.4 MEDICARE – PART D 
This study was presented to individuals at the same time Medicare – Part D was being introduced 
across the nation.  Medicare – Part D is a federal prescription drug coverage that covers both 
brand-name and generic prescription drugs at participating pharmacies.  It was enacted as part of 
the Medicare Prescription Drug Improvement and Modernization Act (2003) that went into effect 
on January 1, 2006.  The aim of the program is to provide protection for people who have very 
high drug costs or unanticipated drug bills in the future and is open to all individuals with 
Medicare.  The drug coverage has several plans that the individual can participate in with a 
monthly premium, which varies by plan and yearly deductible.  The plan chosen determines how 
the cost of the prescription, including a co-payment or co-insurance. 
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4.0  METHODOLOGY 
This is a retrospective, descriptive, cross-sectional study in a general internal medicine outpatient 
clinic (Solano & Kokales Internal Medicine Associates-UPMC) that is part of UPMC.  This 
clinic has been utilizing a CPOE system (PowerChart Office – PCO) for two years.  This was an 
ideal clinic as the physicians were familiar with the program and are utilizing it on a continual 
basis.  This study started recruiting participants in November, 2005. 
4.1 HUMAN SUBJECTS 
Eligibility criteria for the study includes being over the age of 40 years, having been diagnosed 
with arthritis, diabetes or hypertension, and has either Highmark Blue Cross Blue Shield or 
UPMC as his/her insurance provider.  The racial, gender and ethnic characteristics of the 
proposed subject population reflects the demographics of Pittsburgh and the surrounding area 
and/or the patient population of the University of Pittsburgh Medical Center. There were no 
exclusion criteria based on race, ethnicity, gender or HIV status.   Children were not enrolled 
into the study.  Women who are pregnant were not excluded from the study.  University of 
Pittsburgh Institutional Review Board approval was obtained prior to the initiation of the study. 
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4.2 RECRUITMENT PROCEDURES 
The clinic staff identified return patients diagnosed with arthritis, hypertension or diabetes that 
have been seen for at least the last year, who have an appointment scheduled over the next month 
and have UPMC Healthplan or Highmark Blue Cross Blue Shield as their provider.  Arthritis, 
hypertension, or diabetes can be concomitant with other conditions.  To be in compliance with 
HIPAA regulations, one month in advance, clinic staff of the participating practice mailed letters 
on practice letterhead from the respective physician with a matching coded, postage-paid 
postcard to potential participants who have either the diagnostic code of hypertension or diabetes 
(see invitation letter).  The postcard asked if the individual was interested in being contacted by 
the research group (yes or no), requested his/her phone number, best time to call, and comments.  
By coding the postcard, the returned postcards were matched to the patients without having them 
to put their name on the postcard where others can see it thus preserving confidentiality.   
 
Only those potential participants who have indicated on the postcard that they were willing to 
be contacted by the research group were contacted.  Prior to the upcoming medical appointment, 
the researcher contacted them to explain the study and ask them some screening questions (see 
screening script).  A waiver for screening over the phone prior to obtaining informed consent 
was requested as this research study present no more than minimal risk of harm to the subjects 
and involves no procedures for which written consent normally required outside of the research 
context.   
 
Once the individual is determined to be eligible, the researcher asked each participant a series 
of open-ended questions.   The participant was mailed two copies of the consent form (one to 
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sign, date and return, and one for his/her records), a form to list their medications including 
name, dose, frequency as prescribed and as taken, and for what indication was recorded from the 
participant, and authorization for release of records from his/her primary care physician, 
insurance company and all of the pharmacies that the individual has visited in the last six 
months.  The researcher coordinated the requests for copies from each of the medication 
documentation sources and conducted a chart review of the medication documented.  The source, 
dates of entry, name of the medication, dose and frequency were recorded.   
4.3 RISK/BENEFIT RATIO 
Breach of confidentiality was possible as a result of participating in this study.  There were no 
other risks associated with this study as it gathered retrospective data and did not involve any 
intervention.   
 
All study information was located in a password secure database on a password secure server 
accessible only to the research team.  Paper information were kept in a locked drawer behind 
locked doors in the researcher’s office.  Once the information was gathered from all the potential 
sources, the participant’s identifiers and their information was coded with a number and 
identifiers stripped.  This allowed for analysis in a masked fashion. 
4.4 COSTS AND PAYMENTS 
There were no costs or payments given to participants in this study. 
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4.5 CHANGES TO STUDY DESIGN 
After meeting with the first few participants, the methodology was reassessed and it was 
determined that the method of gathering medication information would be changed.  The two 
changes were: 
 
1  In the original design of the study, prior to the appointment, the researcher would contact 
the prospective participant to explain the study and request him/her to bring in all of his/her 
prescribed and alternative medications to the appointment.  At the appointment, the 
researcher would review and ask him/her to sign the consent form, a records release form 
from the practice, as well as, from the insurance company, specialists, pharmacies that the 
participant has utilized in the last six months.   
 
 Very few brought in all of his/her medications, had the original containers with the 
name and dose of the medication (i.e. were transferred to pillboxes), brought in his/her 
vitamins/alternative medicines, and were unaware of the names and addresses of the 
pharmacies.  Space constraint was also an issue to identify a room to speak privately with 
the participants versus in the general waiting room.  In all of the cases, the researcher 
requested permission to speak with the participant later to gather the information.  It was 
decided then that the same information was able to be gained from the participant through a 
phone call and via the mail.  This method was also preferred to avoid any potential 
participant biases or extraneous entries by the physicians or clinic staff as they were unaware 
of who agreed to participate.  Collection of information outside of the medical appointment 
setting allowed for a separation from his/her physician and the researcher.   
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2.  In the original design, the researcher was going to also request copies of the participant’s 
medical record from the specialists that the participant has seen in the last six months.   
 
 Many of the specialists declined forwarding copies of the chart and instead the letters 
from the specialists in the chart were used as source documentation.  This change allowed 
examining what information is communicated between health care providers.  This became 
part of the research question indicating what of the prescribed medications is being 
communicated to the primary care physician. 
4.6 INSTRUMENTATION 
A list of medications including name, dose and frequency that were filled during an eight month 
period were requested from all of the reported documentation sources (EMR, chart, 
pharmacist(s), specialists, insurance provider, and participant).  The eight month period takes 
into account what medications that were prescribed before the initiation of the study.  These were 
documented in a spreadsheet and examined for what information was and was not shared in 
common with the other documentation sources. 
 
The study also had a qualitative component where participants were asked: 
1. Does someone attend your doctor’s appointments with you or assists you with your 
medications? 
2. Are the instructions from your physician or pharmacist clear and easy to understand? 
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3. Can you tell me what CAM/OTC or sample medications you have taken in the last six 
months? 
4. How do you pay for your medications – co-pay or out-of-the-pocket? 
4.7 STUDY VARIABLES 
The table below outlines the outcome variables that were collected as part of the study. 
 
Table 11:  Study Variables 
Quantitative Variables Qualitative Variables 
Age 
Sex 
Insurance Provider 
Number of conditions 
Number of medications 
Number of CAMs 
Number of adverse events - major, moderate and minor 
Number of sources of medication 
Percentage of medications/CAM in common with the ‘gold 
standard’ 
Indicators of Independence 
• appointment accompanients 
• instructions from 
physician/pharmacist 
• assistance with medications 
Prescription Coverage  
• method of payment 
Sample Medications 
4.8 DATA ANALYSIS 
The medication, CAM and OTC data collected from the paper chart, CPOE, specialist, insurance 
company, pharmacy, and patient were combined to form the ‘gold standard’ to which the various 
sources were compared for differences.  These discrepancies were then categorized.  Data was 
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compiled and categorized according to error type:  difference in name of medication, dose and 
frequency.  These drugs and CAMs/OTCs were then entered into a pharmaceutical database, 
Drugs Interaction Checker, to determine drug-drug interactions.  The Drugs Interaction Checker 
accessed via Drugs.com is a free internet service provider by Cerner Multum, Inc (Multum).  The 
drug interactions database provides a list of reactions that may occur when different drugs are 
taken at the same time.  While there are many internet drug interaction checkers, this one was 
used as it represents what is accessible to the general public, that includes over-the-counter 
medication and the most common alternative medicines.  Several of the other internet accessible 
databases did not include in OTC or CAM. 
 
Data analysis involved descriptive statistics by comparing the correctness, which is the 
proportion of recorded observations for completeness, listed as part of the ‘gold standard’,versus 
incompleteness, which is the proportion of absent observations for each of the various sources.  
Additionally, a logistic regression analysis using the software program MedCalc was done to 
determine which variables are correlated with a higher percentage of medications/CAM in 
common with the ‘gold standard’ and factors that create a higher risk for adverse events. 
 
The collected data open-ended questions were examined within the context of the participant 
and overall to determine whether there were common themes emerging. 
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5.0  RESULTS 
5.1 RESPONSE RATE 
A total of 110 were invited to participate in the study of which 54 (49%) individuals agreed to 
participate in the study.  Of the total number of individuals, four were omitted due to insufficient 
data for a triangulation approach needed to establish the “gold standard’ of the medication/herbal 
medicines.  Several other individuals had expressed interest either through responding ‘yes’ on 
the postcard or by calling the researcher.  However, these individuals later declined participation 
once they realized that this study was unrelated to the Medicare – Part D drug coverage plan 
which was also being introduced at the same time, or misunderstood the goals of the study and 
stated that they already had prescription drug coverage.  Many who did participate in the study 
were interested as they realized that medication documentation was a problem or alternatively, 
were encouraged by family members in the medical profession to participate. 
5.2 CHALLENGES TO THE STUDY 
There were two challenges to the original methodology that resulted in the study design being 
changed.  One of the goals was to obtain all of the medication sources including the specialists 
for comparison of what information is documented in establishing the ‘gold standard’.    This 
proved to be very difficult as many of the specialists had the information interspersed throughout 
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the patient chart and thus had difficulty producing copies of the records.  Thus the design of the 
study was changed to what is being reported by the specialists to the primary care physician as 
recorded in the patient chart.  In communication with one of the primary care physician as there 
are now so many drugs for various ailments, he relies on the specialists to prescribe the 
appropriate care.   Across all of the 50 participants, there were a total of 8 patient letters from 
specialists that mentions medications.  One individual had two different specialist letters in the 
chart.  While this number seems very low, it is difficult to ascertain the significance of this 
number as it was neither asked of participants how many specialists were seen in the last six 
months, nor was it recorded how many specialists letters were received without mention of 
medication.  Of the eight letters from the specialists, only two provided the name of the drug and 
dosage.  In the other six cases, only the name of the drug was mentioned.  In one letter, the 
physician wrote ‘standard glaucoma medications’.   
 
The second challenge was encountered in the first two participants who when asked to bring 
in the bottles of all medications and CAM, including vitamins and herbs, brought in either a list 
of medications or a pre-filled daily pill box.  This was changed to speaking with individuals over 
the phone and asking them to read the bottles.  The majority stated that they do not report to their 
physician the vitamins and herbs that they take as they did not feel this was necessary 
information.  One individual recognizing the potential effects had reported what she had been 
taken, but noticed that the physician did not write it down.  Even when the researcher asked for 
all CAM taken, some of CAMs (particularly a company-specific formulation or a combination of 
CAMs) could not be located in Drugs.com to determine whether there was a potential drug-drug 
interaction.  Thus while it is understood that CAM and lesser extent OTC can vary by strength in 
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a formulation, a generic classification closest to the item was selected in the Drug Interaction 
Checker.   
 
In obtaining medication documentation from the insurance company and pharmacies, each 
source was asked to provide the name, dose and frequency of each medication recorded for an 
individual over the last six months.  What was received from all of the insurance companies was 
the name of the drug (brand or generic) and how much was paid.  The information from the 
pharmacies was not much clearer in that the drug name and dose was given, but typically not 
how often it is to be taken.  In these reports, the number of refills and cost by the participants 
were included.  While it can be said that the drug information is in the computer system of these 
organizations, it is of concern that the requested information could not be readily produced. 
 
The EMR system contained information about the drug name (brand and generic), dose, 
frequency, and the physician whom prescribed the medication.  In several instances, it also 
included CAMs.  It did not however, include the medications prescribed by the specialists, 
sample medications, nor could it be ascertained whether the prescription was filled and taken.  
The chart similar to the pharmacies contained the name of the medication and the dose, but not 
the frequency nor CAMs.  Using the table 7 presented earlier, the resultant sources of 
information from the study are presented below.  The check mark denotes information that is 
expected and present in a source, and the ‘x’ marks what is expected but not observed in the 
source documentation. 
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Table 12:  Revised location of medication documentation by source 
Medication 
Sources of Medication Documentation 
Patient EMR Chart Specialist Pharmacist Insurance Company 
Name  √ √ √ √ √ √ 
Dose  √ √ √ rarely √ √ 
Frequency √ √ √ X X X 
Route √ rarely rarely √ rarely √ 
Cost  √    √ √ 
Sample  √ X X X   
Over-the-Counter √ X X X   
Alternative  √ X X X   
X = not present, Y = present 
5.3 DESCRIPTIVE STATISTICS 
5.3.1 PARTICIPANT DEMOGRAPHICS 
The resultant 19 (38%) male and 31 (62%) female participants were analyzed in this study.  The 
age range of the participants was 42 to 91 with a median of 66 years.  The average number of 
conditions reported by the participant and/or recorded in the paper medical chart ranged from 1 
to 12 with a median of 3.5 and an average of 4.1.  Nearly equivalent numbers of participants, 22 
(44%) and 28 (56%), had UPMC HealthPlan or Highmark Blue Cross/Blue Shield coverage,  
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respectively.  Inclusive in these numbers is one individual whom had both plans.  A total of 690 
medications and herbs were reported by all of the participants, with a range of 3 to 38, median of 
14 and mean of 13.8.   
5.3.2 DATA COLLECTION 
For each participant, Appendix C tabulates the range of missing values, number of conditions 
reported/recorded, number of over-the-counter and herbal medicines, and the number of sample 
medications. A Venn diagram illustrates how many of the reported/recorded medication/CAM 
are in common or different amongst the various sources (i.e. electronic medical record, 
participant, paper chart, specialist letter within the chart, insurance company and pharmacies).  
Also included are the types of drug-drug interaction errors when drugs are taken in combination 
and the level of significance (major, moderate or minor) as identified through Drugs.com.  This 
research did not include drug-food interactions that are known to occur that affect the 
bioavailability of a compound, absorption, and/or have an additive or diminished effect on a 
drug.  
 
As an example of the tabulated data, Subject #10 has 3 sources of medication documentation 
(EMR, Participant, and the Pharmacy).  Of the observed 14 in total medications/CAMs, 5 were 
shared in common amongst the 3 sources and 1 was shared between the EMR and the participant 
but not with the pharmacy.  Additionally, there were medications/CAMs not found in the other 
sources of 2 and 5 not listed in the EMR or participant, respectively.  Of the 5 listed only by the 
participant, 3 of them were CAMs, Oscal, Centrum Silver, and Aspirin, that were not 
documented in either the EMR or the pharmacy as these are available over-the-counter.   
79 
  
 
Participant (-3) 
 
5
 
EMR (-6) 
2 
1 
5 
Pharmacy (-9) 
 
 
 
 
 
 
 
Figure 3:  Venn Diagram Showing Documentation Sources with Gold Standard 
 
In this participant, a total of 8 moderate and 3 minor risk potential drug-drug interactions 
were identified.  Management guidelines for these drug-drug interactions included: monitoring 
for signs of muscle pain, tenderness or weakness; altered blood pressure control (noted 3 times); 
effective calcium channel blocker therapy; diminished or inadequate analgesic and anti-
inflammatory effects; altered renal function; recommendations for adjusting dosing and amount; 
and reported observations however, the clinical significance is unknown.  Of these 11 identified 
potential drug-drug interactions in this participant, 6 moderate and 2 minor involved over-the-
counter medications/CAMs that were self-prescribed by the participant and were not documented 
either by the physician or the pharmacy. 
 
All of the continuous variables were determined to have a normal distribution.   
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5.3.2.1 NUMBER OF CONDITIONS 
In total, 206 conditions were reported by all participants.  The range was from 1 to 12 conditions 
per participant with a mean of 4.12 and a median of 3.5.  While 3 participants had only one 
condition, the remaining 47 had equal or greater than two conditions.  Thus 94% of participants 
had co-morbidity that require co-management of more than one condition and subsequently 
presents a greater risk for polypharmacy.  
5.3.2.2 TOTAL NUMBER OF OVER-THE-COUNTER/CAM 
Of the 50 participants, 38 (76%) reported taking Over-the-Counter (OTC)/CAM which sums in 
total 107.  The range of number of OTC/CAM per participants was from 1 to 10, with a mean of 
2.82 and a median of 3.  The large majority of OTC/CAM were classified as CAM – such as 
vitamins, minerals, herbs; and were lesser classified as over-the-counter medication – such as 
ibuprofen that were taken on a regular basis.  With the exception of a suggestion from a 
physician in two cases (4%) to take either a multivitamin or calcium supplement, all of the other 
observations of CAM were self-prescribed. 
5.3.2.3 SOURCES OF MEDICATION/CAM 
The overall number of medication sources for each participant ranged from 3 to 9 with a mean of 
4.48 and a median of 4.  To establish the gold standard, the name of the medication/herbal 
medicine alone was used to compare the sources as this was the only most consistent information 
available across all of the documentation sources.  
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5.3.2.4 DRUG-DRUG INTERACTIONS 
In looking at all of the participants, 637 drug-drug interactions were identified in 50 individuals, 
39 (26%) individuals had a major, 48 (96%) moderate and 32 (64%) minor risks.  Of the 637 
drug-drug interactions, 74 (12%) involved a CAM which includes vitamins and supplements.  
Nearly all of the CAMs were self-prescribed.  The number of drug-drug interactions in the 
participants ranged from 0 to 101 with a mean of 12.74 and a median of 8.  There were in total 
637 potential drug-drug interactions of which 39 were major, 490 were moderate and 114 were 
minor.  The management of the drug-drug interactions can be classified into three groups:  major 
(i.e. extreme caution in co-administration, dosing interval recommendation); moderate (i.e. 
monitor of clinical and laboratory work - serum potassium levels, blood glucose, etc. and 
monitor for symptoms of disease - CNS and respiratory depression, hypotension, hematological 
complications, etc.); and minor (i.e. clinical significance unknown). 
 
Many of the major interactions were cautioning against concomitant medications of the same 
class.  For example in the potential drug-drug interaction between Trazodone and Cymbalta, the 
use of agents with serotonergic activity such as serotonin inhibitors, monamine oxidase 
inhibitors, tricyclic depressants, 5-HT 1 receptor agonists ergot alkaloids, lithium, St. John’s 
wart, phenylpiperidine opiods, dextromethorphan, and 5-hydroxytryptophan any of which may 
potentiate the risk of serotonin syndrome.  Thus, caution is advised to consider whether the 
potential benefit of the medication treatment outweighs the risk of concomitant use of multiple 
serotonergic agents (Multum).  It is possible that these medications were not administered 
concomitantly rather that they were prescribed sequentially to determine which medication 
would be appropriate for the individual.  Recalling that the medication documentation source is 
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the most accurate when the information is gathered, reviewed and updated, it is possible that the 
medication discrepancy represents information at different points in time.  However, this 
temporality also creates uncertainty in the validity and timeliness of the information documented. 
5.4 DATA ANALYSIS 
5.4.1 MEDICATION DOCUMENTATION SOURCES VERSUS GOLD STANDARD 
To determine the percentage of the documented medications from the various sources that were 
shared with the ‘gold standard’, the total number of reported medication/CAM for each source 
was divided by the ‘gold standard’.  The assumption was that all of the listed medications/CAM 
carry equal value to the participant’s health and are important for the healthcare providers to be 
aware.  Thus, it was assumed that it was equally important to know whether the participant has 
been taking a hypertension medication, as it was to know whether an over-the-counter or CAM 
was being taken.  It is however, recognized that clinically some medications to control disease 
are more significant if it was missed or not taken versus having missed taking a multivitamin.  
For the purpose of this study, all medications/CAMs are considered equally important to the 
participant’s health.  Thus, continuing with the above example, the percentage each source shares 
with the ‘gold standard’ is 57% (8/14) in the EMR, 79% (12/14) in the patient, and 36% (5/14) in 
the pharmacist.   
 
For each of the subjects, the source of medication documentation that was shared the most in 
common with the ‘gold standard’ was determined to be the best source of medication 
documentation.  The highest percentage was plotted against the source for each participantThe 
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various best sources for the participants are plotted on the figure below.  If there were more than 
one documentation source that shared the highest number of medications/herbal medicines in 
common with the gold standard, they both were plotted in the respective category.  This was 
done as either source can serve as an accurate indication of what the patient is or is to be taking.   
 
Figure 4:  Graph of Highest Percentage in Common with Gold Standard by Source 
 
As shown in the figure above, both the EMR and the patient were the most frequently 
observed to have medications/herbal medicines in common with the ‘gold standard’ as compared 
to the other documentation sources.  The EMR and patient had 21 and 28 observations, 
respectively.  With a similar frequency and the exact same range of observations in common 
with the gold standard (43% to 100%), it is difficult to visually detect a difference between the 
EMR and patient source of documentation.  Thus to distinguish between the two documentation 
sources, a correlation between the EMR and ‘gold standard’ and the patient and ‘gold standard’ 
was done using Pearson correlation coefficient.  All of the participants were included in the 
calculation to represent the best source of documentation overall if one had a choice.  The results 
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are shown in the table and scatter diagrams below.  The patient source had a sample size of 47 
due to lack of data for 3 individuals. 
 
Table 13:  Correlation between the EMR and the Patient with the Gold Standard 
Variables Sample Size Correlation coefficient r 
Significance 
level 
95% Confidence 
interval for r 
EMR, Gold Standard 50 0.5585 P<0.0001 0.3318 to 0.7243 
Patient, Gold Standard 47 0.8174 P<0.0001 0.6929 to 0.8946 
 
 
Figure 5:  Graph of Correlation of EMR and Patient, and Gold Standard 
 
 Based on the frequency data, the scatter diagrams and correlation coefficients for both the 
patient and the EMR have a positive correlation as expected.  Both with a p < 0.0001, the 
correlation coefficient of 0.8174 versus 0.5585 is slightly higher and with a smaller confidence 
interval in the patient versus EMR source and noted by a smaller spread on the graph.  The 
number of patient observations and number of Gold Standard observations are more closely 
related thus suggesting that the patient is a best source of medication/CAM documentation. 
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5.4.1.1 Highest Shared Medication/CAM with Gold Standard 
Amongst participants, the lower limit percentage range of shared documented medications/CAM 
from the various documentation sources with the gold standard was 0% to 60%, with a mean and 
median of 27%.  The upper limit percentage range of shared documented medications/CAM 
from the various documentation sources was 42.9% to 100%, with a mean of 76.1% and a 
median of 75%.  The upper limit percentage for each participant is diagrammed in the 
cumulative frequency graph below.  This is the highest observed percentage of 
medications/CAM shared with the ‘gold standard’ for each participant regardless of the source.  
As shown in figure 6, the results have a significant range and follow a normal distribution.   
 
 
 
 
 
 
 
 
 
Figure 6:  Graph of Cumulative Frequency of Highest Percentage in Participants 
 
Hypothetically, if having greater than 80% of an individual’s medications/CAM documented 
is considered a good estimate to appropriately manage an individual’s care, then 20 individuals 
would fall into this category.  This group was called the more accurate group.  Thus, for the  
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remaining 30 individuals, regardless of the source, the healthcare provider would be challenged 
to determine what the participant is or has been taking.  The later group was referred to as the 
less accurate group. 
5.4.1.2 Characteristics of the Highest Shared Medication/CAM with Gold Standard 
Are there characteristics within the more accurate group, the subset of 20 individuals which have 
80% or greater in common with the gold standard regardless of source, that results in more 
reliable information?  Results of the statistical analysis of the two groups are shown in the two 
tables below.  In the first table, the ratio of males and females, and the ages of the participants 
between the two groups were very similar. 
    
Table 14: Sex Ratio and Percentage in Common with Gold Standard 
More Accurate 
 
Less Accurate 
Females Males Ratio Females Males Ratio 
13 7 1.65 18 12 1.6 
 Age Range Mean Median  Age Range Mean Median 
40-80 59.5 60  40-90 62.67 60 
 
The graphs below compare the source of documentation between the more accurate 
against the less accurate.  If there were two sources indicating the highest in common with the 
gold standard, both sources were indicated.  For the more accurate group, the most commonly 
reported source was the EMR, followed by the patient and the chart.  In contrast in the less 
accurate group, the most commonly reported source was the patient, followed by the EMR and 
the chart. 
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In comparing the two groups, using the Pearson correlation coefficient between the 
source and the total number of medications (gold standard), the results are indicated in the table 
below.  
  
Table 15:  Pearson Coefficient of Two Source with the Gold Standard 
  More Accurate Less Accurate 
r P r P 
EMR 0.5371 0.0146 0.7692 <0.0001 
PT 0.4931 0.0272 0.8205 <0.0001 
 
These results indicate that in the more accurate group, both the EMR and Patient source was 
closely correlated with the EMR being more highly correlated.  In the less accurate group, the 
difference between the EMR and patient source were both statistically significant with a P 
<0.0001.  The correlation between the patient versus EMR and the total number of medications 
was slightly greater with the patient versus EMR group.  Thus for the more accurate group, the 
EMR was more closely related to the gold standard, whereas in the less accurate group the 
patient source was more closely related to the gold standard.  
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Figure 7:  Documentation Source of the More (L) versus Less (R) Accurate Groups 
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Logistical regression analysis was performed comparing the two populations in the table 
below.  Three variables were found to be statistically significant at p < 0.001 - the total number 
of medications, number of drug-drug interactions, and number of moderate drug-drug 
interactions.  There was no difference in age, number of conditions, number of sample 
medications, number of CAMs/OTC, and Health Plan between the two groups. 
 
Table 16:  Comparison of More and Less Accurate Groups 
 More Accurate Less Accurate  
 No. Range Mean Median No. Range Mean Median t-test DF 
Significance 
level 
No. 
conditions 
20 2-10 3.9 3.0 30 1-12 4.27 4.0 0.36 48 0.7211 
No. Sample 
Medications 
2 1 1 1 4 1 1 1 - - - 
No. of 
CAMs/OTC 
10 1-5 1.9 1 28 1-10 3.14 3 1.96 36 0.0574 
Total Meds 20 3-18 9.2 8.5 30 7-38 16.83 15 4.31 48 0.0001 
No. Drug-
drug 
interactions 
20 0-20 6.85 4.5 30 1-101 16.67 11.5 2.22 48 0.0311 
Minor 9 1-6 1.78 1 23 1-24 4.26 3 1.46 30 0.1542 
Moderate 18 1-17 6.28 4.5 30 1-63 12.57 8.5 2.02 46 0.0494 
Major 3 1-5 2.67 2 10 1-14 3.1 1.5 -0.17 11 0.8668 
 
The variable with the lowest p-value (0.0001) was the total number of medications.  In 
looking at the difference between the two groups, the less accurate group had not only a large 
mean number of total medications (16.83 versus 9.2) that were taken, but also the range number 
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of medications taken was greater (7 to 38 versus 3 to 18).  Similarly for drug-drug interactions, 
the mean number (16.67 versus 6.85) was greater in the less accurate group and the range was 
wider (1 to 101 versus 0 to 20).  Of the drug-drug interactions including drug/OTC/CAM, the 
number of moderate drug-drug interactions was the most significant.  In the less accurate group, 
the mean number of moderate drug-drug interactions was 12.57 versus 6.28 in the more accurate 
group.  While the number of CAMs/OTCs between the two groups was not significant, a higher 
percentage of individuals took CAMs/OTCs in the less accurate group (93.3%) versus (50%) in 
the more accurate group. 
5.5 QUALITATIVE QUESTIONS 
A series of open-ended questions were asked to gather information on how participants managed 
their medications.   
5.5.1 INDICATORS OF INDEPENDENCE 
Three questions were asked of individuals to assess the level of independence and cognitive 
ability.   
5.5.1.1 Accompaniment to Doctor’s Appointment 
The first question was whether someone accompanies them to the appointment.   Eight 
individuals (16%) had someone accompany him/her to the doctor’s appointment.  This was a 
family member with the most often being a spouse.  They report having a family member/spouse 
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accompany him/her to the appointment was optional except in one case where the daughter 
attends all of the appointment with her father.   
5.5.1.2 Assistance with Medications 
The second question was whether they needed assistance with their medications.  All of the 
participants said that they could manage getting and sorting out their own medications.  One 
participant commented that he let his wife do it for him so that she would have something to do.  
The final question was whether the instructions from the physician or pharmacist were clear.  All 
of the participants reported that the instructions from their physician/pharmacist were clear and 
all reported that they seek clarification from their physician and not of their pharmacist.  
Additionally, all but one of the participants were able to correctly identify which drug was 
presented for which condition.  The one female individual who could not correctly identify her 
drugs relied upon the comprehensive AIDS clinic that managed all of her care including having 
all of her prescriptions filled at a specific pharmacy.   
5.5.1.3 Prescription Coverage and Method of Payment 
In the third question, participants were asked about the extent of their prescription coverage and 
how were medications purchased.  Forty-two individuals (84%) had a co-pay, where most 
individuals did not report difficulties with their co-pay.  However, one individual reported that in 
the prior year three months into the coverage, the individual had already reached the maximum 
coverage and thus the remaining costs had to be paid by the participant.  Two individuals 
reported that they had a ‘poor deductible’ in that the participant had to pay out of pocket $2500, 
and the other $4000 per year in medication costs before coverage started.  Thus, the individuals 
had to pay first a significant amount before the coverage began.   
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The most surprising data were from the eight individuals (20%) who paid out of pocket.  The 
main reasons given were difficulties in not being covered last year; no prescription coverage; and 
the insurance company pays only 20%.  Two of the eight individuals reported using $10 coupons 
that were received in the mail upon switching pharmacies.  One individual reported traveling half 
an hour to a different pharmacy location part of the same chain in order to receive the discount.  
In the past, this individual had reported to having her prescription filled at 5 different 
pharmacies.  The difference in price of paying out-of-pocket was found by one individual to be 
$7.50 at a warehouse club store versus $10.00 through the insurance company.  Many times this 
was not ‘advertised’ rather the pharmacist informed them of the difference.  In a third individual, 
a friend had received a bag of a sample medication through her son who is a physician.  She has 
since then been taken off this medication and had given it to the participant who takes the exact 
same medication.  The participant then refills his medication bottle with the sample medication.  
Another individual reported ‘altering’ the frequency of taking the medication as this would 
lengthen the number of pills.  These later four participants mentioned this in confidence and 
asked that it not be reported to their physician.   
5.5.1.4 Sample Medications 
The participants were then asked if they had taken any sample medications or medications 
prescribed to someone else.  No one reported taking someone else’s medication.  A total of 6  
(12%) sample medications were reported when asked to report what medications they were 
taking.  Many of these individuals did not consider being given a sample from their doctor for a 
new prescription or for seasonal medications such as allergies taking a sample medication.  One 
individual reported that even though the medication is not new, he still asks at every appointment 
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for sample medications to help cover costs.  He also reports that his wife disproves of his asking 
due to embarrassment.   
5.5.1.5 Other Comments 
Two individuals reported that they were discontinuing a medication after completion of the filled 
prescription. One participant had discontinued the medication due to side effects and the other 
participant had already thrown the medication away.  They were going to inform their physician 
at the next appointment.   
 
As part of their health plan, several individuals reported obtaining their medications through 
the hospital pharmacy, but were required to obtain their injectable medications through mail-
order.  One individual commented on ordering his medications online through a pharmacy in 
Canada to save costs.  In this later case, the individual paid for the medication out-of-pocket.   
 
At the time of the study, none of the pharmacies that are part of a grocery store or drug store 
chain shared the same database.  Each store had its own database and thus could not detect if a 
patient had previously visited the chain of stores at a different location.  Consequently this 
diminished the pharmacist’s ability to detect drug-drug interactions. 
 
Overall, there were two frequent comments arising from the qualitative questions: (1.) Drug 
affordability and strategies on reducing costs; and (2.) vitamins and herbs are not medications 
and thus are not important to be told to their physician.   
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6.0  DiSCUSSION 
Of the 50 participants, the average profile of a participant had 4.12 conditions and 76% of the 
participants took on average 2.82 over-the-counter medications or CAMs.  The mean number of 
drug-drug interactions per participant was 12.74 with the majority presenting moderate risks to 
the participant.  Recommendations for monitoring include clinical and laboratory work, and 
symptoms to look out for.  The risks noted in drug-drug interaction database are based on 
reported cases and animals studies (minor risks) and provide guidance to the physicians.  The 
interplay of the drug and the individual, changing of medications and delayed effects of 
medications is a complex environment that makes it difficult to identify an ADR and attribute it 
specifically to one medication.  However, whether the risks were minor, moderate or major, as 
the pharmacodynamics and pharmacokinetics of each individual is so unique, the aim is to 
reduce the number of potential drug-drug interactions. 
 
Obtaining accurate information about the medication and CAM that a patient is taking is 
complex due to the number of risk factors that are involved.  Of the fourteen risk factors for 
medication errors listed in Section 2.0, ten of the risk factors were identified in this study.  These 
include patient’s and caregiver’s knowledge, co-morbidity, polypharmacy, multiple sources of 
pharmaceuticals, sample medications,, over-the-counter products, herbal medicines, health 
information over the internet, changing medication schedules, and identifying an adverse event.  
94 
The other risk factors of similar drug names, health literacy, pharmacokinetic and 
pharmacodynamic changes, and cognitive impairment of older populations may not have been 
identified as these were not targeted in this study.  Each of these risk factors can lead to an ADR, 
and there is a high probability that several risk factors are inter-playing at the same time.   
6.1.1 AIM 1:  BEST SOURCE OF MEDICATION DOCUMENTATION 
This study had three aims.  The first aim was to determine whether medication documentation in 
a (a) chart; (b) computerized physician order entry system (CPOE – i.e. EasyScript); (c) 
pharmacy record; (d) insurance company; (e) specialist, and (f) as reported by the patient are 
comprehensive (i.e. does their medication list includes medications prescribed by all healthcare 
providers).  On average, a participant had 4.48 sources of medication.  Of the six sources of 
documentation examined in across all of the participants (EMR, patient, chart, pharmacy, 
insurance provider, and specialist), both the patient and the EMR had a similar frequency and the 
exact same range of observations, and were found to be statistically significant as the best source 
of documentation.  However, the patient source had a higher correlation coefficient and a smaller 
confidence interval with the gold standard in comparison to the EMR with the gold standard.  
Therefore, this suggests while both the EMR and patient are good sources of documentation, the 
patient source is a better source than the EMR.   
 
In an effort to identify one referral source for a physician that would result in the highest 
percentage of medication/CAM of a source shared with the gold standard, a secondary analysis 
was done.  The population was separated into two groups:  individuals whose highest source is 
80% or higher consistent with the gold standard versus individuals whose highest reported 
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source was less than 80%.   Individuals with the highest source of 80% or higher consisted of 20 
individuals, resulting in the second group with 30 individuals.  This first group was called the 
more accurate group and the second group was referred to the less accurate group.   
 
In comparing the characteristics between the more accurate and less accurate groups, the 
highest reported source documentation for these two groups differed.  In the more accurate group 
it was the EMR in 65% of the individuals, versus in the less accurate group, the patient was 
reported to be the highest source in 83.3% of the individuals that were in common with the gold 
standard.  While the Pearson correlation coefficient comparing the EMR and patient sources with 
the two groups were almost the same in the more accurate group, the EMR was slightly higher.  
In the less accurate group, the resultant Pearson correlation coefficeint was statistically 
significant for both the EMR and patient sources with the patient being slightly higher. 
 
To answer what would account for the different sources in the two populations, the question 
‘What are the characteristics of each of the groups that would result in one group being more 
accurate than the other?’ was addressed.  There was no difference in age, sex, insurance 
providers or number of sample medications.  There was however, statistical significant 
difference between the number of total medications reported, and the number of potential drug-
drug interactions specifically the number of moderate risk drug-drug interactions.  While the 
number of individuals taking CAMs/OTC was higher in the less accurate group than in the more 
accurate group, the number of CAMs/OTC was not statistically different. 
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This suggests that factors contributing to the less accurate group are more individuals taking 
CAMs/OTC, which also contributes to a higher number of total medications and in turn a higher 
risk for moderate drug-drug interactions.  Since CAMs/OTC are not consistently recorded in any 
of the sources, the physician is likely unaware of the CAMS/OTC as well as, potential drug-drug 
interactions to be able to monitor the patient appropriately.  This then accounts for why the 
patient as a source has a higher correlation with the gold standard.   
6.1.2 AIM 2: EXTENT OF AWARENESS OF A PATIENT’S MEDICATIONS 
The second aim of the study is related to the first to determine the extent of awareness by the 
various physicians on which and how medications are taken by a patient (medication 
discrepancy).  This includes determining the extent to which medications are prescribed but not 
filled, administered differently than is prescribed, not taken on a consistent basis, or taken in a 
self-medicating manner outside of the prescribed route.   
 
None of the sources of medications consistently listed the name, dose, route, or frequency of 
the medication to allow for an accurate comparison.  This includes letters from other physicians 
who are participating in the care of the patient.  The information provided in the letter sometimes 
included the name of the drug and less frequently the dose and frequency.  There is also a 
potential delay for the primary care physician to receive the letter due to time required for 
transcription, receipt, and filing, thus the information may not be in real time.  Letters from 
specialists are typically filled separately from the patient visits and thus are not readily available 
with the other list of medications often listed either in the front of the chart or with the patient 
visit.  This can be further complicated when the clinic utilizes an EMR system.  The letter is 
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either scanned into the system and thus becomes one of the many screens to search or is filed 
separately from the EMR system.  Given the EMR and patient had a higher correlation with the 
gold standard,, a feedback mechanism from the insurance provider, the pharmacist, or specialist 
would not necessarily increase gathering of complete information.  The expectation of an EMR 
system amongst family physicians and specialists who are using the same EMR to record drug 
information is that this information could be shared more easily.   
 
Additional factors identified through the qualitative questions are that CAMs/OTCs taken by 
a patient are not consistently reported by the patient nor recorded in either the EMR or paper 
chart, and the patient does not always report that they have discontinued a medication or taken 
someone else’s medication.  Sample medications were often given by the physician or requested 
by the patient for medications that were on a trial basis to determine the efficacy, or were for 
seasonal ailments.  These were also not consistently noted in the patient’s chart or the electronic 
medical record.  Additionally, participants reported requesting samples for a drug that was 
costly.  These requests were sporadically filled and even less noted in the patient’s record.  In 
one case, a participant was taking sample medications that were received through a family 
member of a friend who had access to the medication.  This later case and all undocumented 
sample medications possesses an increased risk to the patient as any drug recalls will not be able 
to be traced to the patient.  Thus the medication discrepancy between the physician and patient 
can have considerable gaps.   
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6.1.3 AIM 3: POTENTIAL DRUG-DRUG INTERACTIONS 
The third aim of the study was to determine the potential impact of errors on disease 
management of a patient and clinical alerts (includes drug-drug interactions, drug allergies, 
dosage checks, duplicate therapies).  A total of 637 drug-drug, drug-CAM/OTC interactions 
were identified in 50 individuals.  Using the web-accessible Drug Interaction Checker, 26% of 
individuals had a major, 96% moderate and 64% minor risk potential of having a drug-drug or 
drug-CAM/OTC interaction.  Recommendations for major risks included cautioning co-
administration and self administration prior to consulting a healthcare provider (CAMs), 
moderate risks included monitoring for signs of additive/diminished drug effects, toxicity and 
signs of organ dysfunction, and minor risks were reported when the clinical significance was 
unknown due to a lack of studies/reports or based on animal studies.   
 
It is unknown in the process where identifying the potential drug-drug interactions is to 
occur.  Theoretically, the primary care physician managing the patient’s overall care receives the 
letters from the specialists and is able to identify potential drug-drug interactions.  However, this 
study found that not all of the specialist’s letters contained the patient’s medications, and if the 
medication was listed, it rarely contained the dose and frequency.  All of the specialists letters 
were filed in the patient chart and were not integrated into the patient’s EMR unless the 
healthcare provider documented it into the EMR.  One physician reported that they could not be 
aware of all the different types of medications and relied upon the specialists to inform them.  
Only on a few occasions were OTC/CAMs recorded on the patient record and even less frequent 
in the EMR system.  There are several reasons why the OTC/CAM is not documented:  (1). it is 
not often reported by the patient, (2). there is no mechanism for recording it in the EMR, (3) 
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there is no standardization for CAMs and thus there is wide variation in formularies, and (4) 
even if it was documented it is unclear what could be the potential effects.  Thus, the potential 
for drug-drug interactions exist, however, the exact mechanism or recommendations for 
monitoring are unclear. 
 
The second logical point in the process for checking drug-drug interactions is at the 
pharmacy as the pharmacists have the knowledge and information on prior filled medications to 
check and explain drug-drug interactions.  There are several challenges to this that have been 
observed in this study:  (1). People visit different pharmacies including online pharmacies for a 
variety of reasons (convenience, as required by the healthcare plan, cost).  Even with an 
integrated pharmacy system, as patients have been shown to choose different pharmacy chains it 
is difficult for a pharmacist to accurately perform a drug-drug interaction check.  (2). Pharmacies 
do not keep track of CAM/OTCs.  (3). All of the participants reported asking their physician and 
not pharmacist for information.   
 
The third logical point in the process for checking drug-drug interactions is that the health 
insurance provider processes the claims regardless of which pharmacy a patient visits.  Insurance 
companies have information on the name, dose and frequency of a medication.  By using the 
dose and amount supplied, the insurance company can also project when a refill is needed.  If the 
patient is not refilling a prescription according to the estimated completion date, this may then 
suggest non-compliance or altering of the medication schedule thus providing a feedback 
mechanism to the physician.  However, as the insurance company knows only of prescriptions 
that have been filled, they are unaware if the patient decides not to fill a medication.  The 
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insurance company is also unaware of OTC/CAM and sample medication that a patient may be 
taking.  This study also reported due to drug affordability and limited allowances, many 
individuals are choosing to pay out-of-pocket thus avoiding the insurance company.  Several 
grocery stores such as Walmart, Sam’s Club, Giant Eagle, are offering reduced set prices on 
generic and OTC drugs that are paid out-of-pocket once again bypassing the insurance 
companies.   
6.1.4 OTHER FINDING 
6.1.4.1 Extent of Drug Affordability 
Patients who do not take their medications as prescribed are often considered non-compliant by 
the health care community.  Addressing the underlying assumption of non-compliance, different 
strategies have been developed including pill reminders, physicians counseling patients on the 
importance of regularly taking medications, pharmacies sending refill notices to patients 
following the medication frequency schedule.  Non-compliance was not the focus of this study 
and many individuals reported knowing what the drug name, dose, frequency and indication 
were, but due to cost developed their own strategies for affordability.   
 
Several of the participants mentioned visiting different pharmacies to take advantage of 
discounts when a prescription is transferred.  At the time of this study, none of the pharmacy 
chains including grocery stores had an integrated pharmacy record system.  Thus a pharmacy in 
another neighborhood could not detect that a patient visited the pharmacy chain before.  This was 
discussed earlier in that it limits the ability of a pharmacy to perform drug-drug interactions.  
One patient even reported driving two neighborhoods over to avoid detection and to take 
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advantage of the coupon received in transferring her prescription.  In all of the cases where this 
was reported, the participants did not wish to tell their physician as they were embarrassed that 
they could not afford the medication.     
 
In this study of fifty participants, out of the fourteen risk factors, 10 (71%) of these risk 
factors were observed patient’s and caregiver’s knowledge, co-morbidity, polypharmacy, 
multiple sources of pharmaceuticals, sample medication, over the counter products, herbal 
medicines, health information by other sources, changing medication schedules, and identifying 
an adverse event.  One of the possible reasons that the other risk factors were not noted was that 
there were not questions designed to obtain this information.  However, an additional risk factor 
was identified in this study, drug affordability.  It is therefore, quite amazing given all the 
identified risk factors that more major adverse events are not observed.  Since it is difficult for 
both patients and physicians to identify an adverse event, there are perhaps more ADRs that are 
not detected. 
 
Any of the actions of not reporting regular taking of OTC/CAM, switching pharmacies, 
discontinuing or altering the dose or frequency of a medication without consulting the physician, 
and taking sample medications results in the patient being the most accurate source of 
medication documentation.  By doing these things, the patient takes responsibility into their own 
hands for the management of their health to monitor the symptoms and to take the appropriate 
action. 
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6.1.5 SECOND OBJECTIVE OF THE STUDY 
The second objective of the study given the findings in the first objective is to identify the 
potential feasibility of establishing a collaboration of shared information between the academic 
medical institution utilizing a CPOE system, health plan and pharmacy to help improve patient 
care and thereby reduce medication errors.  The benefits to the physician are readily obvious in 
providing better care by knowing what the individual is taking, and both the physician and 
pharmacy are then able to check for drug-drug- or drug-homeopathic interactions.  Incorporating 
the use of insurance or health plan data, which contains all of the reimbursed medical 
interactions on a patient is extremely helpful to physicians, but as well serves to encourage and 
be able to market to individuals to stay within the medical, pharmacy system as they are able 
provide comprehensive care.   
 
Reducing potential adverse drug events helps all the players involved including avoidable 
sick time to the patient, physician time and medical expenses to the healthcare provider.  It has 
already been discussed that information from insurance companies and pharmacies while helpful 
adds a lesser extent to the completeness of the medication documentation.  Given the findings of 
the study, there are perhaps other strategies that should be considered.  This study hopes to shed 
some light on what factors should be considered in order to provide healthcare providers and 
patients with the most accurate, up-to-date and readily accessible information that will be 
addressed in the next section. 
 
 
103 
7.0  INTERPRETATION 
A medication error is defined as any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the health care 
professional, or patient.  Such events may be related to professional practice, health care 
products, procedures and systems, including prescribing; order communication; product labeling, 
packaging, and nomenclature; compounding, dispensing; distribution; administration; education; 
monitoring; and use.  The medication error process can be related to the Swiss cheese model 
developed by James Reason in 1990.  In the Swiss cheese model, each step in the medication 
pathway is like multiple slices of Swiss cheese, stacked together, side-by-side.  Reason 
hypothesized that most accidents or in this case, medical errors, can be traced to one of more of 
four levels of failure:  organizational influence, unsafe supervision, preconditions for unsafe acts, 
and the unsafe acts themselves.   
 
As shown in the figure below, in the Swiss cheese model, each slice of cheese represents an 
organization's defenses or barriers against failure (Gregory and Kaprielian 2005). While each 
hole in the cheese slices represent individual weaknesses in separate parts of the system, and are 
continually varying in size and position in all slices. Each slice of cheese is an opportunity to 
stop an error and when there are smaller and fewer number of the holes, there is a lesser risk for 
an error.  In the second figure, when there is an alignment of holes, the system as a whole 
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produces failures permitting (in Reason's words) "a trajectory of accident opportunity".  Thus all 
of the defenses are absent allowing an error to occur. 
 
 
Horn and Hansten (Horn and Hansten 2004) applied the Reason’s Swiss Cheese Model to 
drug therapy errors.  They comment in tracing back an adverse event, it is always where 
someone – e.g. the prescriber, pharmacist, nurse of patient – could have taken action to prevent 
it. 
 
Figure 8:  Reason's Swiss Cheese Model 
Figure 9:  Swiss Cheese Model Applied to an ADR 
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Similar to Reason’s model the slices represent the defenses against adverse outcomes from a 
drug interactions, however, unlike Reason’s Swiss Cheese Model the holes are dynamic, 
opening, closing and changing location as the individual defenses change over time.  In the 
figure above, the initiating event is Drug A and Drug B.  When one of the defenses, such as a 
pharmacist checking for possible drug interactions between drugs, a trajectory of a hazard arrow  
or ADR can occur.  Alternatively, when a patient visits more than one pharmacy, takes CAMs 
without their physician’s knowledge, a patient maybe be creating or enlarging more holes thus 
leading to a trajectory of accident opportunity.  There are active defenses, i.e. when someone 
intervenes, and latent defense, i.e. a patient’s pharmacogenetics renders him/her resistant to the 
ADR, or the dose or duration of the drug is insufficient to produce an ADR.  Additionally, even 
when all the holes line up there are some ADRs where the outcome is not clinically significant 
such as the example given earlier about the combined use of angiotensin-converting enzyme 
inhibitor and a potassium-sparing diuretic.  This combination is used with good results, although, 
occasionally predisposes a patient to developing life-threatening hyperkalemia. 
What is missing from this model and the surprising finding of this study is the influence of 
drug affordability on patient’s behavior by not reporting OTC/CAM to their physicians.  In this 
study, patients were taking sample medications, switching pharmacies, and altering 
dose/frequency with the underlying rationale to reduce costs.  This becomes not a non-
compliance issue to taking medication, rather survival of the patients in affording healthcare and 
maintaining/achieving better health status.  Individuals are actively taking responsibility for their 
healthcare in their own hands by their own actions, thus intentionally or unintentionally 
individuals are shifting the health locus of control to themselves (internal versus to powerful 
others or chance) and enlarging the holes in the Swiss Cheese Model.  These observations are 
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contrary to the IOM’s report on medical errors being largely basic flaws in the way health 
systems are organized as the report fails to take into account human behavior for survival. 
Drug affordability may be defined as the absence of economic barriers to a good or service.  
The two frequently used measures are: a consumer’s ability to pay and his or her physical access 
to a good or service.  The popular magazine Consumer Reports conducted a study and found that 
29% of people who had health insurance were ‘underinsured’ with coverage so poor that they 
postponed medical care because of costs (Consumer Reports, 2007).  While most health 
insurance programs are designed to subsidize costs based on income, it cannot measure or 
address the consumer’s unwillingness to pay in light of other expenditures.   As costs have 
increased this has forced some individuals to pay by credit cards in order to maintain or achieve 
a better health status.  Other individuals have resorted to altering their own medication therapy 
(i.e. changing dosing from twice a day to once a day) to lengthen the drug supply.  Cost barriers 
often lead to not filling a prescription or skipping or splitting doses owing to cost.   
 
There is very little research literature on this topic, but to help individuals manage the cost of 
prescription medication, in a recent article published in the popular magazine Smart Money, the 
author lists four ways to cut drug costs.   
 
Table 17:  Recommendations for Saving Prescription Costs 
1. Take advantage of store promotions – four supermarket chains offer for free generic 
antibiotic giveaways to shoppers with club cards.   
2. Go for generics – recommends readers to ask their physician for a generic equivalent or for a 
comparable drug. 
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          Table 17 continued
3. Shop around – compare drug prices at various pharmacies and ask for price matching to 
another pharmacy which is often not advertised.  The author cautions that if different 
prescriptions are filled at different pharmacies that they tell the pharmacist of all the 
medications to avoid any possible adverse events. 
4. Split pills – some pills are available at twice the dose and at the same price as lower doses. 
 
They also suggest that the reader ask their physician if they can take the medicine every other 
day or once a day instead of three times a day (Spina, Glassman et al. 2005).  While many of the 
five recommendations may help save money for the consumer, these suggestions actually 
increase an individual’s risk for ADRs and encourage self-management outside of the care of a 
healthcare provider.  For example, obtaining and taking antibiotics on their own; buying in 
bulking means less visits and monitoring by a physician; shopping around reduces the ability of 
one pharmacy to accurately detect potential drug-drug interactions; and splitting pills could alter 
the dose taken are all personal behaviors. 
 
In looking at the influence of drug affordability on a drug purchase, Ranji, Wyn et al. looked 
at a sample size of 1177 women ages 18-64 who use greater than 1 prescription drug on a regular 
basis.  Of non-elderly women, 54%  reported that they were taking a prescription medication on 
a regular basis and 32% reported >1 affordability barrier in the prior year and either forgo or 
delay a prescription and/or reduce facing a cost barrier, regardless of income level.  Uninsured 
women had the highest odds of facing a cost barrier, regardless of income level.  Low-income, 
uninsured women were nearly seven times as likely to face a cost barrier to prescription drugs, 
compared with higher income women with insurance.  Even uninsured women with incomes 
>200 % of the federal poverty level had 5 times the odds of facing a prescription medicine cost 
108 
barrier, and low-income, insured women experienced two times the odds of a prescription 
medicine cost barrier, compared with their higher income, insured counterparts.  Lack of health 
insurance coverage was significantly associated with experiencing cost barriers, regardless of 
income level, underscoring the critical role that insurance coverage plays in protecting women 
from out-of-pocket costs and for accessing prescription medicines.  Limiting out-of-pocket 
spending was found to be important for low-income women who have insurance, because even 
minimal costs can act as barriers for this group (Ranji, Wyn et al. 2007). 
 
Of 1606 elderly patients sampled, half of whom had exceeded their drug benefits from the 
previous year, and all had total drug expenditure in their cap level.  Two-thirds reported 
difficulty paying for medications, and 25% decreased medication use because of cost.  Most 
wanted providers to ask about medication affordability (81%), consider cost (86%), offer choices 
(70%) and to persuade them or decide for them which medication to use (88%), but few said 
providers asked about affordability (17%), usually or always discussed prices (19%) or offered 
choices (45%), although nearly all said providers chose their medications (93%).  Sixty-two 
percent had asked providers for help with drug costs, although, 34% used less medications 
because of cost or had difficulty paying for medications had not asked for help (Tseng, Dudley et 
al. 2007). 
 
As the economy has moved from a manufacturing-based to a service economy, health 
insurance coverage has become less stable as the service sector has less access to health 
insurance.  With rising health insurance premiums, many small employers can no longer afford 
to offer health benefits which results in employees contributing a larger share to their coverage.  
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According to the US Census Bureau, nearly 46 million Americans or 18% of the population 
under 65 years were without health insurance in 2007  (DeNavas-Watt, Proctor et al. 2008).  
Similarly, the Agency for Healthcare Research and Quality, using the Medical Expenditure Panel 
Survey (MEPS) estimated that 54 million Americans (27%) under the age of 65 are uninsured.  
With the change in economy, most laid-off workers lost their health insurance with their incomes 
and private healthcare coverage is becoming too costly to afford.  This in turn will increase the 
number of individuals seeking Medicaid and State Children’s Health Insurance Programs thus 
driving up state expenses as revenues are declining (Chu and Rhoades 2008).  The Urban 
Institute estimates that nearly 65.7 million Americans may be unemployed by 2019 posing an 
enormous cost to the Medicaid and states programs (Holahan, Garrett et al. 2009). 
McKinsey Consulting estimates that Americans spend $294 billion on out-of-pocket medical 
costs annually including doctors’ office co-payments to surgeries and prescription medications.  
Of this about 25% ($74 billion) of the annual expenses is being charged to regular standard credit 
cards.  Unlike optional purchases, medical expenses are often unavoidable thus making it a 
appealing for lenders to create special financing.  Viewing a growing industry, GE Money and 
Citibank both have special credit cards that can only be used for elective medical procedures, 
such as LASIK vision correction, liposuction, and cosmetic dentistry, which are generally paid 
out of the pocket.  GE Money’s CareCredit card limits their 7 million users to a network of 
doctors, and there are plans for MasterCard Worldwide and OptiumHealth to issue a debit card 
that draws funds from existing healthcare spending and flexible spending accounts.  While 
making it easier for consumers to pay and hospitals to collect, one missed pay can raise interest 
rates to 27% (Kavilanz 2009).  Thus what is a good strategy to build a layer of defense to 
increase detection and prevention, and reduce the number of ADR? 
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The cause and effect model presented earlier in this study needs modification.  It accounts for 
system factors, but not personal behaviors that are fluid and dynamic.  Thus the framework for 
this study must be revisited to incorporate the findings from this study.  In the diagram on the 
following page, the prior identified risk factors are the double lined box in pink and the hatched 
lines and shaded in blue are the additional risk factors identified in this study. Many of the 
potential causes (inputs) are patient-related thus, emphasis should be placed on the patient’s role 
in the medication process. 
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Figure 10:  Revised Cause and Effect Model for the Medication Process
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7.1.1 CONSIDERATIONS FOR DEVELOPING A STRATEGY 
The approach to reduce the possibility of ADRs is a multi-step process.  As discussed, there have 
been several systems approaches (use of a medication sheet / list, medication reconciliation by 
patients / health care provider, pre-printed order sheets, computerized physician order entry, 
clinical decision support system, personal digital assistant medication safety via the internet, a 
common EMR system).  Because one cannot seal off all the holes in the defense system, 
strategies must involve a systematic approach to strengthen all of the defenses. 
7.1.1.1 Healthcare Professional and Patient Awareness 
Reducing the number of ADRs involves developing awareness of everyone in the medication 
process, including physicians, nurses, pharmacists, patients and their families.  This can involve 
reminding the healthcare team to collect and the patient to report the medication history 
including name, dose, frequency, and indication in a culture that minimizes blame and 
maximizes communication.  Tools to gather the information can include a medication list for 
patient’s to complete, a readily access method for healthcare professionals to gather and record 
the information and a mechanism for a healthcare professional to review the medication history 
and determine whether there are any potential drug-drug interactions. 
 
The Institute for Healthcare Improvement (IHI) in December 2006 launched the 5 Million 
Lives Campaign aiming at reducing harm from high-alert medications.  The campaign focuses on 
four categories of drugs – anticoagulants, narcotics and opiates, insulin and sedatives, as they are 
more likely to be associated with harm.    The IHI has developed several tools for medication 
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reconciliation and suggestions for healthcare organizations to implement.  Thus a feasible 
strategy for medication reconciliation and review of indiscriminate polypharmacy is to target the 
higher risk groups.  These would include:  patients over 40 years, having co-morbidity of greater 
than 3 concurrent conditions, polypharmacy of greater than 6 medications and on medications for 
longer than 6 months.  Thus, one could identify higher risk individuals by weighting the risk 
factors similar to the Medication regimen complexity as described by Maddigan et al. discussed 
earlier.  Thus individuals would be scored 1 (over the age of 40 years) + 1 (more than 3 
conditions) + 1 (greater than 6 medications) + 1 (on medication for longer than 6 months) + 1 
(takes herbal medicines) + 1 (involves either an anticoagulant, narcotic and opiate, insulin and 
sedative) = 6.  Individuals over the score of 4 would be flagged for medication reconciliation and 
review.   
7.1.1.2 Central Database Accessible to Healthcare Providers 
The second objective of this study was to determine the feasibility of establishing a collaboration 
of shared information.  The benefit of shared information is that collectively it gathers 
information from multiple sources and is thus not dependent upon the communication between 
the physicians, nor upon the understanding and recall of the patient.  It also is a mechanism to 
detect polypharmacy and unnecessary drug use.  The best system is one that captures all of the 
information (name, dose, frequency, route, and indication of the medication) and not just pieces.  
It has worked for the Alberta Government who invested billions of dollars into creating Alberta 
Netcare EHR which captures all testing, prescribed dispensed drugs, known allergies and 
intolerances, thus providing up to date, accurate medical information to authorized health 
professionals.  It also has incorporated decision support tools such as drug-to-drug and drug-to-
allergy interaction alerts to avoid prescriptions that conflict.  It now contains over 90% of all 
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prescription activity on patients across Alberta.  The main reason for the success is in contrast to 
the United States, Alberta has a one payor system.   
7.1.1.3 Drug Plan for Patients 
For various reasons, individuals may be unable to pay whether for a temporary period or over a 
time span.  Individuals should not be forced to weigh their health status against their basic food 
and shelter costs, nor should they go into debt with credit cards paying for medication.  This can 
include fixed pricing so individuals are not forced to search out opportunities to save money.  
While the focus is on reducing costs, New York State designed and developed an integrated 
workers’ compensation/health plan prescription drug program that also captures drug 
information.  The ONECARD RX indicates to the pharmacy that the visit is part of the client’s 
insurance prescription drug plan network and the prescription is filled at no cost.  The 
ONECARD RX is accepted where the program has negotiated generic substitution, reduced 
administrative fee and negotiated pricing.  Obtaining a prescription at no cost is an incentive for 
the clients, it reduces the overall cost for the plan and controls where the clients go to get the 
prescriptions filled.  Similarly, pharmacies are offering clients different incentives to encourage 
clients to have prescriptions filled at only their pharmacy chain.  These include cheaper generics, 
pill packaging broken into days of the week, and drug-drug interaction checks.  These are 
examples of individual efforts and collaboratively working together to capture drug information 
is one step in the multi-step process.  This can be a challenge due to the number of stakeholders 
involved each with different interests and systems, but is a method of not only controlling costs 
but where a patient obtains their medications for better record keeping.  It would be also 
informative to find out whether the effect of Medicare- Part D that was being introduced when 
this study was being conducted has any effect on patient behavior. 
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7.1.1.4 Increasing Access for Patients to Medications 
Even though affordability is a barrier, some healthcare plans do not allow a patient access to 
medications.  In some cases, patients can only obtain a 30-day supply for routine medications 
where a 90-day supply would be more affordable.  There was some rational to the article in the 
magazine Smart Money.  Additionally, some brand medication is more effective to patients who 
are only able to purchase the generics.  One of the eligibility criteria for this study was having an 
insurance provider.  It would be interesting to see the perspectives of individuals who do not 
have health insurance and what their attitudes and approaches are to medication therapy.   
7.1.1.5 Mechanism to Identify, Report, Assess, and Feedback of Drug-Drug Interactions 
A mechanism for identifying, reporting, assessing at a global level to better define higher risk 
ADRs, and feeding back to healthcare professionals drug-drug and drug-OTC/CAM interactions 
is key for detecting and preventing real ADR.  Pharmacists were found the most often to 
voluntarily report ADRs and have been shown to be very beneficial when they are part of the 
healthcare team.  They are knowledgeable in prescription drugs, OTC and many CAM available 
in their store that they would be able to filter out some of the confusing, non-essential alerts.  
However, as pharmacies extend longer hours resulting in multiple pharmacists, ordering through 
the internet, etc, the one-on-one relationship with a pharmacist is becoming lost.    There is also 
the reality of whom does the pharmacist have responsibility to report the ADR to – a central 
database, but also to the physician?  And is the pharmacist or another healthcare specialist the 
best able to navigate through all of this information? 
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7.1.1.6 Patient’s Behavior 
The patient has a variety of rationale for not reporting OTC/CAM; altering the frequency and/or 
dose of a medication; non-compliance; taking sample medications without their physician’s 
knowledge; visiting multiple pharmacies which all makes determining drug-drug interactions 
extremely difficult.  As long as there is a cost to healthcare and barriers to cost, patients will 
always be seeking and developing different strategies to make healthcare more affordable.  A 
key strategy would be to educate patients on what types of information to provide to their 
physicians.  This includes a written list of all the medications from other physicians including 
name, dose, frequency, route and indication; what is a side effect and who and when it needs to 
be reported to; and what to do if they decide to discontinue a medication.  It has been shown that 
patients seek information first online and receive a lot of information through direct-to-consumer 
advertising.  Information through these vehicles can help steer patients towards reliable 
individuals, who can help them discern the information.  One challenge is that this study showed 
that patients are reluctant due to embarrassment of informing their physicians about their 
strategies to reduce costs.  Therefore, further research needs to be done on understanding the 
barriers and perspectives of the patients. 
7.1.1.7 Use of an ADR Helpline 
The resultant multi-prong approach is centralizing information with mechanisms for detecting 
and reporting ADRs relayed through a qualified healthcare provider that respects the variety of 
patient’s behaviors and multiple stakeholders.  Until a collaborative agreement can be made 
amongst the stakeholders (physicians, insurance companies, pharmacies, patient), one approach 
that does not interfere with the physician-patient relationship of the patient who is too 
embarrassed to inform the physician is a third party such as the state health department which 
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has no stated interest.  A healthcare provider such as a nurse who understands the various 
conditions, medications, patient behaviors can weed out the unnecessary information and triage 
the questions so that a patient can more appropriately inform a physician, or a patient can report 
all the medications and find out if there are drug-drug interactions.  A drug information 
telephone line can be established that would also help individuals with health literacy, 
understand side effects, the role of informing their physicians of medications or even help build 
the medication list for the patient to share with healthcare providers with a list of potential drug-
drug interactions with evidence based guidance for a physician to consider in terms of 
monitoring.  The cost would be for the health department and the savings across the health 
system. 
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8.0  CONCLUSION 
Patient safety needs to be a state of mind and not a technology.  As human error can never be 
taken from the equation, more research needs to be done to further understand the barriers and 
challenges so that a better solution can be developed that would reduce ADRs.  While the 
suggestions for building a better defense system against ADRs does not address all the gaps or 
holes in the Swiss cheese, it has highlighted more clearly some of the holes and the importance 
of not only system changes but also patient behavior.  A secondary study would be worthwhile to 
explore the implementation of using the public health department as a resource for patients in 
drug information, as well as, further studies into understanding the role of drug affordability and 
the health locus of control with the aim of building the best system.  As aging population 
associated with co-morbidity and polypharmacy expands, coupled with the economic challenges 
with the changes in the economy, the results and questions raised during this study are important 
to consider as the problem will likely grow with time. 
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APPENDIX A 
INVITATION LETTER TO PARTICIPANTS ON PRACTICE LETTERHEAD 
Dear (Patient): 
Solano & Kokales Internal Medicine Associates – UPMC is participating in a research 
study looking at the documentation of medication in a patient’s chart, computer record (where 
applicable), insurance company, pharmacies, and as reported by the patient.  The purpose of this 
study is to examine the various sources of medication documentation and compare them for 
accuracy and completeness. 
 
We invite you to participate in a study looking at Evaluating Patient Medication and 
Complementary Therapies being conducted through the Department of Behavioral and 
Community Health Science at the Graduate School of Public Health at the University of 
Pittsburgh. 
 
We are inviting: 
• Individuals over the age of 40 
• Who have been diagnosed either with arthritis, diabetes or hypertension 
• Have either UPMC Healthplan or all Highmark Blue Cross Blue Shield products to include 
by not limited to the following ClassicBlue, COMPLETE-care, Security 65, Signature-65, 
SelectBlue POS, KeystoneBlue HMO, SecurityBlue, DirectBlue, PPOBlue, Medigap, 
Preferred Blue, Freedom Blue, Community Blue, Keystone HMO, and Direct Pay Keystone 
as your insurance provider 
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Participation involves: 
• Answering a few questions about your medical history and medications taken over the last 
six months 
• Authorizing the release of medication records from your physicians, insurance plans and 
pharmacies 
• This study requires a one-time visit only 
 
You are under no obligation to participate in this study as it is voluntary.  I will continue 
to be responsible for your ongoing medical care, regardless of your decision.  The study does not 
alter the management of your condition and your records have not and will not be released to the 
research group without your consent.  We can gather all the necessary information at your next 
appointment and over the phone.  There is no required ongoing follow-up or evaluation for the 
study.  There is also no cost to participate. 
 
If you are interested in finding out more about the study, please return the enclosed pre-
addressed postage-paid postcard and a member of the research team will contact you within a 
few weeks.  If you have any questions about this study, please do not hesitate to Ms. Tammy 
Mah at 412-647-8235.  She would be delighted to discuss the study with you.  Thank you and we 
look forward to hearing from you. 
 
Sincerely, 
 
Patient’s attending physician 
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APPENDIX B 
SCREENING SCRIPT 
Thank you for inquiring to find out more our research study.  My name is ___________, 
and I am a research coordinator at the University of Pittsburgh.  The purpose of this research 
study is to compare the accuracy of documentation of medication in various sources including 
the patient’s medical chart, PowerChart Office / EasyScript (a computerized medical chart 
system in some offices at the University of Pittsburgh Medical Center), pharmacies utilized by 
the patient and as recorded by his/her insurance provider.  This is accomplished by asking the 
patient to report as well as, the researchers examining the various sources of medication 
documentation on the dosage, frequency and route of all medications that is either physician 
prescribed, self-prescribed, herbal and vitamin supplements, and medication samples. 
 
Participation involves answering questions about your medical and medication history, 
authorizing the release of your health records from all of your physicians who you have seen for 
the past six months or more, any pharmacies where you have your prescriptions filled, and from 
your health insurance company.  Do you think you might be interested in participating in this 
study? 
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[If No]:  Thank you very much for allowing me to speak with you today.  Please feel free 
to contact us if you have any future questions or if you decide you might be interested in the 
future. 
 
[If Yes]:  But before enrolling people in this study, we need to determine if they are 
eligible.  I would like to ask you a few questions regarding your age and medical history.  You 
don’t have to answer these questions if you don’t want to.  Our eligibility status with respect to 
the study may change as more information is gathered regarding your medical history.  You also 
need to understand that all information that I receive from you by phone, including your name 
and any other identifying information will be kept strictly confidential in our locked offices.  The 
purpose of these questions is to determine whether you are eligible for our study.  Your 
participation is voluntary; you do not have to complete these questions. 
 
Screening Script (cont.) 
1. Do I have your permission to ask you these questions? Yes_______ No________ 
2. Are you over the age of 40 years? Yes_______ No________ 
3. Have you been diagnosed with hypertension, arthritis, 
or diabetes? Yes_______ No________ 
4. Do you have either Highmark Blue Cross Blue Shield 
or UPMC Healthplan as your insurance provider? Yes_______ No________ 
 
Coordinator __________________________________ Date _______________________ 
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APPENDIX C 
PARTICIPANT PROFILES 
In the tables and diagrams below are the profiles for each of the participants.  The table 
includes information on the participant’s demographic information (sex, age), number of medical 
conditions at the time of participation, range of missing medications / herbs / alternatives 
medicines identified from the various sources (EMR, participant’s medical chart (paper), 
participant, pharmacist(s), insurance company, specialist(s) letter(s) found in the participant’s 
medical chart as available.  Also included in the number of medications / herbs / over-the-
counter medicines as reported by the participant and how many sample medications are taken. 
The Venn diagram is a pictorial representation of how many of the sources share the 
same information from a drug list, this looks only at the occurrence of a medication / herbal 
medicine.  The center where all the circles intersect is considered the ‘gold standard’ which is all 
of the reported medications / herbals combined.  Indicated in brackets beside each of the sources 
is the number of medications / herbals that are missing.  i.e. -5 states that five medications were 
not listed as compared to the gold standard.   
The types of errors are indicated in the table beside the figure with associated risks. 
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Participant 
(-12) 
0 
6 
1 
2 
5 
8 
 1 
1 
4 
1 
1 
EMR (-14) 
Chart 
(-30) 
Pharmacy1 
(-22) 
Participant #1 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
No. of Sample 
Meds 
M 87 7 9 2-5 1 0 
        
 
 
 
 
 
 
Management: 
- Monitor – blood pressure (2), diuresis, electrolytes, renal function; calcium channel 
blocker therapy 
- Monitor for signs of prolonged bleeding and reduced antihypertensive effect;  
- Clinical significance is unknown. 
 
Participant #4 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 57 12 36 12-30 1 0 
 
 
 
 
  
 
Management: 
- Monitor for signs of GI ulceration and bleeding; muscle pain, tenderness or weakness (2); 
torsade de pointes; CNS and respiratory depression (2) 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Furosemide-Lisinopril Moderate 
Drug-Drug Verapamil-Centrum Silver Moderate 
Drug-Drug Aspirin-Lisinopril Moderate 
Drug-Drug Verapamil-Aspirin Moderate 
Drug-Drug Verapamil-Lipitor Moderate 
Drug-Drug Verapamil-Lisinopril Minor 
Drug-Drug Furosemide-Aspirin Minor 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Motrin-Medrol Dosepak Moderate 
Drug-Drug Zithromax-Lovastatin Moderate 
Drug-Drug Zithromax-Seroquel Moderate 
Drug-Drug Lovastatin-Prevacid Moderate 
Drug-Drug Neurontin-Remeron Moderate 
Drug-Drug Neurontin-Seroquel Moderate 
Drug-Drug Remeron-Seroquel Moderate 
Participant 
(-2) 
 
 
 
 3 
EMR (-5) 
Specialist (-2) 
1 
2 
1 
2 
Chart 
(-5) 
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0 
EMR (-5) 
1 5 
1 4 
2 
Participant 
(-3) 
Pharmacy 
(-11) 
Participant #2 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
No. of Sample 
Meds 
M 68 2 13 3-11 3 0 
       
 
  
 
 
 
 
 
 
Management: 
- Monitor for signs of hypoglycemia (4);  
- Monitor – blood glucose (1); blood pressure; renal function (2) 
- Caution against self-medication without first consulting a healthcare provider 
-  
Participant #3 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
No. of Sample 
Meds 
M 67 2 5 1-4 1 0 
 
 
 
Management: 
- Monitor for signs of CNS stimulation; arrhythmia 
- Dosing interval recommendations 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Micronase Moderate 
Drug-Drug Lisinopril-Glucophage Moderate 
Drug-Drug HCTZ-Glucophage Moderate 
Drug-Drug HCTZ-Lisinopril Moderate 
Drug-Drug Micornase-Lisinopril Moderate 
Drug-Drug Aspirin-Lisinopril Moderate 
Drug-Drug Micronase-Testim Moderate 
Drug-Drug Aspirin-Vitamin E Moderate 
Drug-Drug Micronase-HCTZ Moderate 
Drug-Drug Aspirin-Avalide Moderate 
Drug-Drug Doxycycline-HCTZ Minor 
Errors 
Type Event Risk 
Dose 80 mg (pt) vs 180 mg (EMR) - 
Frequency Missing - 
Drug-Drug Cipro-Aspirin Moderate 
Drug-Drug Cipro-Mefloquine Moderate 
Drug-Drug Cipro-Centrum Silver Moderate 
 
  
1 
EMR (-1) 
2 
1 
1 Participant 
(-2) 
Insurance 
(-4) 
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3 
EMR (-1) 
6 
1 
2 
Chart 
(-7) 
Insurance 
(-8) 
Participant #5  
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 77 5 12 1-8 0 0 
   
 
Management: 
- Dosage adjustment, dosing interval recommendations 
- Monitor for signs of hematologic bleeding; excessive or prolonged CNS and respiratory 
depression; serotonergic activity; gastric ulcers; systemic glucocorticoid effects; 
excessive calcium channel blocker effects (2) 
- Monitor – blood pressure (2) 
- Clinical significance unknown 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Diltiazem-Clorazepate Moderate 
Drug-Drug Diclofenac-Celexa Moderate 
Drug-Drug Clorazepate-Celexa Moderate 
Drug-Drug Diltiazem-Celexa Moderate 
Drug-Drug Diclofenac-Diovan Moderate 
Drug-Drug Diclofenac-Fosamax Moderate 
Drug-Drug Calcium + D-Fosamax Moderate 
Drug-Drug Lotrisone-Advair Diskus Moderate 
Drug-Drug Diltiazem-Lotrisone Moderate 
Drug-Drug Dilitazem-Diclofenac Moderate 
Drug-Drug Diltiazem-Calcium + D Moderate 
Drug-Drug Lotrisone-Celexa Moderate 
Drug-Drug Clorazepate-Calcium + D Minor 
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0 
EMR (-18) 
 
15 2 
 Pharmacy 
(-16) 
Participant 
(-1) 
Participant #6 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 63 2 18 1-18 3 1 
 
 
 
Management: 
- Monitor for signs of hypotension (2); excessive or prolonged CNS and respiratory 
depression (2) 
- Dosing interval recommendation (3) 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Atenolol-Elavil Moderate 
Drug-Drug Atenolol-Endocet Moderate 
Drug-Drug Elavil-Endocet Moderate 
Drug-Drug Atenolol-Calcium + D Moderate 
Drug-Drug Elavil-Hydrocodone Moderate 
Drug-Drug Calcium + D-Iron Moderate 
Drug-Drug Zinc-Iron Minor 
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7 
EMR (-9) 
 
8 
 6 
1 
Chart 
(-8) 
Participant 
(-7) 
Participant #7 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 66 4 22 7-9 5 0 
 
 
 
Management: 
- Extreme caution when co-administration can reduce the seizure threshold 
- Monitor blood pressure (3); renal function 
- Concomitant administration not recommended (4) 
- Monitor for signs of GI ulceration and bleeding; celecoxib toxicity; hypoglycemia; 
excessive CNS and respiratory depression 
- Dosing interval recommendations 
- Caution self-medication prior to consulting healthcare provider 
- Clinical significance unknown (3) 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Bupropion-Reglan Major 
Drug-Drug Diovan HCT-Celebrex Moderate 
Drug-Drug Diovan HCT-Metformin Moderate 
Drug-Drug Metoprolol-Diovan HCT Moderate 
Drug-Drug Aspirin-Diovan HCT Moderate 
Drug-Drug Bupropion-Valsartan Moderate 
Drug-Drug Metoprolol-Celebrex Moderate 
Drug-Drug Aspirin-Celebrex Moderate 
Drug-Drug Gemfibrozil-Celebrex Moderate 
Drug-Drug Diovan HCT-Celebrex Moderate 
Drug-Drug Toprol-XL-Metformin Moderate 
Drug-Drug Toprol-XL-Viactiv Calcium Moderate 
Drug-Drug Diovan HCT-Bisacodyl Moderate 
Drug-Drug Toprol-XL-Bupropion Moderate 
Drug-Drug Toprol-XL-Diovan HCT Moderate 
Drug-Drug Bupropion-Diovan HCT Moderate 
Drug-Drug Toprol-XL-Restoril Moderate 
Drug-Drug Bupropion-Restoril Moderate 
Drug-Drug Diovan HCT-Restoril Minor 
Drug-Drug Reglan-Restoril Minor 
Drug-Drug Aspirin-Prilosec Minor 
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Participant 
(-5) 
0 
5 
3 1 1 
1 
1 
1 
EMR (-8) 
Chart 
(-8) 
Pharmacy1 
(-11) 
Participant #8 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 80 5 13 5-11 4 1 
 
 
 
 
Management: 
- Monitor for signs of GI ulceration and bleeding, toxicity  
- Dosing interval recommendations (2) 
- Clinical significance unknown 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Ibuprofen-Aspirin Major 
Drug-Drug Aspirin-Calcium carbonate Moderate 
Drug-Drug Calcium carbonate-alendronate Moderate 
Drug-Drug Levothyroxine-Calcium carbonate Moderate 
Drug-Drug Ibuprofen-Alendronate Moderate 
Drug-Drug Aspirin-Omeprazole Moderate 
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 0 
EMR (-5) 
 
1 
3 
Participant (-0) 
1 
Pharmacy 
#1 (-4) 
Pharmacy 
#2(-4) 
Participant #9 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 81 2 5 3-9 5 0 
 
 
 
 
 
 
 
 
 
 
Management: 
- Monitor serum potassium levels; blood pressure, blood glucose 
- Dosing interval recommendation 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Atenolol-Hyzaar Major 
Drug-Drug Atenolol-Centrum Silver Moderate 
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5
 
EMR (-6) 
2 
1 
 
6 
Participant 
(-2) 
Pharmacy 
(-9) 
Participant #10 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 81 2 14 3-8 3 0 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Management: 
- Monitor for signs of muscle pain, tenderness or weakness; altered blood pressure control 
(3); effective calcium channel blocker therapy; diminished or inadequate analgesic and 
anti-inflammatory effects; altered renal function 
- Dosing interval (2) and amount adjustments recommended 
- Clinical significance unknown 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Niacin-Zocor Moderate 
Drug-Drug Aspirin-Felodipine Moderate 
Drug-Drug Calcium-Fosamax Moderate 
Drug-Drug Felodipine-Calcium Moderate 
Drug-Drug Aspirin-Calcium Moderate 
Drug-Drug Nitroglycerin-Temazepam Moderate 
Drug-Drug Felodipine-Nitroglycerin Moderate 
Drug-Drug Aspirin-Diovan Moderate 
Drug-Drug Temazepam-Calcium Minor 
Drug-Drug Aspirin-Nitroglycerin Minor 
Drug-Drug Aspirin-Niacin Minor 
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5 
EMR (-5) 
 
4 
1 
1 2 Pharmacy 
(-7) 
Participant 
(-3) 
Participant #11 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 91 2 13 3-7 3 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Management: 
- Monitor for signs of prolonged bleeding time and antihypertensive effect; hypotension; 
excessive serotonergic activity; altered calcium channel blocker therapy (2); diminished 
or inadequate analgesic and anti-inflammatory effects; hematologic complications 
- Dosing interval (2) and amount adjustments recommended 
- Clinical significance unknown
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Diltiazem-Aspirin Moderate 
Drug-Drug Lasix-Celexa Moderate 
Drug-Drug Diltiazem-Celexa Moderate 
Drug-Drug Calcium carbonate-Ferrous Gluconate Moderate 
Drug-Drug Diltiazem-Centrum Silver Moderate 
Drug-Drug Diltiazem-Proscar Moderate 
Drug-Drug Aspirin-Calcium carbonate Moderate 
Drug-Drug Diltiazem-Calcium carbonate Moderate 
Drug-Drug Aspirin-Celexa Moderate 
Drug-Drug Ranitidine-Calcium Carbonate Minor 
Drug-Drug Lasix-Aspirin Minor 
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2 
EMR (-3) 
1 
Participant (-0) 
0 
Chart 
(-3) 
Pharmacy 
(-1) 
Participant #12 
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 63 2 3 0-3 1 0 
 
 
 
 
 
 
 
 
 
 
 
Management: 
- Clinical significance unknown 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Propanolol-Acetaminophen Minor 
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Pharmacy 
(-2) 
Participant 
(-1) 
EMR (-1) 
Insurance  
(-1) 
3 
1 
1 
Chart (-1) 
Participant #13 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 72 4 5 2 0 0 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug No interactions  
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Pharmacy 
(-10) 
Participant 
(-4) 
EMR (-3) 
Insurance  
(-10) 
2 
1 
1 2 
1 
3 
1 
3 
1 
Chart (-6) 
Participant #14 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 83 6 15 2-9 1 0 
 
 
 
Management: 
- Monitor serum potassium levels; blood pressure (5); blood glucose; renal function (4); 
electrolytes 
- Monitor for signs of GI ulceration and bleeding; hypotension; diuresis; hypotension 
- Clinical significance is unknown (6) 
 
 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Fursemide-Metoprolol Moderate 
Drug-Drug Aspirin-Diclofenac Moderate 
Drug-Drug Metroprolol-Diclofenac Moderate 
Drug-Drug Furosemide-Diclofenac Moderate 
Drug-Drug K-Dur 10-Lisinopril Moderate 
Drug-Drug Aspirin-Lisinopril Moderate 
Drug-Drug Lorazepam-Lisinopril Moderate 
Drug-Drug Furosemide-Lisinopril Moderate 
Drug-Drug Furosemide-Lorazepam Moderate 
Drug-Drug Lisinopril-Diclofenac Moderate 
Drug-Drug K-Dur 10-Cyanocobalamin Minor 
Drug-Drug Metoprolol-Levothyroxine Minor 
Drug-Drug Metoprolol-Aspirin Minor 
Drug-Drug Levothyroxine-Zocor Minor 
Drug-Drug Furosemide-Aspirin Minor 
Drug-Drug Metoprolol-Lorazepam Minor 
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Participant 
(-27) 
EMR (-36) 
Insurance  
(-19) 
0 
2 
3 
19 
5 
8 
Pharmacy 
(-25) 
Participant #15 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 52 10 38 19-36 2 0 
    
 
       
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Prilosec-Atazanavir Major 
Drug-Drug Zoloft-Mirtazapine Major 
Drug-Drug Mirtazapine-Citalopram Major 
Drug-Drug Atropine-Potassium Chloride Major 
Drug-Drug Imitrex-Citalopram Major 
Drug-Drug Atenolol-Reyataz Major 
Drug-Drug Kaletra-Lipitor Major 
Drug-Drug Inderal-Reyataz Major 
Drug-Drug Colchicine-Reyataz Major 
Drug-Drug Digitek-Reyataz Major 
Drug-Drug Zoloft-Imitrex Major 
Drug-Drug Lipitor-Reyataz Major 
1rug-Drug Colchicine-Kaletra Major 
Drug-Drug Prevacid-Reyataz Major 
Drug-Drug Prevacid-Lipior Moderate 
Drug-Drug Inderal-Diovan Moderate 
Drug-Drug Prednisone-Diovan Moderate 
Drug-Drug Combivir-Lipitor Moderate 
Drug-Drug Zithromax-Lipitor Moderate 
Drug-Drug Potassium Chloride-Diovan Moderate 
Drug-Drug Hydromorphone-Diovan Moderate 
Drug-Drug Digitek-Lipitor Moderate 
Drug-Drug Prilosec-Lipitor Moderate 
Drug-Drug Atenolol-Diovan Moderate 
Drug-Drug Temazepam-Mirtazepine Moderate 
Drug-Drug Warfarin-Kaletra Moderate 
Drug-Drug Inderal-Kaletra Moderate 
Drug-Drug Digitek-Kaletra Moderate 
Drug-Drug Metoclopramide-Kaletra Moderate 
Drug-Drug Prednisone-Kaletra Moderate 
Drug-Drug Zoloft-Kaletra Moderate 
Drug-Drug Glimepiride-Kaletra Moderate 
Drug-Drug Kaletra-Mirtazapine Moderate 
Drug-Drug Atenolol-Mirtazapine Moderate 
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Participant #15 (cont.)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Errors 
Type Event Risk 
Drug-Drug Inderal-Mirtazapine Moderate 
Drug-Drug Bumetanide-Mirtazapine Moderate 
Drug-Drug Hydromorphone-Mirtazapine Moderate 
Drug-Drug Metoclopramide-Mirtazapine Moderate 
Drug-Drug Bumetanide-Actonel Moderate 
Drug-Drug Tums-Actonel Moderate 
Drug-Drug Zoloft-Lantus Moderate 
Drug-Drug Kaletra-Lantus Moderate 
Drug-Drug Citalopram-Lantus Moderate 
Drug-Drug Prednisone-Kaletra Moderate 
Drug-Drug Glimepiride-Kaletra Moderate 
Drug-Drug Lantus-Kaletra Moderate 
Drug-Drug Warfarin-Reyataz Moderate 
Drug-Drug Lantus-Reyataz Moderate 
Drug-Drug Prednisone-Reyataz Moderate 
Drug-Drug Tums-Reyataz Moderate 
Drug-Drug Glimepiride-Reyataz Moderate 
Drug-Drug Kaletra-Reyataz Moderate 
Drug-Drug Prednisone-Lantus Moderate 
Drug-Drug Bumetanide-Lantus Moderate 
Drug-Drug Inderal-Lantus Moderate 
Drug-Drug Atenolol-Citalopram Moderate 
Drug-Drug Warfarin-Citalopram Moderate 
Drug-Drug Inderal-Citalopram Moderate 
Drug-Drug Bumetanide-Citalopram Moderate 
Drug-Drug Hydromorphone-Citalopram Moderate 
Drug-Drug Metoclopramide-Citalopram Moderate 
Drug-Drug Prilosec-Citalopram Moderate 
Drug-Drug Temazepam-Citalopram Moderate 
Drug-Drug Zoloft-Citalopram Moderate 
Drug-Drug Glimepiride-Citalopram Moderate 
Drug-Drug Kaletra-Citalopram Moderate 
Drug-Drug Atenolol-Lantus Moderate 
Drug-Drug Mirtazapine-Reyataz Moderate 
Drug-Drug Zoloft-Glimepiride Moderate 
Drug-Drug Atropine-Pyridostigmine Moderate 
Drug-Drug Atenolol-Prednisone Moderate 
Drug-Drug Warfarin-Prednisone Moderate 
Drug-Drug Inderal-Prednisone Moderate 
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Participant #15 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Management: 
- Concomitant medication not recommended (16) 
- Monitor for signs of serotonin syndrome (4); GI injury; unexplained muscle pain, 
tenderness, or weakness (6); musculoskeletal toxicity (1); hypotension (13); excessive or 
prolonged CNS and respiratory depression (14); hydrocorticism; hypoglycemia (18); 
hypocalcemia (2); signs of bleeding (11); adrenal function; cardiac function; excessive 
serotonergic activity (3); cholinergic crisis; altered prokinetic efficacy 
- Monitor – serum colchicine levels (2); blood pressure (5); electrolyte level (5); body 
weight (4); serum potassium; serum digitoxin levels (5); serum digitalis levels (2); serum 
sodium 
- Dosing interval recommendation (8) 
- Clinical significance unknown (21)
Errors 
Type Event Risk 
Drug-Drug Atenolol-Tums Moderate 
Drug-Drug Inderal-Tums Moderate 
Drug-Drug Atropine-Tums Moderate 
Drug-Drug Atenolol-Zoloft Moderate 
Drug-Drug Kaletra-Reyataz Minor 
Drug-Drug Warfarin-Bumetanide Minor 
Drug-Drug Warfarin-APAP Minor 
Drug-Drug Inderal-APAP Minor 
Drug-Drug Combivir-APAP Minor 
Drug-Drug APAP-Atropine Minor 
Drug-Drug Prilosec-Glimepiride Minor 
Drug-Drug Prevacid-Kaletra Minor 
Drug-Drug Amoxicillin-Zithromax Minor 
Drug-Drug Combivir-Kaletra Minor 
Drug-Drug Digitek-Prevacid Minor 
Drug-Drug Digitek-Tums Minor 
Drug-Drug Prednisone-Tums Minor 
Drug-Drug Temazepam-Tums Minor 
Drug-Drug Warfarin-Vitamin C Minor 
Drug-Drug Inderal-Vitamin C Minor 
Drug-Drug Warfarin-Lipitor Minor 
Drug-Drug Metamucil-Glimepiride Minor 
Drug-Drug Digitek-Prilosec Minor 
Drug-Drug Warfarin-Inderal Minor 
Drug-Drug Potassium Chloride-Lantus Minor 
Drug-Drug Digitek-Metoclopramide Minor 
Drug-Drug Metamucil-Lantus Minor 
Drug-Drug Atropine-Digitek Minor 
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Participant 
(-11) 
0 
6 
1 
3 
1 
3 
1 
3 
2 
1 3 
1 1 
Pharmacy2 
(-14) 
EMR (-12) 
Chart 
(-21) 
Pharmacy1 
(-23) 
  
Participant #16 
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 61 4 28 11-23 5 0 
     
 Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Motrin-Aspirin Major 
Drug-Drug Percocet 10/325-Lomotil Moderate 
Drug-Drug Percocet 10/325-Imodium Moderate 
Drug-Drug Synthroid-NovoLog Moderate 
Drug-Drug Synthroid-Humulin R Moderate 
Drug-Drug Synthroid-Glucophage Moderate 
Drug-Drug Synthroid-Calcium Moderate 
Drug-Drug Lomotil-Loperamide Moderate 
Drug-Drug Lomotil-Calcium Moderate 
Drug-Drug Lomotil-Percocet 10/325 Moderate 
Drug-Drug Percocet 10/325-Effexor XR Moderate 
Drug-Drug Percocet 10/325-Neurontin Moderate 
Drug-Drug Novolin L-Avandia Moderate 
Drug-Drug Humulin R-Avandia Moderate 
Drug-Drug Glucophage-NovoLog Moderate 
Drug-Drug Glucophage-Novolin L Moderate 
Drug-Drug Glucophage-Humulin R Moderate 
Drug-Drug Avandia-NovoLog Moderate 
Drug-Drug Effexor XR-Neurontin Moderate 
Drug-Drug Lotrisone-Avandia Moderate 
Drug-Drug Lotrisone-Flonase Moderate 
Drug-Drug Calcium-Fosamax Moderate 
Drug-Drug Aspirin-NovoLog Moderate 
Drug-Drug Aspirin-Novolin L Moderate 
Drug-Drug Motrin-Fosamax Moderate 
Drug-Drug Atenolol-Exffexor XR Moderate 
Drug-Drug Atenolol-Motrin Moderate 
Drug-Drug Motrin-Effexor XR Moderate 
Drug-Drug Atenolol-Novolin L Moderate 
Drug-Drug Atenolol-Calcium Moderate 
Drug-Drug Atenolol-Oxycodone Moderate 
Drug-Drug Ranitidine-Glucophage Moderate 
Drug-Drug Atenolol-Humulin R Moderate 
Drug-Drug Atenolol-Lomotril Moderate 
Drug-Drug Atenolol-Glucophage Moderate 
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 Participant #16 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
Management: 
- Monitor for signs of GI ulceration and bleeding; excessive or prolonged CNS depression 
and constipation (3); respiratory depression (2); hypoglycemia (15); additive CNS effects 
(2); excessive serotonergic activity; cardiovascular adverse events (2); systemic 
glucocorticoid effects; gastric ulcers; hypotension (2); hematologic complications; lactic 
acidosis; diminished or inadequate analgesic anti-inflammatory effects; bleeding; gastric 
adverse effects (2) 
- Monitor – TSH levels; serum glucose levels (9); blood pressure 
- Dosing interval recommendations (4)  
- Clinical significance unknown (6)
Errors 
Type Event Risk 
Drug-Drug Aspirin-Calcium Moderate 
Drug-Drug Aspirin-Effexor XR Moderate 
Drug-Drug Aspirin-Humulin R Moderate 
Drug-Drug Atenolol-NovoLog Moderate 
Drug-Drug Lotrisone-Avandia Moderate 
Drug-Drug Aspirin-Protonix Minor 
Drug-Drug Atenolol-Synthroid Minor 
Drug-Drug Atenolol-Aspirin Minor 
Drug-Drug Lotrisone-Novolin L Minor 
Drug-Drug Lotrisone-Humulin R Minor 
Drug-Drug Lotrisone-Glucophage Minor 
Drug-Drug Lotrisone-Allegra Minor 
Drug-Drug Motrin-Ranitidine Minor 
Drug-Drug Ranitidine-Percocet 10/325 Minor 
Drug-Drug Ranitidine-Fosamax Minor 
Drug-Drug Percocet 10/325-Lomotil Minor 
Drug-Drug Aspirin-Omeprazole Minor 
Drug-Drug Lotrisone-NovoLog Minor 
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Participant 
(-5) 
4 
7 
5 
3 
1 
Pharmacy1 
(-15) 
EMR (-7) 
Chart 
(-15) 
Participant #17 
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 52 9 20 5-15 3 0 
     
 
Management: 
- Monitor for development of signs of serotonin syndrome (2); upper GI injury; altered 
renal function; excessive or prolonged CNS and respiratory depression (3); torsades de 
pointes; hypotension (2) 
- Caution patients against self-medication prior to consulting healthcare provider (2) 
- Interval dosing (2) and adjustment recommendation 
- Clinical significance unknown (3) 
-  
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Trazodone-Cymbalta Major 
Drug-Drug Potassium chloride-Compazine Major 
Drug-Drug Bactrim DS-Potassium chloride Moderate 
Drug-Drug Trazodone-Vicodin Moderate 
Drug-Drug Diovan HCT-Caltrate + D Moderate 
Drug-Drug Bactrim DS-Diovan HCT Moderate 
Drug-Drug Potassium chloride-Diovan HCT Moderate 
Drug-Drug Reglan-Cymbalta Moderate 
Drug-Drug Compazine-Cymbalta Moderate 
Drug-Drug Vicodin-Cymbalta Moderate 
Drug-Drug Compazine-Vicodin Moderate 
Drug-Drug Compazine-Zofran Moderate 
Drug-Drug Diovan HCT-Compazine Moderate 
Drug-Drug Reglan-Compazine Moderate 
Drug-Drug Diovan HCT-Trazodone Moderate 
Drug-Drug Reglan-Trazodone Moderate 
Drug-Drug Compazine-Trazodone Moderate 
Drug-Drug Diovan HCT-Caltrate + D Moderate 
Drug-Drug Synthroid-Caltrate + D Moderate 
Drug-Drug Caltrate + D-Boniva Moderate 
Drug-Drug Synthroid-Trazodone Minor 
Drug-Drug Caltrate + D-Cymbalta Minor 
Drug-Drug Protonix-Cymbalta Minor 
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Participant 
(-8) 
1 
5 
7 2 
1 
1 1 1 
3 
Pharmacy1 
(-14) 
EMR (-9) 
Chart 
(-19) 
Participant #18 
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 44 4 22 8-19 5 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Management: 
- Monitor for signs of altered renal function; hypotension (8); bleeding (3); GI ulceration; 
increased seizure activity (2); excessive or prolonged CNS effects; celecobix toxicity 
- Monitor serum potassium levels, blood pressure (2), blood glucose; renal function 
- Concomittant administration not recommended (3) 
- Dosing interval and adjustment recommendations (1) 
- Clinical significance is unknown (6). 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Bupropion-Trazodone Major 
Drug-Drug Bupropion-Interferon Beta 1B Major 
Drug-Drug Atenolol-Hyzaar Moderate 
Drug-Drug Flagyl-NuvaRing Moderate 
Drug-Drug Aspir-Low-Celebrex Moderate 
Drug-Drug Hyzaar-Celebrex Moderate 
Drug-Drug Xanax-Wellbutrin SR Moderate 
Drug-Drug Xanax-Trazodone Moderate 
Drug-Drug Trazodone-Celebrex Moderate 
Drug-Drug Flagyl-Celebrex Moderate 
Drug-Drug Provigil-Nexium Moderate 
Drug-Drug NuvaRing-Provigil Moderate 
Drug-Drug Provigil-NuvaRing Moderate 
Drug-Drug Atenolol-Xanax Moderate 
Drug-Drug Atenolol-Wellbutrin SR Moderate 
Drug-Drug Atenolol-Trazodone Moderate 
Drug-Drug Xanax-Hyzaar Moderate 
Drug-Drug Wellbutrin SR-Hyzaar Moderate 
Drug-Drug Hyzaar-Trazodone Moderate 
Drug-Drug Trazodone-Hyzaar Moderate 
Drug-Drug Aspir-Low-Hyzaar Moderate 
Drug-Drug Hyzaar-Celebrex Moderate 
Drug-Drug Atenolol-Aspir-Low Minor 
Drug-Drug Xanax-NuvaRing Minor 
Drug-Drug NuvaRing-Ester-C Minor 
Drug-Drug Xanax-Provigil Minor 
Drug-Drug Trazodone-Provigil Minor 
Drug-Drug Aspir-Low-Nexium Minor 
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Participant 
(-2) 
0 
2 
1 
1 
1 
1 
1 
Pharmacy 
(-4) 
EMR (-5) 
Chart 
(-4) 
Insurance 
(-5) 
Participant #19 
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 55 1 7 2-6 2 0 
   
 
 
 
 
*Not included in the figure is Pharmacy 2 – 1 observation listed; 6 missing observations 
 
Management: 
- Monitor for hemodynamic response and tolerance (2);  
- Monitor – serum potassium levels (2); blood pressure (2); blood glucose (2) 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Atenolol-Verapamil Major 
Drug-Drug Atenolol-Nifediac CC Moderate 
Drug-Drug Atenolol-HCTZ Moderate 
Drug-Drug Atenolol-Triamterene Moderate 
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Participant 
(-3) 
1 
1 2 1 1 
1 
3 
Pharmacy 
(-4) 
EMR (-5) 
Chart 
(-6) 
Insurance 
(-5) 
Participant #20 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 71 4 10 3-6 3 0 
     
 
 
 
Management: 
- Monitor – renal function 
- Dosing interval recommendation (2) 
- Clinical significance unknown (2) 
 
 
 
 
Errors 
Type Event Risk 
Dose 25 mg/day (Pt) versus  50 mg/day (EMR, Chart, Pharm) - 
Frequency Missing - 
Drug-Drug Aspirin-Asacol Moderate 
Drug-Drug Toprol-XL-Centrum Moderate 
Drug-Drug Levoxyl-Centrum Moderate 
Drug-Drug Toprol-XL-Aspirin Minor 
Drug-Drug Toprol-XL-Levoxyl Minor 
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Participant 
(-4) 
0 
3 
1 2 
1 
1 1 
2 
Pharmacy 
(-8) 
EMR (-4) 
Chart 
(-8) 
Specialist 
(-9) 
Participant #21 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 53 2 11 4-10 3 0 
 
 
 
 
 
 
*Not diagrammed is the Insurance Company – is 1 of the 2 drugs shared with EMR, Participant, 
Specialist, and Pharmacy, missing from the Insurance Company is 10 drugs 
 
Management: 
- Potential additive GI toxicity – advised to report signs and symptoms 
- Monitor for prolonged CNS depression and constipation; antihypertensive response 
- Monitor – laboratory work, blood pressure 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Compliance Participant not taken med - 
Drug-Drug Advil-Aspirin Major 
Drug-Drug Atenolol-Advil Moderate 
Drug-Drug Hydrocodone-Detrol Moderate 
Drug-Drug Zocor-Zetia Moderate 
Drug-Drug Atenolol-Aspirin Minor 
Drug-Drug Acetaminophen-Detrol Minor 
    
Chart 
(-8) 
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6 
EMR (-1) 
6 
2 
1 
1 
Participant 
(-7) 
Chart 
(-9) 
Participant #22 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 77 7 16 1-9 0 0 
 
 
 
Management: 
- Caution is recommended of concomitant administration (6) 
- Clinical monitoring for signs of CNS stimulation/depression (3); digoxin toxicity; 
hypokalemia 
- Clinical monitoring of electrolyte levels; hypotension; blood pressure; body weight 
- Dosing interval recommendations 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Compliance Part. threw out med. - 
Drug-Drug Prednison-Avelox Major 
Drug-Drug Methadone-Avelox Major 
Drug-Drug Diltiazem-Methadone Moderate 
Drug-Drug Celebrex-Avelox Moderate 
Drug-Drug Iron Polysach-Avelox Moderate 
Drug-Drug Salmeterol-Avelox Moderate 
Drug-Drug Prednisone-Celebrex Moderate 
Drug-Drug Oxycodone-Celebrex Moderate 
Drug-Drug Methadone-Salmeterol Moderate 
Drug-Drug Lanoxin-Prednisone Moderate 
Drug-Drug BuSpar-Prednisone Moderate 
Drug-Drug Diltiazem-BuSpar Moderate 
Drug-Drug Methadone-BuSpar Moderate 
Drug-Drug Diltiazem-Lanoxin Moderate 
Drug-Drug Diltiazem-Oxycodone Moderate 
Drug-Drug Methadone-Oxycodone Moderate 
Drug-Drug BuSpar-Oxycodone Moderate 
Drug-Drug Diltiazem-Prednisone Moderate 
Drug-Drug Prednisone-MiraLax Moderate 
Drug-Drug Probenecid-Avelox Minor 
    
147 
Participant 
(-2) 
0 
1 
3 
2 1 
2 
Pharmacy1 
(-7) 
EMR (-1) 
Chart 
(-4) 
Pharmacy2 
(-6) 
 
 
 
 0 
EMR (-9) 
1 
6 
2 
Chart (-6) 
1 
1 1 
1 Pharmacy (-11) 
Participant 
(-8) 
Participant #23 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 57 2 9 1-7 0 0 
 
 
 
Management: 
- Caution is recommended of concomitant administration (3) 
- Monitoring – serum potassium; blood pressure (2), blood glucose; antihypertensive 
response 
- Recommends concomitant administration avoided in heart failure patients 
 
Participant #25 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 68 3 13 6-11 2 0 
 
 
 
 
 
 
Management 
- Cautioned against self-medication without first consulting Healthcare Provider
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Fluoxetine Moderate 
Drug-Drug Atenolol-HCTZ Moderate 
Drug-Drug Fluoxetine-HCTZ Moderate 
Drug-Drug Atenolol-Valsartan Moderate 
Drug-Drug Aspirin-Valsartan Moderate 
Drug-Drug Atenolol-Aspirin Minor 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Hyzaar-Calcium Moderate 
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Participant 
(-5) 
1 1 
1 
1 
4 
2 
Specialist 
(-6) 
EMR (-6) 
Insurance 
(-7) 
Pharmacy1 
(-10) 
2 
1 
3 
1 
Participant #24 
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 73 3 17 4-16 2 0 
 
 
 
*Not diagrammed are: Chart - 1 listed (6 missing) and Pharmacy#2 - 4 listed (13 missing) 
Management: 
- Caution is recommended for concomitant administration (4) 
- Monitor for signs of hyperkalemia 
- Dosing interval recommendations 
  
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Lasix-Albuterol Moderate 
Drug-Drug Lasix-Advair Moderate 
Drug-Drug Lasix-Lexapro Moderate 
Drug-Drug K-Dur-Avapro Moderate 
Drug-Drug Avapro-Lexapro Moderate 
Drug-Drug Zantac-Tylenol Minor 
Drug-Drug Zantac-Os-Cal Minor 
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Participant 
(-1) 
3 1 
1 
1 
1 
1 
Pharmacy2 
(-12) 
EMR (-7) 
Pharmacy1 
(-8) 
Chart  
(-6) 
3 
1 
 
3 
1 
Participant #26 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 64 10 15 1-12 3 0 
 
 
 
Management: 
- Monitoring – blood pressure; electrolytes; body weight 
- Monitoring for signs of NSAID toxicity; hypercalcemia; hypokalemia; GI ulceration; 
renal function 
- Dosing interval recommendations (2) 
- Cautioned against self-medication without first consulting Healthcare Provider 
 
 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Naprosyn-Plendil Moderate 
Drug-Drug Naprosyn-Plavix Moderate 
Drug-Drug Medrol Dosepak-Avalide Moderate 
Drug-Drug Naprosyn-Avalide Moderate 
Drug-Drug Synthroid-Centrum Silver Moderate 
Drug-Drug Plendil-Centrum Silver Moderate 
Drug-Drug Avalide-Calcium Moderate 
Drug-Drug Synthroid-Calcium Moderate 
Drug-Drug Avalide-Calcium Moderate 
Drug-Drug Plendil-Calcium Moderate 
Drug-Drug Plendil-Medrol Dosepak Moderate 
Drug-Drug Naprosyn-Medrol Dosepak Moderate 
Drug-Drug Lipitor-Plavix Moderate 
Drug-Drug Medrol Dosepak-Calcium Minor 
Drug-Drug Naprosyn-Calcium Minor 
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 2 
EMR (-5) 
3 
2 
3 
Pharmacy2 (-8) 
1 
1 2 
1 Pharmacy1 
(-7) 
Participant 
(-8) 
Participant #27 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 59 4 15 5-8 3 0 
 
 
Management: 
- Monitoring for signs of excessive serotonergic activity; hypotension (2); CNS depression 
(2); anticholinergic intoxication; 
- Monitoring – potassium level (2) 
  
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Oxycodone-Cymbalta Moderate 
Drug-Drug Oxycodone-Benicar HCT Moderate 
Drug-Drug Oxycodone-Hyzaar Moderate 
Drug-Drug Oxycodone-Robinul Moderate 
Drug-Drug Benicar HCT-Serevent Diskus Moderate 
Drug-Drug Benicar HCT-Albuterol Moderate 
Drug-Drug Benicar HCT-Roxicel Moderate 
Drug-Drug Atropine-Robinul Moderate 
Drug-Drug Atropine-Roxicet Moderate 
Drug-Drug Benicar HCT-Robinul Minor 
Drug-Drug Atropine-Benicar HCT Minor 
Drug-Drug Roxicet-Robinul Minor 
Drug-Drug Roxicet-Atropine Minor 
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Participant 
(-7) 
3 
1 
2 
1 
1 
Pharmacy2 
(-12) 
EMR (-5) 
Insurance 
(-7) 
Pharmacy1  
(-8) 
3 
1 
 
3 
1 
Participant #28 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 82 5 16 5-12 3 0 
 
 
Management: 
- Concomitant administration not recommended (3) 
- Co-administration can result: 
o additive effects (6) - hypotension 
o sub-therapeutic effects (1) 
- Monitored for potentially excessive or prolonged CNS and respiratory depression. (1) 
- Close monitoring is recommended – clinical and laboratory (2) 
o Excessive seronergic activity – i.e. CNS irritability, altered consciousness, etc. (1) 
o Hematologic complications – i.e. signs of bleeding (2) 
o Impaired renal function (1) 
- Clinical significance is unknown (3) 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Naprosyn-aspirin Moderate 
Drug-Drug Naproxyn-Nexium Moderate 
Drug-Drug Avapro-Citalopram Moderate 
Drug-Drug Ambien-Citalopram Moderate 
Drug-Drug Doxazosin-Citalopram Moderate 
Drug-Drug Temazepam-Citalopram Moderate 
Drug-Drug Prilosec-Citalopram Moderate 
Drug-Drug Aspirin-Citalopram Moderate 
Drug-Drug Naprosyn-Citalopram Moderate 
Drug-Drug Ambien-Avapro Moderate 
Drug-Drug Naprosyn-Prilosec Moderate 
Drug-Drug Temazepam-Doxazosin Moderate 
Drug-Drug Doxazosin-Ambien Moderate 
Drug-Drug Naprosyn-Avapro Moderate 
Drug-Drug Aspirin-Avapro Moderate 
Drug-Drug Temazepam-Avapro Moderate 
Drug-Drug Aspirin-Prilosec Minor 
Drug-Drug Aspirin-Nexium Minor 
Drug-Drug Citalopram-Nexium Minor 
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Participant 
(-7) 
2 
1 
5 
7
 
Chart 
(-8) 
EMR (-16) 
Insurance 
(-18) 
Pharmacy1  
(-12) 
2 
1 
 
1 
0 
Participant #29 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 63 4 19 7-18 3 0 
 
 
 
Management: 
- Monitoring – liver function; serum hydantoin levels; blood pressure, weight 
- Monitoring for signs of CNS and respiratory depression (7); reduced antiemetic effects; 
increase risk of ventricular arrhythmias; anti-tumor activity may be reduced (3); 
increased heart failure; bowel movement changes (2); hypotension; phenytoin toxicity 
(2); reduced corticosteroid dosages;  
- Dosing interval recommendation (2) 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Acetaminophen-Phenytoin Moderate 
Drug-Drug Prochloroperazine-Keppra Moderate 
Drug-Drug Phenytoin-Zofran Moderate 
Drug-Drug Prochloroperazine-Zofran Moderate 
Drug-Drug Morphine-Transderm Scop Moderate 
Drug-Drug Phenytoin-Camptosar Moderate 
Drug-Drug Dexamethasone-Camptosar Moderate 
Drug-Drug Vitamin E-Camptosar Moderate 
Drug-Drug Colace-Camptosar Moderate 
Drug-Drug Vitamin E-Temodar Moderate 
Drug-Drug Morphine-Kappra Moderate 
Drug-Drug Prochloperazine-Hytrin Moderate 
Drug-Drug Morphine-Hytrin Moderate 
Drug-Drug Pepcid-Phenytoin Moderate 
Drug-Drug Phenytoin-Lorazepam Moderate 
Drug-Drug Phenytoin-Dexamethasone Moderate 
Drug-Drug Phenytoin-Morphine Moderate 
Drug-Drug Lorazepam-Morphine Moderate 
Drug-Drug Phenytoin-Prochlorperazine Moderate 
Drug-Drug Lorazepam-Prochloroperazine Moderate 
Drug-Drug Morphine-Prochlorperazine Moderate 
Drug-Drug Lorazepam-Hytrin Moderate 
Drug-Drug Dexamethasone-Hytrin Moderate 
Drug-Drug Acetaminophen-Transderm Scop Minor 
Drug-Drug Prochlorperazine-Camptosar Minor 
Drug-Drug Pepcid-Vitamin B12 Minor 
Drug-Drug Dexamethasone-Vitamin E Minor 
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Participant 
(-8) 
2 
1 
 
1
 
Chart 
(-13) 
EMR (-8) 
Specialist 
(-12) 
Pharmacy1  
(-8) 
1 
1 
 
3 
0 
1 
1 
1 
Participant #30 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 51 1 14 8-13 3 0 
 
 
 
 
Management: 
- Monitored for potentially excessive or prolonged CNS and respiratory depression 
- Blood glucose should be monitored (4) 
- Decrease absorption (1) 
 
Errors 
Type Event Risk 
Dose   
Drug-Drug Valium-Astelin Moderate 
Drug-Drug Multivitamin-Avelox Moderate 
Drug-Drug Humulin-Avelox Moderate 
Drug-Drug Humalog-Avelox Moderate 
Drug-Drug Avelox-Lantus Moderate 
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Participant 
(-8) 
2 1 
 
2
 
Chart 
(-10) 
EMR (-6) 
Specialist 
(-17) 
Pharmacy1  
(-12) 
1 
3 
 
3 
0 
3 
2 
1 
Participant #31 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 72 3 18 6-17 2 0 
 
 
 
Management: 
- Monitor – increased muscle toxicity; CNS adverse events (3); hypotension (3) 
- Monitor – serum thyrotropin; serum potassium levels; blood pressure; blood glucose; 
laboratory monitoring; serum TSH levels 
- Caution self-treatment prior to consulting healthcare professional (2) 
- Cautions co-administration  
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Clarithromycin-Lipitor Moderate 
Drug-Drug Darvocet-N 100-Trazodone Moderate 
Drug-Drug Synthroid-Estradiol Moderate 
Drug-Drug HCTZ-Calcium Moderate 
Drug-Drug Atenolol-HCTZ Moderate 
Drug-Drug Atenolol-Valsartan Moderate 
Drug-Drug Darvocet-N 100-Valsartan Moderate 
Drug-Drug Atenolol-Detrol LA Moderate 
Drug-Drug Clarithromycin-Detrol LA Moderate 
Drug-Drug Synthroid-Calcium Moderate 
Drug-Drug HCTZ-Calcium Moderate 
Drug-Drug Atenolol-Calcium Moderate 
Drug-Drug Atenolol-Darvocet-N 100 Moderate 
Drug-Drug HCTZ-Darvocet-N 100 Moderate 
Drug-Drug Atenolol-Trazodone Moderate 
Drug-Drug Clarithromycin-Trazodone Moderate 
Drug-Drug HCTZ-Trazodone Moderate 
Drug-Drug Darvocet-N 100-Detrol LA Moderate 
Drug-Drug Estradiol-Lipitor Minor 
Drug-Drug Synthroid-Trazodone Minor 
Drug-Drug Tylenol-Detrol LA Minor 
Drug-Drug Atenolol-Synthroid Minor 
Drug-Drug HCTZ-Detrol LA Minor 
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Participant 
(-0) 
1 
 
Chart 
(-1) 
EMR (-0) 
Insurance 
(-4) 
Pharmacy 
(-3) 
1 
1 
2 
Participant #32 
 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 72 3 5 0-3 0 0 
 
 
 
 
 
 
Management: 
- Monitored for diminished or inadequate analgesics or anti-inflammatory effects; renal 
impairment 
- Cautioned self-medication prior to consulting a healthcare professional 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Calcium carbonate Moderate 
Drug-Drug Avalide-Calcium carbonate Moderate 
Drug-Drug Aspirin-Avalide Moderate 
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 4 
EMR (-3) 
1 
1 
1 
Chart (-3) 
1 
2 
1 
1 
1 
Pharmacy 
(-4) 
Participant 
(-3) 
Participant #33 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 79 4 12 3-4 0 0 
 
 
 
Management: 
- Monitor for CNS and respiratory depression (3); hypotension (4); calcium channel 
blocker therapy (2); hematological complications (2); diminished or inadequate analgesic 
and anti-inflammatory effects 
- Caution self-treatment prior to consulting healthcare professional 
- Monitor – serum potassium levels, blood pressure (3), blood glucose 
- Dosing interval recommendations (2) 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Celexa-Lexapro Moderate 
Drug-Drug Avalide-Calcium carbonate Moderate 
Drug-Drug Avalide-Celexa Moderate 
Drug-Drug Avalide-Lexapro Moderate 
Drug-Drug Calcium carbonate-Norvasc Moderate 
Drug-Drug Norvasc-Centrum Silver Moderate 
Drug-Drug Gabapentin-Celexa Moderate 
Drug-Drug Gabapentin-Lexapro Moderate 
Drug-Drug Avalide-Celexa Moderate 
Drug-Drug Avalide-Lexapro Moderate 
Drug-Drug Aspirin-Lexapro Moderate 
Drug-Drug Aspirin-Celexa Moderate 
Drug-Drug Atenolol-Avalide Moderate 
Drug-Drug Atenolol-Calcium carbonate Moderate 
Drug-Drug Atenolol-Norvasc Moderate 
Drug-Drug Atenolol-Centrum Silver Moderate 
Drug-Drug Atenolol-Celexa Moderate 
Drug-Drug Atenolol-Lexapro Moderate 
Drug-Drug Aspirin-Calcium carbonate Moderate 
Drug-Drug Aspirin-Norvasc Moderate 
Drug-Drug Aspirin-Avalide Moderate 
Drug-Drug Avalide-Norvasc Minor 
Drug-Drug Atenolol-Aspirin Minor 
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0 
EMR (-10) 
2 
5 2 
 
3 
Participant 
(-4) 
Pharmacy 
(-7) 
Participant #34 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 49 2 12 4-10 1 0 
 
 
 
Management: 
- Alternative or additional methods should be considered 
- Monitor – serum thyroxine 
- Monitor – increased risk of hypermagnesemia 
- May decrease bioavailability of drug 
 
Errors 
Type Event Risk 
Dose missing - 
Frequency missing - 
Drug-Drug Cephalexin-Junel Fe 1/20 Moderate 
Drug-Drug Junel Fe 1/20-Levothyroxine Moderate 
Drug-Drug Levothyroxine-Calcium Moderate 
Drug-Drug Calcium-Lisinopril Moderate 
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Participant 
(-3) 
1 
 
Chart 
(-1) 
EMR (-2) 
Insurance 
(-4) 
Pharmacy 
(-4) 
1 
4 
2 
Participant #35 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 67 4 8 1-4 1 0 
    
 
 
 
 
 
 
 
 
 
Management: 
- Monitor for signs of hypoglycemia (2); diminished or inadequate analgesic and anti-
inflammatory effects; renal function assessment 
- Dosing interval recommendations (2) 
 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Glipizide Moderate 
Drug-Drug Aspirin-Actonel Moderate 
Drug-Drug Glipizide-Lisinopril Moderate 
Drug-Drug Actonel-Lisinopril Moderate 
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 1 
EMR (-3) 
0 
2 
1 
Pharmacy (-3) 
1 
Participant 
(-0) 
Chart 
 (-4) 
 Participant #36 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 42 3 5 0-4 2 1 
 
 
 
 
 
Management: 
- Clinical significance unknown 
 
Errors 
Type Event Risk 
Dose missing - 
Frequency missing - 
Drug-Drug Atenolol-Aspirin Moderate 
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Participant 
(-3) 
1 
Chart 
(-10) 
EMR (-6) 
Insurance 
(-6) 
Pharmacy 
(-6) 
2 
2 
3 
1 
2 
Participant #37 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 45 1 12 3-10 2 0 
 
 
 
 
 
 
 
 
*Not diagrammed are observation (present,missing) from the Pharmacy 2 (1,11) , Pharmacy 3 
(3,9) Pharmacy 4 (1, 11), and Pharmacy 5 (5,7)  
 
Management: 
- Monitor for signs of hypoglycemia (3); GI ulceration and bleeding;  
- Dosing adjustment recommendations (2) 
- Clinical significance unknown (2) 
   
  
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Prednisone-Novolin Moderate 
Drug-Drug Prednisone-Humalog Pen Moderate 
Drug-Drug Prednisone-Celebrex Moderate 
Drug-Drug Albuterol-Novolin R Moderate 
Drug-Drug Albuterol-Humalog Pen Moderate 
Drug-Drug Claritin-Celebrex Moderate 
Drug-Drug Effexor-Celebrex Moderate 
Drug-Drug Prednisone-Vitamin E Minor 
Drug-Drug Prednisone-Calcium + D Minor 
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Participant 
(-11) 
3 
Chart 
(-12) 
EMR (-11) 
Specialist 
(-15) 
Pharmacy 
(-15) 
2 0 
2 2 
2 2 
1 
2 
1 
1 
1 
Participant #38 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 73 6 20 11-15 1 1 
 
 
 
Management: 
- Monitor for signs of additive GI toxicity; diminished or inadequate analgesic and anti-
inflammatory effects; renal function 
- Monitor – blood pressure (3); serum potassium levels; blood glucose 
- Cautions self-medication prior to consulting healthcare provider 
- Dosing interval recommendations (3) 
- Clinical significance unknown (2) 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Motrin-Aspirin Major 
Drug-Drug Atenolol-Motrin Moderate 
Drug-Drug HCTZ-Calcium Acetate Moderate 
Drug-Drug Atenolol-Calcium acetate Moderate 
Drug-Drug Aspirin-Calcium acetate Moderate 
Drug-Drug Synthroid-Calcium Acetate Moderate 
Drug-Drug Motrin-HCTZ Moderate 
Drug-Drug Atenolol-HCTZ Moderate 
Drug-Drug Atenolol-Synthroid Moderate 
Drug-Drug Atenolol-Calcium Acetate Minor 
Drug-Drug Atenolol-Aspirin Minor 
Drug-Drug Aspirin-Niacin Minor 
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2 
EMR (-6) 
2 
6 
Participant 
(-2) 
Pharmacy 
(-8) 
Participant 
(-6) 
2 
Chart 
(-8) 
EMR (-2) 
Pharmacy 
(-7) 
2 
1 1 1 
1 2 
1 
3 
Participant #39 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 66 3 10 2-8 0 0 
 
 
 
Management:  
- Caution self-medication prior to consulting healthcare provider (3) 
- Monitor for signs of diminished or inadequate analgesic or anti-inflammatory effects 
- Monitor – blood pressure; renal function 
 
Participant #40 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 66 3 14 2-8 0 0 
 
 
 
 
 
 
 
 
Management: 
- Concomitant administration not recommended (3) 
- Monitor for signs of musculoskeletal toxicity (3); GI ulceration and bleeding; adrenal 
function 
- Clinical significance unknown (2) 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Vitamin E Moderate 
Drug-Drug Aspirin-Calcium Moderate 
Drug-Drug Hyzaar-Calcium Moderate 
Drug-Drug Aspirin-Hyzaar Moderate 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Cosopt Major 
Drug-Drug Aspirin-Azopt Major 
Drug-Drug Biaxin XL-Viagra Major 
Drug-Drug Baxin XL-Zocor Major 
Drug-Drug Niacin-Zocor Major 
Drug-Drug Zocor-Vytorin Moderate 
Drug-Drug Aspirin-Triamcinolone Moderate 
Drug-Drug Biacin XL-Triamcinolone Moderate 
Drug-Drug Biacin XL-Allegra Minor 
Drug-Drug Aspirin-Niacin Minor 
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Chart 
(-10) 
4 
Pharmacy1 
(-11) 
EMR (-6) 
Pharmacy2 
(-11) 
2 1 
1 
1 
 
2 
1 
4 Insurance 
(-13) 
Participant #41 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 80 3 16 6-11 0 0 
 
 
Management: 
- Concomitant administration not recommended 
- Monitor for signs of musculoskeletal toxicity; torsades de pointes; excessive or prolonged 
CNS and respiratory depression (3); hypotension (5)  
- Monitor – serum potassium levels (2); blood pressure (2); blood glucose (2) 
- Dosing interval recommendation (2) 
 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Cosopt Major 
Drug-Drug Clarithromycin-Zocor Major 
Drug-Drug Clarithromycin-Prochlorperazine Moderate 
Drug-Drug Trazodone-Lyrica Moderate 
Drug-Drug Prochlorperazine-Lyrica Moderate 
Drug-Drug Maxzide-Cosopt Moderate 
Drug-Drug Viactiv Calcium-Fosamax Moderate 
Drug-Drug Trazodone-Neurontin Moderate 
Drug-Drug Prochlorperazine-Neurontin Moderate 
Drug-Drug Trazodone-Maxzide Moderate 
Drug-Drug Prochlorperazine-Maxzide Moderate 
Drug-Drug Prochlorperazine-Trazodone Moderate 
Drug-Drug Maxzide-Trazodone Moderate 
Drug-Drug Clarithromycin-Trazodone Moderate 
Drug-Drug Maxzide-Prochlorperazine Moderate 
Drug-Drug Neurontin-Lyrica Moderate 
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 0 
EMR (-13) 
1 
1 10
 
Chart (-11) 
2 
1 
1 
Participant 
(-4) 
Pharmacy 
(-15) 
 
Participant 
(-5) 
1 
Pharmacy1 
(-12) 
EMR (-11) 
Pharmacy2 
(-10) 
2 
1 
1 1 
2 
1 
5 
Chart 
(-11) 
1 
Participant #42 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 52 6 16 4-15 10 0 
 
 
 
 
   
 
Management: 
- Monitor for signs of hypercalcemia (2) 
- Caution for self-medication prior to consulting a healthcare provider 
 
Participant #43 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 56 3 15 5-12 5 0 
 
 
 
 
 
Management: 
- Monitor blood pressure  
- Monitor for signs of hypotension (2); CNS and respiratory depression 
- Dosing interval recommendations 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Dyazide-Calcium Moderate 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Atenolol-Ibuprofen Moderate 
Drug-Drug Atenolol-Lorazepam Moderate 
Drug-Drug Atenolol-Ambien Moderate 
Drug-Drug Lorazepam-Ambien Moderate 
Drug-Drug Atenolol-Centrum Silver Moderate 
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 2 
EMR (-9) 
3 
3 
5 
Chart (-10) 
1 
1 
Participant 
(-7) 
Pharmacy 
(-11) 
Participant #44 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 73 3 15 7-11 5 1 
 
 
Management: 
- Monitor blood pressure (5); electrolytes; serum potassium levels; blood glucose 
- Monitor for signs of hematologic complications; diuresis; renal function (4); bleeding 
- Caution against self-medication without first consulting a healthcare provider (2) 
- Dosing interval recommendations 
- Concomittant administration not recommended 
- Clinical significance unknown 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Naprosyn-Lopressor Moderate 
Drug-Drug Aspirin-Gingko Biloba Moderate 
Drug-Drug HCTZ-Citracal Moderate 
Drug-Drug Lopressor-Citracal Moderate 
Drug-Drug HCTZ-Lisinopril Moderate 
Drug-Drug Aspirin-Lisinopril Moderate 
Drug-Drug Naprosyn-Lisinopril Moderate 
Drug-Drug Aspirin-Vitamin E Moderate 
Drug-Drug Lopressor-HCTZ Moderate 
Drug-Drug Naprosyn-HCTZ Moderate 
Drug-Drug Naprosyn-Aspirin Moderate 
Drug-Drug HCTZ-Gingko biloba Moderate 
Drug-Drug Lopressor-Aspirin Minor 
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Participant 
(-5) 
3 
Pharmacy1 
(-10) 
EMR (-5) 
Pharmacy2 
(-15) 
1 
5 
1 
2 1 3 
Chart 
(-15) 
Participant #45 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 73 5 16 5-15 2 0 
 
 
 
Management: 
- Monitoring – blood pressure (3); blood glucose (3); 
- Monitor for signs of CNS and respiratory depression (2); musculoskeletal toxicity; 
hypotension (6); hemodynamic response and tolerance 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Clonidine-Lopressor Moderate 
Drug-Drug Aspirin-Avapro Moderate 
Drug-Drug Lopressor-Glucophage Moderate 
Drug-Drug Lasix-Glucophage Moderate 
Drug-Drug Percocet 5/325-Neurontin Moderate 
Drug-Drug Clonidine-Neurontin Moderate 
Drug-Drug Prilosec-Zocor Moderate 
Drug-Drug Oxycodone-Norvasc Moderate 
Drug-Drug Aspirin-Norvasc Moderate 
Drug-Drug Lopressor-Norvasc Moderate 
Drug-Drug Lopressor-Oxycodone Moderate 
Drug-Drug Lasix-Oxycodone Moderate 
Drug-Drug Clonidine-Oxycodone Moderate 
Drug-Drug Lasix-Lopressor Moderate 
Drug-Drug Oxycodone-Avapro Moderate 
Drug-Drug Aspirin-Prilosec Minor 
Drug-Drug Lopressor-Aspirin Minor 
Drug-Drug Lasix-Aspirin Minor 
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Participant 
(-2) 
1 
Pharmacy1 
(-3) 
EMR (-2) 
Specialist 
(-3) 
1 1 
1 
1 
1 
4 
Chart 
(-2) 
1 
Participant #46 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 72 6 10 2-9 0 0 
 
 
 
* Not included in the diagram is the Insurance Company which shares 1 observation with all the 
sources, and is missing 9 observations; Specialist 2 which shares 1 observation and is missing 9. 
 
Management: 
- Monitor – blood pressure (3); electrolyte levels (2); body weight (2) 
- Dosing interval recommendation (2) 
- Monitor – renal function; effectiveness of calcium channel blocker (2); hypokalemia; GI 
ulceration 
- Caution self-medication without first consulting healthcare provider (2) 
 
 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Plendil Moderate 
Drug-Drug Caltrate-Actonel Moderate 
Drug-Drug Prednisone-Avalide Moderate 
Drug-Drug Aspirin-Avalide Moderate 
Drug-Drug Avalide-Calcium Moderate 
Drug-Drug Plendil-Calcium Moderate 
Drug-Drug Avalide-Caltrate Moderate 
Drug-Drug Caltrate-Plaquenil sulfate Moderate 
Drug-Drug Avalide-Caltrate Moderate 
Drug-Drug Plendil-Caltrate Moderate 
Drug-Drug Aspirin-Caltrate Moderate 
Drug-Drug Avalide-Prednisone Moderate 
Drug-Drug Plendil-Prednisone Moderate 
Drug-Drug Aspirin-Prednisone Moderate 
Drug-Drug Calcium-Actonel Moderate 
Drug-Drug Prednisone-Calcium Minor 
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Participant #47 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 61 6 15 7-10 2 0 
 
 
 
 
 
 
 
 
 
 
 
Management: 
- Monitor for signs of hypotension (4); CNS and respiratory depression (2); excessive 
serotonergic activity 
- Monitor – blood glucose; potassium levels; blood pressure 
- Manufacturer recommends avoiding combination of drugs 
- Clinical significance unknown (2) 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Atenolol-Lorazepam Moderate 
Drug-Drug Diovan HCT-Lexapro Moderate 
Drug-Drug Aspirin-Lexapro Moderate 
Drug-Drug Lorazepam-Lexapro Moderate 
Drug-Drug Atenolol-Lexapro Moderate 
Drug-Drug Aspirin-Valsartan Moderate 
Drug-Drug Atenolol-Valsartan Moderate 
Drug-Drug Lorazepam-Reglan Moderate 
Drug-Drug Lorazepam-Diovan HCT Moderate 
Drug-Drug Atenolol-Diovan HCT Moderate 
Drug-Drug Reglan-Lexapro Moderate 
Drug-Drug Aspirin-Nexium Minor 
Drug-Drug Atenolol-Aspirin Minor 
    
Participant 
(-7) 
1 
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2 
2 
2 
2 
1 
1 
1 
EMR (-7) 
Pharmacy 
(-10) 
Insurance 
(-10) 
Chart  
(-10) 
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 3 
EMR (-1) 
2 
1 
1 
Chart (-3) 
 
Pharmacy 
(-4) 
Participant 
(-2) 
 
  
EMR (-0) 
0 
1 
2 
Pharmacy 
(-1) 
Insurance 
(-0) 
Participant #48 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 51 3 7 1-4 1 0 
     
 
 
 
 
Management: 
- Monitor renal function (2); blood pressure; electrolytes; blood glucose;  
- Monitor for signs of possible signs of lactic acidosis; hypoglycemia; diuresis 
 
Participant #49 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
M 52 2 3 0-1 0 0 
     
  
 
 
 
 
Management: 
- Monitor blood pressure and renal function assessments. 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Lisinopril Moderate 
Drug-Drug HCTZ-Lisinopril Moderate 
Drug-Drug Zantac-Glucophage Moderate 
Drug-Drug HCTZ-Glucophage Moderate 
Drug-Drug Lisinopril-Glucophage Moderate 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Aspirin-Prinivil Moderate 
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Participant 
(-5) 
1 
Pharmacy1 
(-5) 
EMR (-1) 
Pharmacy2 
(-4) 
1 
1 
1 
2 
Chart 
(-3) 
Participant #50 
Sex Age No. of Conditions 
Total No. of 
Meds/CAMs 
Range of Missing 
Meds/CAMs from Sources 
No. of Self 
Prescribed 
 No. of Sample 
Meds 
F 51 6 7 1-5 0 0 
      
 
 
 
 
* Not included in the figure are Pharmacy 3 and 4 – both with 1 observation, 4 missing. 
 
Management: 
- Monitor blood pressure (5); serum potassium levels (3); blood glucose (3); renal function 
(2) 
 
 
 
Errors 
Type Event Risk 
Dose Missing - 
Frequency Missing - 
Drug-Drug Atenolol-Ibuprofen Moderate 
Drug-Drug Atenolol-HCTZ Moderate 
Drug-Drug Ibuprofen-HCTZ Moderate 
Drug-Drug Atenolol-Triamterene Moderate 
Drug-Drug Ibuprofen-Triamterene Moderate 
Drug-Drug Atenolol-Vaictiv Calcium Moderate 
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